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Ghana’s national tuberculosis (TB) prevalence survey in 2013 showed higher than 
expected prevalence, indicating people with TB are being missed. 
Aim 
 
To identify barriers in the pathway to TB diagnosis and treatment initiation for people 
presenting to health facilities and make recommendations for improvement. 
Methods 
 
In Volta region, Ghana, a cross-sectional study was conducted among symptomatic 
patients exiting the health facility to determine TB screening practices of healthcare 
workers (HCWs); a prospective cohort study among presumptive TB patients to 
determine if sputum was submitted; and in-depth interviews with HCWs and clinic 
observations to explore barriers to TB case finding. 
Results 
 
In the cross-sectional study, 386/581 (66.4%) reported their TB-related symptoms to 
a HCW; 157/386 (40.6%) were eligible for a sputum test but only 31 (19.7%) were 
asked to submit a sputum. Prior TB treatment was the strongest predictor of being 
asked to submit a sputum (adjusted odds ratio [aOR]: 6.25, 95% CI: 2.24-17.46). In the 
prospective cohort study, among rural facility attendees, only 45/143 (31.5%) 
submitted a sputum for testing. Travel distance 
>10 km to the diagnostic laboratory was the strongest predictor of sputum not 
submitted (aOR 0.12, 95%CI 0.05-0.33). Barriers identified in the qualitative study 
were either health system- related such as no diagnostic laboratories in rural facilities 
and HCWs’ non-adherence to diagnostic guidelines; or HCW-related such as lack of 





There are gaps in the pre-diagnostic cascade in the steps before a sputum is submitted 
for a TB test. Factors causing these gaps are multifaceted and there is no single 
solution for these barriers. Collaborations between health facilities and the national 
TB control programme to implement patient-centred strategies for improved case 
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Chapter 1: Introduction 
 
1.1 Public health importance of tuberculosis 
 
Tuberculosis (TB) is a highly infectious disease that is a major public health threat. It is the 
leading cause of death from a single infectious agent ranked above the human 
immunodeficiency virus (HIV) [1]. It is estimated that about a quarter of the world’s 
population is infected with Mycobacterium tuberculosis (the bacterium that causes TB) 
and thus at risk of developing TB disease [1]. In 1993, the World Health Organization 
(WHO) declared TB as a global public health emergency and initiated a management 
strategy called directly observed treatment short course (DOTS) [2, 3]. The DOTS 
strategy was aimed at controlling the TB epidemic and had five key elements: political 
commitment with increased and sustained financing; case detection through quality- 
assured bacteriology; standardized treatment, with supervision and patient support; 
an effective drug supply and management system; monitoring and evaluation system, 
and impact measurement [2, 4]. There has been some progress towards TB control; 
between the years 2000 and 2014, 43 million lives have been saved through effective 
TB diagnosis and treatment [5]. Also, there was a 42% reduction in TB deaths among 
HIV-negative people between the period 2000 and 2017 [6]. 
 
Despite this progress, TB remains a disease of major public health importance. In 
2018, it was estimated that 10 million people had TB globally with an estimated 1.2 
million deaths among HIV-negative people and an additional 251,000 deaths among 
HIV-positive people [1]. Africa bore 24% of the global TB burden in 2018 and also had 
the highest burden of HIV-associated TB accounting for 84% of all TB/HIV deaths [1, 
6].  TB is more common in men accounting for 57% of people with TB, and 89% of TB 
is in adults (aged over 15 years). Drug- resistant TB is also a continuing public health 
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threat and in 2018, about half a million people had a new episode of rifampicin-
resistant TB, 78% of them were multidrug-resistant (i.e. resistant to two of the most 
important TB drugs, isoniazid and rifampicin) [1].  
 
1.2 Biology of TB 
TB is caused by a bacterium called Mycobacterium tuberculosis and it is transmitted 
via the airborne route when individuals with active respiratory tract infections expel 
bacilli into the environment. Humans are both the obligate host and vector of this 
organism  [7]. TB has many manifestations, affecting bone, the central nervous system, 
and many other organ systems, but it is primarily a pulmonary disease that is initiated 
by the deposition of the bacilli, contained in aerosol droplets, onto lung alveolar 
surfaces [8]. It is not everyone infected with Mycobacterium tuberculosis that 
becomes sick, therefore, there are two TB-related conditions: latent TB infection and 
TB disease. However, recent research has clearly demonstrated that human TB 
infection, from latent infection to active disease, exists within a continuous spectrum 
of metabolic bacterial activity and antagonistic immunological responses. This revised 
understanding has led to the proposition of two additional clinical states: incipient and 
subclinical TB [9]. The progression of the disease can have several outcomes, 
determined largely by the response of the host immune system. The efficacy of this 
response is affected by intrinsic factors such as the genetics of the immune system 
and extrinsic factors such as the nutritional and physiological state of the host. In 
addition, the pathogen may play a role in disease progression since some 
Mycobacterium tuberculosis strains are reportedly more virulent than others, as 
defined by increased transmissibility as well as being associated with higher morbidity 
and mortality in infected individuals [8]. Some people develop TB disease soon (within 
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weeks) after becoming infected before their immune system can fight the bacteria. 
Other people may develop the disease years later, when their immune system 
becomes weak for other reasons. Many people with TB infection never develop TB 
disease [10]. 
 
1.3 Finding the missing TB cases and ending the epidemic 
 
One of the main challenges in TB control is finding the missed TB cases. The term 
“missed” is the gap between the estimated number of people who became ill with TB 
(incident episodes) in a year and the number of people who were notified to national 
TB programmes [11]. The estimated incidence of TB is calculated by WHO using four 
methods: (i) results from TB prevalence surveys and estimates of the duration of 
disease derived from a model that accounts for the impact of TB/HIV disease and 
antiretroviral therapy (ART) on the distribution of disease duration, (ii) notifications 
adjusted by a standard factor to account for underreporting, overdiagnosis and 
underdiagnosis, (iii) results from national inventory studies that measured the level of 
underreporting of detected TB cases and (iv) case notification data combined with 
expert opinion about case detection gaps [1].  
 
According to the WHO, every year three million people with TB are missed globally. 
There are several reasons for which people with TB are missed: they may not access 
care at all due to limited awareness of TB, inaccessibility to health services or financial 
barriers; others may access health services but are not diagnosed due to inaccurate or 
inappropriate diagnostic tests or overburdened and undertrained healthcare workers 
(HCW). Also, others may get diagnosed but they are not documented because of 
weaknesses in recording and reporting within public health systems or poor linkage 
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between private and public health systems [11]. The high burden of undiagnosed TB 
causes much suffering and economic hardship, and sustains transmission [12]. 
 
There are several global strategies and targets for TB prevention, care and control. The 
United Nation’s sustainable development goals (SDGs) and the WHO’s End TB strategy 
all seek to end the TB epidemic by reducing the global TB incidence rate by 90% and 
95% by 2030 and 2035 respectively compared to the 2015 rate [3, 5]. However, 
progress towards these targets is slow. The global average rate of decline of TB 
incidence was 1.6% per year between 2000-2018 and 2.0% between 2017 and 2018 
[1]. The decline in global TB incidence must increase to 10% per year by the year 2025 
to achieve these goals [3]. Figure 1.1 below shows how the decline in global TB 
incidence can be accelerated by optimization of current tools combined with pursuing 
universal health coverage and social protection from 2015, and the additional impact 
of new tools by 2025. To meet these global targets, it is imperative that people with 
TB are identified promptly and put on treatment to reduce adverse health outcomes, 





























Source: WHO: The End TB Strategy – Global Strategy for tuberculosis prevention, care and control after 2015 [3] . 







1.4 TB control in Ghana 
Ghana is among the 30 TB/HIV high burden countries according to the WHO’s 
classification [13].  TB control in Ghana is managed by the national TB control 
programme (NTP) with regional, district and institutional focal persons.  TB case 
finding is the responsibility of all health facilities in the country. 
 
A national TB prevalence survey conducted in 2013 showed the prevalence of TB in 
Ghana was 253/100,000, almost four times higher than the WHO estimates of 
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148/100,000 (translating to 44,000 TB patients) with estimated deaths of 15,800, 
however, the notification rate was 48/100,000 (translating to 14,289 TB patients) [15] 
indicating a case detection rate of 32%. This implied lots of people with TB in 2018 were 
not identified which could lead to sustained TB transmission in the country and some 
of these people may die. 
 
There are 10 regions in Ghana and in 2019, six regions (Western, Brong Ahafo, Upper 
East, Greater Accra, Eastern and Volta) had case notification rates higher than the 
national average of 48.8/100,000 population [16]. The majority of people notified to 
have TB in Ghana are classified as new and in 2019, 2.5% of TB cases were 
previously treated TB patients. The proportion of bacteriologically-confirmed TB 
increased from 51% in 2013 to 64% in 2019. This increasing trend is likely due to the 
introduction of Xpert MTB/RIF (Cepheid, Sunnyvale CA, USA) as the first line diagnostic 
test for all presumed TB. Among total incident cases notified in Ghana from 2013 to 
2019, the proportion of extra pulmonary TB (EPTB) ranged between 8-9% and the 
proportion of childhood TB remained below 6% which is low compared to the 
expected global average of 10%. Also, in 2019, the prevalence of HIV among TB 
patients tested for HIV was 21.2% of which 74.9% were enrolled on antiretroviral 
therapy  [16]. Since 2013, TB treatment success rates (percentage of notified TB 
patients who were successfully treated) have been above 80% but death rates are high 
ranging from 9-10%. Most of the deaths are among HIV coinfected patients [16]. 
 
In Ghana, TB diagnosis and treatment is mainly done at government health facilities. 
Smear microscopy was the main diagnostic method until the last quarter of 2017 when 
Xpert MTB/RIF (Cepheid, Sunnyvale CA, USA) was introduced as the first-line 
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diagnostic method. Xpert MTB/RIF is an automated polymerase chain reaction 
platform, developed for rapid diagnosis of TB [17]. In 2011, WHO recommended the 
use of Xpert MTB/RIF for diagnosis of TB in HIV positive patients and suspected drug-
resistant TB  [18] with a policy update in 2013 [19]. In 2017, WHO recommended Xpert 
Ultra (Cepheid, Sunnyvale, USA) (Ultra) the next generation of Xpert MTB/RIF, as the 
initial TB diagnostic test for adults and children, regardless of HIV status [20]. In Ghana, 
there are about 370 TB diagnostic laboratories nationwide with 126 GeneXpert 
machines installed at selected health facilities by the NTP [16]. Also, most diagnostic 
laboratories are located at teaching, regional and district hospitals but not at the lower 
levels of care such as health centres and clinics which are more easily accessible. 
Therefore, a person with symptoms of TB might be identified at a health centre but will 
have to travel to the district hospital for a sputum test to confirm the diagnosis. 
Community health workers are supposed to transport sputum samples to the 
diagnostic centres but most often they lack the means of transportation to do this. 
Patients with symptoms suggestive of TB are thus required to visit the diagnostic 
centres themselves for sputum testing. This can lead to loss to follow-up and patients 
with TB might be missed by the health system. 
 
There is a national standard operating procedure (SOP) for TB case finding that outlines 
activities to be carried out in health facilities to improve case detection [21]. The SOP 
requires that all adult patients presenting to health facilities should be asked about 
cough by HCWs regardless of presenting symptoms and those reporting a cough should 
be screened with a symptom questionnaire. Eligible persons, that is, those reporting 
cough longer than two weeks or cough of any duration with at least two other TB-related 
symptoms (chest pain, weight loss, night sweats and fever), should be asked to submit 
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a sputum for a TB test [22]. Patients who are HIV-positive with cough of any duration, 
fever, weight loss or night sweats should also be asked to submit sputum for a TB test. 
 
Figure 1.2 shows the pathway to TB diagnosis and treatment in health facilities in 
Ghana where a person with cough may seek care from different providers 
(pharmacy, private clinic, traditional healer or faith-based healer) where they 
might not be screened for TB. Others too might visit a government health facility 
and must go through several steps in the care cascade to get a TB diagnosis and 
initiated on treatment. Those who first visit other providers may end up at some 






















CHPS (community-based service delivery point) = community health planning services, HCW= healthcare worker, TB= tuberculosis. *Presumptive TB patient= a patient who presents with 
symptoms or signs suggestive of TB 
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1.5 Rationale for the study 
 
The national TB prevalence survey conducted in 2013 showed that the burden of TB 
in Ghana was higher than previously assumed. In 2014 when programme data were 
combined with revised prevalence data, it showed that TB case detection rates were 
low with only 33% of people with TB detected, implying ongoing transmission of 
infection [23]. Improving case finding is a priority of the NTP. This will ensure that 
persons with TB are identified early and put on treatment to reduce the duration of 
infectiousness and reduce transmission. This in the long term will also enable the NTP 
to meet global targets of reduced incidence of TB. 
 
Also, findings from the prevalence survey showed that among persons with prolonged 
cough who visited a health facility, only 25% did a sputum test [14]. This is illustrated in 
figure 1.3 which shows the cascade of care among survey participants who sought care 
from a government health facility. Survey participants were adults aged 15 years and 
above selected from 98 clusters across the ten regions of Ghana and screened with a 
TB symptom questionnaire. They were eligible for the survey based on being a resident 
or visitor who had lived in a household within a cluster for the most of the last two 
weeks preceding the census, conducted two months prior to the prevalence survey. 
The findings from the prevalence survey indicate weaknesses in the diagnostic 









Figure 1. 3: Cascade of prevalence survey participants who did a sputum test 
Source: Ghana national population-based TB Prevalence survey report [14] (data used with permission 
from Ghana’s national TB control programme). No=Number, HF=health facility 
 
 
Many studies have described the health facility contribution to delayed or missed 
diagnosis of TB; however, the methodologies used are mainly cross-sectional in design 
[24, 25]. These mainly involve interviews with TB patients on treatment about when 
they developed symptoms and when they were diagnosed in a health facility [26-28]. 
Most often data related to individual level characteristics of these patients are used to 
determine associations with health system delay (normally dichotomized based on a 
mean or median time interval from the time a patient accessed care at the health 
facility until they get a TB diagnosis or start treatment) [26]. These studies have several 
limitations, including relying on the recall of TB patients already on treatment, which 
might introduce recall bias in remembering when they developed symptoms and the 
steps they went through to get a final diagnosis. Moreover, if a study recruits TB 
patients already on treatment, this implies that persons with symptoms suggestive of 
TB who attended a health facility but did not get diagnosed by the health system are 
not studied. Therefore, the factors associated with their inability to get diagnosed are 

















not determined but such factors are rather relevant for health system improvement. 
 
Although several studies have shown that only small proportions of people with 
symptoms suggestive of TB do a sputum test, none of these studies have been able to 
differentiate between if a patient was asked to do a sputum test or actually did a 
sputum test [29-33]. Few studies have focused on persons with cough who have been 
asked to do a sputum test by a HCW or patients exiting the health facility after seeking 
care to investigate the TB care cascade to find out at which points patients are missed 
or delayed in being diagnosed. In addition, most studies on pre- treatment or 
treatment delays have either a quantitative or qualitative design with limited studies 
employing both quantitative and qualitative designs to understand better the delays 
in the TB care cascade and the barriers and practices within health facilities that 
facilitate these delays or missed diagnosis. 
 
The steps in the pre-diagnostic cascade prior to a sputum specimen being submitted 
at the laboratory are much less studied compared to the post-diagnostic cascade but 
are very important. This is because if a person with symptomatic TB who accesses care 
from a health facility never gets diagnosed, then they will not be treated. This is 
evidenced by findings from Ghana’s national TB prevalence survey as illustrated in 
figure 1.3 above. A person with symptomatic TB who never gets diagnosed may die 
from the disease or remains a source of infection to others. Therefore, the steps in the 
pre-diagnostic cascade were the focus of our study. To better understand the gaps, we 
designed a set of studies to examine the steps in the cascade prior to submission of a 
sputum sample, namely (i) whether people who seek care from health facilities are 
screened for symptoms of TB by a HCW and if eligible, whether a sputum test is 
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requested; (ii) whether patients who have been asked to submit a sputum by a HCW, 
do actually submit a sputum and (iii) identify barriers within the health system that 
hinder early diagnosis and treatment of TB (Figure 1.4). The TB care cascade 
encompasses patient health- seeking behaviour and access to care as well as activities 
and practices within the health system. Factors associated with delayed/missed 
diagnosis or treatment can either be patient-related or health system-related. 
 
Every unidentified person with pulmonary TB, as well as every delayed diagnosis, is a 
missed opportunity to stop the spread of the disease and improve health outcomes 
[34]. It is important to look holistically at TB case finding activities at health facility 
level. This includes cough screening practices of HCWs, requesting a sputum test, 
submitting a sputum sample, the testing pathway, treatment initiation and barriers to 
TB case finding from the perspective and practices of HCWs to identify the gaps and 
recommend appropriate interventions. This PhD study focused on health system-
related factors especially on the steps before a sputum is submitted in order to identify 
modifiable factors that contribute to delayed or missed TB diagnosis in health facilities 
and suggest interventions to reduce diagnostic and treatment delay for people with TB. 
We focused on health system-related factors because we believed they may be more 
important (e.g. system in place for submission of sputum for a TB test in facilities 
without a TB diagnostic laboratory) and are more rarely studied. Also, some health 
system factors (e.g. adherence to guidelines) may be easier to modify than patient 
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The aim of the thesis was to identify barriers in the pathway to TB diagnosis and 
treatment initiation for people presenting to health facilities with symptoms suggesting 
TB in Ghana, and make recommendations for strengthening of health systems to improve 
TB case finding in health facilities. 
 
1.6.2 Specific objectives 
 
The specific objectives to address the aim were: 
 
1. To determine the proportion of health facility attendees eligible for sputum 
test according to national guidelines who were asked to do a sputum test by 
a HCW and the prevalence of having sputum positive on Xpert MTB/RIF 
among health facility attendees who met the criteria for sputum test 
according to study criteria. 
2. To determine the proportion of patients with a request for sputum test who 
submitted a sputum for testing, the time from test request to submitting 
sputum, and factors contributing to non-submission of sputum for   testing. 
3. To compare the time from test request to submitting sputum among 
patients attending a health facility with vs. without a co-located   laboratory. 
4. To explore HCWs’ perspectives concerning barriers to TB case finding in 






1.7 Thesis structure 
 
This thesis follows the research paper style format. A review of the literature is 
presented in chapter 2 and focuses on health systems’ delay or missed diagnosis of TB. 
A general overview of the study setting as well as the quantitative and qualitative 
methods employed are presented in chapter 3. In chapter 4, results of an initial 
situation assessment at the study health facilities are presented. Chapters 5, 6 and 7 
are presented as research papers. 
 
Chapter 5 addresses objective 1 which was to determine the proportion of health 
facility attendees who are eligible for a sputum test according to the national standard 
operating procedures for case detection who were asked to give a sputum by a HCW 
in outpatient clinics of a municipal hospital, and to determine the prevalence of having 
a sputum positive result on Xpert MTB/RIF in this study population. This used a cross 
sectional study design with exit interviews of persons who sought care from the health 
facility for their own health and had at least one TB-related symptom. This was to 
determine TB symptom screening and requesting for sputum testing practices within 
the health facility. The use of exit interviews was a more robust way to determine if 
symptomatic patients were asked to do a sputum test compared to using a 
retrospective approach. It helped reduce the recall bias since patients were 
interviewed immediately after consultation with a HCW rather than after an interval. 
 
Chapter 6 addresses objectives 2 and 3 which aimed to determine the proportion of 
patients with a request for sputum test who actually submitted a sputum for the test 
and the time from test request to submitting a sputum comparing between health 
facilities with vs without co- located laboratory. This was to enable us to identify steps 
in the testing cascade where presumptive TB patients (a patient who presents with 
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symptoms or signs suggestive of TB [35]) might be missed or delayed in getting a 
diagnosis, and factors associated with missed or delayed diagnosis. We used a 
prospective cohort study design to follow up on persons who had been asked to do a 
sputum test to find out if they got the test done. This was to investigate what happens 
after the sputum test has been requested. The prospective cohort design was to ensure 
that the sequence of events in doing a sputum test could be followed, to determine 
factors that might hinder people from doing the test. 
 
Chapter 7 addresses objective 4 which was to explore the barriers to TB case finding 
in health facilities from the perspective, experiences and practices of HCWs. This was 
a qualitative study where we used clinic observations and in-depth interviews with 
HCWs. Since we were focusing on the health system, we needed to find out the 
perspective of HCWs on TB case finding and observe their activities within the health 
facility to determine if there were any barriers to TB case finding especially during the 
pre-diagnostic phase. We used clinic observations and in- depth interviews to help us 
understand and confirm the barriers to TB case finding in health facilities. 
 
Finally, chapter 8 presents the summary of the findings and reflections on these 
findings in relation to existing literature. It also presents the implications of this work 
for TB case finding in health facilities, the conclusions drawn and recommendations 
made. 
 
The PhD study was thus designed to have three components: a cross sectional study 
using exit interviews; a prospective observational cohort study; and a qualitative study 
using clinic observations and in-depth interviews. The different components of the 
study are illustrated in figure 1.4 above. 
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1.8 Contributions to the work presented in this thesis 
 
1.8.1 Conception, study design, protocol development, and regulatory 
approvals  
 
The conception of the idea for this research study started at the beginning of my PhD 
journey from discussions with Prof Alison Grant on issues bordering around improving 
TB case finding in Ghana. This was after I had read the national TB health sector strategic 
plan for Ghana, 2015-2020 to identify areas in TB control that were of priority to the 
national TB control programme (NTP) to improve TB case finding. Once we decided 
what was relevant and feasible to do in the context of a PhD study, I developed the 
study protocol with support from Dr Daniel Grint who provided statistical advice and 
Dr Virginia Bond who advised on the qualitative component of the study. I contacted 
the NTP and had discussions with the programme manager, Dr Frank Bonsu, who made 
inputs to the study protocol and agreed to be the local supervisor for the data 
collection in Ghana. Once all my supervisors approved the study protocol, I applied for 
ethical clearance from the Ghana Health Service Ethics Review Committee and the 
London School of Hygiene & Tropical Medicine Ethics Committee. I also contacted the 
regional and district health directorates of the study area as well as the management 
of all health facilities the study was to be conducted to seek permission. I visited the 
two health facilities where the study was to be conducted and based on preliminary 
findings relating to TB case finding activities in these facilities, I had to apply for an 
amendment to the study protocol to include three more health facilities which was 
approved by the ethics committees. 
 
1.8.2 Study management and data collection 
 
It was my primary responsibility to manage all the three components (cross-sectional 
study using exit interviews, prospective observational cohort study and qualitative 
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study using clinic observations and in-depth interviews) of the study. Open data Kit 
(ODK) which is an electronic platform for data collection was used for data collection 
in this study and since I had no knowledge of ODK at the beginning, Dr Chrissy Roberts 
was very supportive in explaining how it works and provided resources to enable me 
develop the case report forms (CRFs) in ODK format. 
 
I designed and coordinated the piloting of all CRFs as well as writing standard operating 
procedures (SOPs) for all activities to be carried out in the field and developed a training 
manual. I recruited research assistants and trained them on the study protocol, CRFs 
and SOPs. I was involved in the day-to-day activities of data collection: coordinated 
and supervised data collection, conducted some participant interviews for the cross-
sectional and prospective cohort studies, conducted all in-dept interviews for the 
qualitative study and conducted all clinic observations with support from a colleague, 
Dr Clement Narh from the School of Public Health, University of Health and Allied 
Sciences, Hohoe, Ghana. 
 
1.8.3 Data management & analysis 
 
I reviewed all CRFs for consistency and missing data daily after data were collected 
before uploading onto a secure server. I managed all the data for the different 
components of the study and generated dashboards in Excel spreadsheets to monitor 
data collection. All analyses presented in this thesis were done by me with advice from 
Dr Daniel Grint. I developed the do- files for the different data sets in STATA version 15 
(Stata Corp, College Station TX, USA) and was assisted in developing some of the codes 





1.8.4 Multi-authored papers 
 
Three papers are presented in this thesis. Each paper represents a component of the 
study. I carried out all the analyses, wrote the drafts for all the papers and maintained 
overall control of the content of the papers. Dr Daniel Grint made important 
suggestions to statistical methods, presentation of results, table structure and figures 
for papers 1 and 2 while Dr Virginia Bond made important suggestions to the content 
of paper 3. Prof Alison Grant offered guidance and made important suggestions to the 
overall content of all three papers. All authors reviewed and approved the final 
manuscripts prior to submission. 
 
Prof Alison Grant was involved at every stage of the development of this thesis and 





















This chapter reviews the literature on delayed or missed diagnosis of TB. 
 
Early diagnosis of TB disease and prompt initiation of treatment are key elements for an 
effective TB control programme. It was estimated historically that a patient with 
untreated smear positive pulmonary TB may infect on average more than 10 persons 
per year [36], however, this number has been found to be lower (2.6-5.8) in surveys 
conducted in China, Philippines and Republic of Korea in the era of established TB 
control and efficacious TB treatment regimens [37]. It beholds on people in the 
community with symptoms of TB to seek appropriate health care, and it is the 
responsibility of health facilities to diagnose people with TB, initiate them on 
treatment and ensure they are cured. However, the ability of people to recognize their 
TB symptoms and their health seeking behaviour can often lead to missed or delayed 
diagnosis of the disease. Likewise, strategies such as passive case finding (identifying 
TB among people who are actively seeking care in a health facility [38]) employed by TB 
control programmes to identify people with TB can also lead to missed or delayed 
diagnosis of the disease. Passive case finding has been the main strategy employed by 
most TB control programmes to identify persons with TB in health facilities. 
Unfortunately, passive case finding has not been very effective especially in lower-and 
middle- income countries (LMICs) [39]. The effectiveness of this strategy is dependent 
on the health seeking behaviour of patients, the efficiency and ability of HCWs to 
identify symptoms, and the quality of laboratory facilities [40]. Health facilities thus 
play a vital role in TB diagnosis and treatment and ultimately reducing TB incidence. 
There is enormous literature that has documented factors which lead to health system 
diagnostic and treatment delays for TB patients. Delays can occur at different points in 
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the diagnostic pathway shown in figure 2.1 below. 
 
This literature review is focussed on factors within health facilities that lead to missed 
or delayed diagnosis at the various steps in the pathway especially the steps in the 
pathway prior to diagnosis. It also provides a brief overview of factors that affect what 
happens prior to a patient visiting a health facility. The reasons for the focus being on 
health systems are explained in Chapter 1. 
 








2.2 Types of delay in diagnosis and treatment of TB 
 
Studies reporting on delays in TB diagnosis and treatment use different terms to 
classify delay as shown in figure 2.2. Most studies classify delay into three main 
categories: patient delay (time interval between the onset of patient symptom(s) and 
the patient’s first consultation to a healthcare provider), health system delay (time 
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interval between the patient’s first consultation with a healthcare provider and 
initiation of treatment) and total delay (the sum of patient delay and health system 
delay or time interval from onset of symptoms to initiation of treatment) [32, 42-44]. 
Other studies include categories such as diagnostic delay (time interval between onset 
of symptoms and diagnosis of TB), doctor’s delay (time interval between first visit to 
healthcare provider and diagnosis of TB).  TB diagnosis is normally the day a patient is 
confirmed to have TB by the laboratory or a clinician’s judgement and treatment delay 
is time interval between diagnosis of TB to initiation of treatment [34] (Figure 2.2). 
 
These delays are mostly measured in days [32, 42, 43, 45] or weeks [33] and there is a 
lack of consensus in literature about what duration between onset of TB symptoms 
and diagnosis is considered as delay [46]. Some studies use the median duration of 
their findings as a cut-off point and dichotomize it into delay or no delay. Others put a 
specific time limit such as 2 weeks (15 days), 3 weeks (21 days) or 1 month (30 days) 
[39]. However, the WHO recommends that a TB diagnosis within 2-3 weeks of onset of 
symptoms is acceptable delay [47]. Notwithstanding the type of categorization used, 
both patients and health systems can contribute to delayed diagnosis of TB by patients 
deferring their presentation to health care and health systems missing the opportunity 




Figure 2. 2: Conceptual framework of delays in diagnosis and treatment of tuberculosis 
Source: Bello et al, 2019 [34]. HF= Health facility 
 
 
2.3 Method of literature review 
 
The aim of the literature review was to describe the factors that contribute to delayed 
or missed diagnosis of TB focusing on the different steps and gaps in the pre-treatment 
TB care cascade: onset of symptoms and health seeking behaviour of patients; TB 
screening practices of HCWs and adherence to guidelines; laboratory diagnosis; 
receiving of test results, and treatment initiation as shown in figure 2.1. 
 
This literature review was based on a search strategy using relevant search terms on 
health system delay or missed diagnosis of TB conducted in two databases namely 
Medline and Embase for the period 2000-2020. The search terms and strategy used in 




Patient delay Doctor delay Treatment delay 
Diagnostic delay 
Health system delay 
Onset of symptoms First visit to HF Diagnosis Initiation of treatment 
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Table 2. 1: Medline database search terms and strategy 
 
 
 Search terms 
1 Tuberculosis 
2 delayed diagnosis 
3 missed diagnosis 
4 2 OR 3 
5 case detection 
6 case finding 
7 5 OR 6 
8 testing pathway or diagnostic pathway 
9 testing cascade or diagnostic cascade 
10 8 OR 9 
11 healthcare system 
12 Hospital 
13 Clinic 
14 health facility 
15 health cent* 
16 11 OR 12 OR 13 OR 14 OR 15 
17 1 AND 4 AND 7 AND 10 AND 16 
 
 
The search retrieved 2112 potentially relevant titles and abstracts for health system 
delay and missed diagnosis of TB. After removing duplicates, reviewing 
titles/abstracts and excluding all other papers that were not relevant, 50 full text 
articles were reviewed. A search of references of the selected articles and other 
sources added 22 other full text articles. The literature review was thus based on 72 
full text  articles as shown in figure 2.3. At the end of the literature review, 18 out of 
the 72 full text articles reviewed are summarized in table 2.2. These 18 articles were 
selected based on their definition of health systems delay being the time between first 
contact with a public or private health facility and diagnosis of TB or initiation of TB 
treatment. Studies that included pharmacies, drug stores and traditional healers as 
















Factors contributing to patient and health system delays are presented below, 
organised according to steps in the TB care cascade: 
 
2.4 Health-seeking behaviour of patients (onset of 
symptoms and access to care) 
 
Health care seeking behaviour is how people in the community seek help from formal 
or informal sources for their symptoms to attain or regain good health and to prevent 
illness [48, 49].  People in the community who develop symptoms of TB will either access 
care or ignore their symptoms. Several studies have shown TB patients delay in seeking 
care for their symptoms (patient delay). Studies conducted in Ethiopia, Peru and Ghana 
have reported median patient delays of 20, 57 and 59 days respectively [26, 42, 50] 
which were all said to be unacceptable delays according to the definition of patient 
delay used in these studies. A systematic review and meta-analysis on evidence of delay 
in diagnosis and treatment of TB from 78 countries globally found, among 79 studies 
(524,462 patients) enrolling a median of 234 patients, patient delay ranged from 5 to 
1097 days. The pooled mean patient delay was 81 (95% CI: 70–92) days [34]. For as 
long as people in the community with symptoms of TB do not seek care, those with 
2112 potentially relevant 
titles and abstracts 
 
50 full text articles 
 
 
72 full text articles 
reviewed 
 






22 full text articles added from 





pulmonary TB will continue to be a source of infection to others. There are several 
reasons for which people do not seek care for their TB symptoms and these are 
outlined below: 
 
2.4.1 Poor knowledge/awareness of TB symptoms 
 
Studies have found that poor knowledge or awareness of TB symptoms is a main 
reason for which people do not seek care. A systematic review and meta-analysis 
conducted in China found 17 out of 29 studies reporting lack of knowledge or 
awareness as a factor for which TB patients delayed in seeking care  [51] and a similar 
one conducted in LMICs found seven out of 40 studies reported similar findings [39]. 
TB symptoms are very non-specific, and many diseases present with cough or weight 
loss or both. Therefore, most people do not recognize them as symptoms of TB and 
this often led people to think their symptoms were symptoms of an upper respiratory 
tract infection which will self-resolve [33, 52-55]. Mostly, because people do not 
recognise  their symptoms as TB-related, they self-medicate or seek care from different 
sources such as traditional healers, faith-based healers, pharmacies/drug stores, drug 
peddlers or private clinics which do not provide TB services (non-formal providers) 
instead of government health facilities that provide these services (formal providers) 
[26, 33, 42, 45, 50, 54, 56-60]. Seeking care from non-formal providers often leads to 
patient delay. In Northwest Ethiopia, Asres et al found in East Gojjam zone that due to 
lack of awareness of TB symptoms, more than half (53.4%) of TB patients in their study 
delayed seeking care but rather resorted to traditional medicines [61]. Also, 
Gebreegziabher et al found in West Gojjam zone that TB patients who first consulted 
non- formal providers had a median patient delay of 60 days compared to 14 days for 
those who first consulted formal providers [50]. Other studies have reported that first 
seeking care from non- formal providers led to patient delay [42, 50, 54]. However, 
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when patients felt their symptoms were severe, they visited a health facility because 
they thought their illness was at its terminal stage [59]. 
 
2.4.2 Access to health facilities 
 
One of the reasons for which patients with symptoms of TB delay in seeking health 
care from formal sources is the availability of health facilities and this is mostly a 
challenge for people who live in rural areas. Community members and TB patients in a 
qualitative study conducted in Nepal said most health centres were in areas that were 
not easily accessible [62]. This was particularly because politicians who lobby for these 
health facilities especially in rural areas ask that the facilities are built in their village or 
close to their residence making it difficult for the majority of people to access them 
[62]. They also complained that the geographical nature of the area where most 
villages are located in mountainous areas and where settlements are sparse with uphill 
routes, forested paths towards health centres coupled with the long distance mostly 
discouraged patients from accessing health services. The difficult terrain was further 
complicated by the lack of roads for vehicles and means of public transportation. 
Similarly, a study among pulmonary TB patients in rural Nigeria reported there was 
poor availability of public health facilities and this caused patients to walk more than 
one hour to the nearest public health facility to access care [60]. This caused patients 
in rural areas to resort to non-formal provider [42]. Again, the systematic review on 
delay in diagnosis of pulmonary TB in LMICs also revealed five studies reported long 
travel distance to public health facilities and three studies reported rural residence as 
determinants of patient delay. The reason for this could be that mostly in rural areas 
they have a health post which is the lowest level of care and these facilities do not offer 
TB services so patients have to travel a longer distance to access care from health 
centres or hospital [39]. Several studies also reported long travel distance to the 
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nearest health facility and rural dwelling as risk factors for patient delay in seeking care 
[24, 33, 43, 63, 64]. 
 
Also, as distance to the health facility can result in patient delay, it can also lead to 
unfavourable outcomes for people with the disease. Robsky et al in their retrospective 
cohort study in Uganda among all patients initiating TB treatment in six health facilities 
reported that unfavourable treatment outcomes occurred in 20% of TB patients and 
those living ≥2 km from the facility had increased risk of death compared to those who 
lived <2 km from the facility [65]. Long distance to the health facility could have led to 
delayed diagnosis causing severity of illness and invariably leading to increased risk of 
death as explained in the Ugandan study [65]. 
 
2.4.3 Financial constraints and opportunity cost 
 
 TB is considered as a disease of poverty because it mainly affects poor and 
socially disadvantaged people [39]. In a qualitative study in Peru on social 
determinants underlying TB diagnostic delay among TB patients, it was universally 
agreed that indirect and direct costs associated with healthcare visits often contributed 
to patients' delay in seeking professional care [58]. Even though TB services in Peru 
were free, the anticipated cost of a visit to a hospital often deterred people from 
seeking care from the hospital. Also, most participants admitted they will prioritize 
working over seeking professional medical attention when sick. This is because they 
needed the income to take care of their families. Often because most people in 
resource-constrained settings struggled to maintain sufficient household income, they 
fear seeking care from health facilities because that could lead to repeated visits to the 
hospital which could cause them to lose their job so they prefer to self-medicate [58]. 
This study however excluded extrapulmonary TB (EPTB) patients who were even more 
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likely to incur more cost, due to longer delay in diagnosis resulting in repeated visits, 
than pulmonary TB patients. Similarly, in Nepal, a qualitative study found that although 
attending and accessing health care services was free, indirect costs associated with 
travelling, and opportunity costs relating to household chores or employment, led to 
patient delay [62]. 
 
In Ghana, Osei et al found that patients who were not medically insured were at risk 
of patient delay. People who were poor were those who could not afford medical 
insurance and this mostly discouraged them from seeking prompt medical care for 
their TB symptoms [26]. A lack of medical insurance as a risk factor for patient delay 
was found in Arkhangelsk, Russia where they also reported that out of pocket payment 
for TB services such as liver protection drugs and computerized tomography (CT) scan 
was a reason for which patients did not seek medical care [53]. A systematic review in 
Ethiopia on health-seeking behaviour among presumptive TB patients found lack of 
money as one of the main reasons why patients delay in seeking care from formal health 
providers [66]. Severe socioeconomic hardships and low-income levels have all been 
reported as determinants of patient delay in TB care [24, 64, 67]. Bogale et al in their 
study in Ethiopia found that increased household income was associated with a shorter 




Stigma has been reported to be an important factor in delaying healthcare seeking 
despite decades of public health efforts. In Malawi, a qualitative study found perceived 
TB stigma to be linked with HIV in two forms. Firstly, there was the general community 
belief of TB and HIV coexistence where it is assumed that a person with TB is HIV 
positive leading to stigmatization of TB patients. Secondly, the management for a 
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person diagnosed with TB includes having an HIV test but this caused fear in patients. 
Most patients were afraid of having a positive HIV test result because of the stigma 
associated with it, so they feared to seek care from the hospital for a cough [68]. In the 
systematic review on delayed diagnosis of TB in LMICs, three studies reported stigma 
relating to HIV being associated with TB, and two studies reported on perceived social 
stigma of TB [39]. In Peru, Bonadonna et al reported that TB patients faced 
discrimination within their communities, causing fear among people with cough of a 
possible diagnosis of TB [58] and in North Ethiopia, more than half (59.7%) of TB 
patients who delayed in seeking care had high perceived stigma [59]. Other studies in 
Nepal, Ghana and Ethiopia all reported high TB- associated stigma and for fear of being 
diagnosed with TB, patients with TB- related symptoms did not seek care until their 
symptoms became worse [26, 32, 62]. Stigma, therefore, could cause delay in care 
seeking for patients with symptoms of TB because of the associated stigma relating to 
HIV. This stigma could be individual level stigma or stigma from the  community. 
 
2.5 Health system related factors contributing to delayed or 
missed diagnosis of TB 
 
The health system plays a crucial role in the identification of people with TB and 
initiating them on treatment. However, the organization and quality of health care can 
lead to delayed or missed diagnosis of TB [69]. 
 
2.5.1 Practices of healthcare workers 
 
2.5.1.1 Index of suspicion of TB among healthcare workers 
 
Some studies have shown that the reason why there is delayed or missed diagnosis of 
TB in health facilities is because of the low index of suspicion of the disease among 
HCWs. Several factors account for this and they include: 
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2.5.1.1.1 Clinical presentation of disease 
 
Persons with TB can present with non-specific symptoms thus making it difficult for 
the disease to be easily identified by HCWs. The coexistence of cough with other 
chronic diseases [54, 70], EPTB presenting with a wide range of clinical symptoms [42, 
43], smear negative TB [50, 71, 72], fever and short duration of cough [73] makes it 
difficult for HCWs to recognize these less common presentations of TB and patients 
are often misdiagnosed. These clinical presentations are non-specific since very many 
diseases can result in cough and / or weight loss and therefore might not trigger 
suspicion of TB by HCWs. Such patients are likely to suffer diagnostic delay and may 
need to make repeated visits to the health facility before they finally get diagnosed 
with TB. The non-specific symptoms are one challenge faced by clinicians in high 
income, low TB incidence countries where the absence of respiratory symptoms 
might not trigger a suspicion for TB. Even when patients have respiratory symptoms 
or classical TB symptoms like prolonged cough, they are often not recognized because 
TB is a rare disease in low incidence countries. Therefore, even in low TB incidence 
countries, not all patients with TB get a prompt and rapid diagnosis [46]. 
 
2.5.1.1.2 Type of health facility visited by a patient 
 
Literature has shown that persons with symptoms suggestive of TB who first visit lower 
level public health facilities (primary health centres, clinics or health post) or private 
providers (private clinics, pharmacies/drug stores and traditional healers) might 
experience diagnostic delay compared to those who visit secondary and tertiary level 
health facilities [25, 27, 33, 42, 43, 50]. These studies claim that HCWs at lower levels 
of care are mostly less qualified clinical staff with a low index of suspicion of TB among 
persons presenting with symptoms [25, 27, 33, 42, 43, 50]. Also, clinical staff in private 
health facilities lack adequate knowledge in TB diagnosis and management [56, 60]. 
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Since TB is not suspected in these lower-level facilities and private providers, they 
resort to treatment with antibiotics for upper respiratory tract infections [45, 74, 75]. 
At times, inappropriate antibiotic treatment like the use of fluoroquinolones can 
modify the clinical picture and give patients temporary relief; however 
fluoroquinolones monotherapy in a person with TB may result in acquisition of 
fluoroquinolone-resistant TB [26, 45].   
 
The low index of suspicion leads to a cycle of repeated visits to different care providers 
or at times to the same care provider. This has been demonstrated by a number of 
cross-sectional studies: in India, Ghana, Ethiopia and Mozambique, 50%, 59%, 70% and 
74% respectively of patients taking TB treatment reported that they were diagnosed 
after two or more health visits to a health care provider [26, 42, 54, 74]. Because these 
studies recruited TB patients on treatment, presumptive TB patients who accessed 
care but did not start TB treatment were not studied. Such patients may have made 
more repeated visits to health facilities without being tested. There is a need for 
prospective cohort studies enrolling presumptive TB patients that can directly measure 
the health system delays and factors associated with these delays. The cross- sectional 
designs prevented the investigators from measuring directly the delays caused by 
these multiple visits to different or same health providers. Evidence from Uganda 
showed the median number of  visits before a TB diagnosis was 4 (range:1-30) and 97% 
of study respondents consulted on average two providers before a diagnosis was made 
[76]. Some patients even make as many as five visits to a health facility before being 
diagnosed with TB. This is evidenced by a study conducted in Ethiopia in 2016 among 
296 adults visiting health facilities for TB treatment where they found more than half 
of patients sought care from more than five health care providers  prior to TB diagnosis, 
however, delay in diagnosis was shorter among people who were HIV positive [25]. A 
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study in Iran on diagnostic error found among 158 hospitalized TB patients, 42.3% 
were referred to four or more physicians before a diagnosis of TB was made [77]. These 
multiple visits or referrals may result in high expenditure for patients and cause them 
to drop out of the diagnostic pathway [78]. Therefore, the type of health facility a 
presumptive TB patient accesses care may determine whether they get a TB diagnosis 
and how soon they get the diagnosis. 
 
2.6 Screening for TB symptoms and requesting for sputum test 
by HCWs 
 
The International Standards for TB Care (ISTC), 3rd Edition developed by TB Care 1 and 
endorsed by almost all TB programmes worldwide aims to describe a broadly accepted 
level of care that all public and private sector providers should employ in managing 
patients with symptoms of TB, those who have TB or at increased risk of developing TB 
[79]. The standards that focus on TB diagnosis recommend that all patients with 
unexplained cough lasting two weeks or more should have at least two sputum 
specimens submitted for smear microscopy and be treated if the test result is positive 
for acid-fast bacilli (AFB). This was before the advent of Xpert MTB/RIF because now 
in most places, only one sputum is requested for a TB test. However, several studies 
have shown that HCWs do not adhere to these guidelines. In Zambia, a national TB 
prevalence survey showed only 12.1% of persons with cough of more than two weeks 
reported being asked to do a sputum microscopy test [29]. Other studies including 
prevalence surveys and cross-sectional studies in Uganda, Ghana and Ethiopia showed 
15%, 25% and 44% respectively of persons reporting symptoms of TB did a sputum test 
[32, 33, 80]. The Ghana study was a national TB prevalence survey and comparable 
with the Zambian study in that they both recruited representative sample of the 
general population while the Ugandan and Ethiopian studies were cross-sectional 
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studies that recruited TB patients already on treatment. A limitation with all these 
studies is that they did not differentiate between a patient being asked to do a sputum 
test by a HCW and a patient actually going ahead to do a sputum test. This is because 
a patient could be asked to do a sputum test but due to several factors, they might not 
do the test. It is important to determine if it is the HCWs who are not requesting the 
sputum test or whether patients encounter challenges that prevent them from doing 
the test. These findings will help inform appropriate intervention to reduce diagnostic 
delay. 
 
In South Africa, a pragmatic cluster-randomised trial (the XTEND trial) aimed to 
determine whether replacing microscopy with Xpert as first line test for TB reduced 
six-month mortality among people being investigated for TB. An ancillary study of this 
XTEND trial was designed using exit interviews among patients to determine if the new 
diagnostic method influenced HCWs practice in requesting a sputum test, but findings 
showed only slightly more than a quarter (28.2%) out of 3604 participants self-
reported being asked to do a sputum test after they reported their TB symptoms to a 
HCW [81]. In a second study in South Africa that sought to determine if HCWs asked 
about respiratory symptoms related to TB, among 423 adults exiting health facilities 
with respiratory symptoms, the authors found 21 (5%) were culture-positive for TB. Of 
this 5%, none had sought care at the facility for their respiratory symptoms, none were 
asked about respiratory symptoms during their visit and none were asked to produce 
a sputum sample [82]. The limitation of this study was that there was a high non-
response rate of 62%, possibly introducing selection bias. If the non-responders 
differed significantly from the responders, then that could affect the outcome. Even 
though the non-response rate was high, the study still showed that HCWs screening 
practices of TB-related symptoms was sub-optimal. Yet another study conducted in 
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South Africa in 2015 investigating the number of pulmonary TB patients missed by 
primary health care clinics estimated that the health system missed 62.9– 78.5% of TB 
patients attending primary health clinics for TB-related symptoms and 89.5–100% of 
those attending a clinic for other reasons. This was attributed to low rates of TB 
screening and testing by the health system [83]. However, this study was not able to 
report a response rate because the investigators could not fully account for the number 
of persons eligible for the study and the number of persons who declined to be part of 
the study making it difficult to judge if there were any biases. Several cross-sectional 
and qualitative studies have reported patients with TB not appropriately screened and 
a sputum test not requested for those who are eligible [24, 52, 63, 68, 84, 85]. 
 
The reasons for which HCWs might not screen for symptoms of TB or request a sputum 
test are varied and include: 
2.6.1 Lack of diagnostic facilities 
 
Some health facilities especially at the lower levels of care do not have diagnostic 
facilities for sputum testing and are not able to confirm if a person has TB [33, 42, 71]. 
In addition, in most LMICs, the referral systems for referring symptomatic patients to 
facilities that have diagnostic capacity may not work effectively [51, 86-88] and this 
leads to diagnostic delay. Moreover, the location of most TB diagnostic facilities is 
mostly far from the patient’s residence or community making it difficult for a patient 
to travel to these facilities for a TB diagnosis or to complete follow up diagnostic 
procedures since a TB diagnosis requires more than one visit to the health facility. A 
number of studies have reported distance to the diagnostic facility as a significant 





2.6.2 Inadequate human resources 
 
Qualitative studies among HCWs on barriers they encounter in TB diagnosis have 
shown shortage of human resources can lead to not requesting a sputum test. This is 
because few staff result in high workload especially at outpatient department (OPD) 
of health facilities [53, 68, 90]. This prevents them from properly evaluating patients 
with symptoms suggesting TB and requesting a sputum test [53, 68, 90]. Also, 
shortage of experienced staff and constant turnover of staff might lead to the use of 
less experienced staff who might not screen for cough or request a sputum test [51, 
87, 91-93]. Other studies have shown that the shortage of staff and high workload 
coupled with various activities competing for HCWs attention are some of the 
reasons for not requesting a sputum test [87, 90, 94]. In some instances, inadequate 
staff leading to high workload resulted in poor patient-provider interaction 
causing underassessment of patients for symptoms of TB  [95]. 
 
2.6.3 Fear of infection 
 
In some settings, fear of infection with TB caused some HCWs to neglect presumptive TB 
patients leading to inadequate screening of patients and requesting sputum tests. In 
Malawi, HCWs in a qualitative study said fear of infection at times made some HCWs 
not very approachable, so patients were not comfortable telling them their symptoms 
leading to them not being fully assessed [68]. In Uganda, Ghana and Mozambique, 
qualitative studies found HCWs fear of infection to affect TB diagnosis [93, 96-98]. In 
Mozambique, fear of infection caused HCWs not to want to contact or manage TB 
patients. They neglected TB patients because of stockouts of N95 respirators [93]. In 
Ghana, fear of infection caused HCWs to shun, avoid or maltreat TB or presumptive TB 
patients. There were times when TB patients were wrongly accused of spreading 
infection. HCWs claimed TB patients spat around indiscriminately and started to 
51 
 
cough as soon as they got closer to a HCW with the intention of infecting the staff [98]. 
Cattamanchi et al in Uganda reported that laboratory staff did not want to process 
sputum specimen for testing for fear of getting infected with TB, and that other HCWs 
were deeply concerned about the risk of contracting the disease from their patients 
causing fear of working in the TB wards [97]. In all these studies, HCWs felt it was not 
worth it to risk their lives doing TB-related work since no incentive packages or 
compensation would be given to them if they got infected with TB. 
 
2.7 Laboratory testing for TB 
 
Delays or missed diagnosis of TB can occur at the point of doing the sputum test. 
Literature from both quantitative and qualitative studies have shown factors relating 
to laboratory testing that can cause delay. Some of these factors are: 
2.7.1 Multi-day sputum smear microscopy testing 
 
Per the design of the testing pathway for TB, a patient with symptoms suggestive of 
TB may be required to make at least two visits to the laboratory to have a sputum test 
done. In some health facilities, a patient needs to visit the laboratory to produce a spot 
sputum specimen and return the following day with an early morning specimen before 
they can receive a test result. In some instances, they might need to make a third visit 
for their test result. The need for multiple visits can lead to loss to follow-up [97, 99]. 
Patients might be too weak or may not have money for transportation to return to 
complete this testing pathway and initiate treatment for those with a positive test 
result. Chandra et al in their study in India suggested the use of two spot sputum 
specimen for smear microscopy on the same day to reduce patients failing to return to 





2.7.2 Sensitivity of the diagnostic method 
 
In most LMICs, sputum smear microscopy is still the main diagnostic method for TB. 
This technique is known to have a low sensitivity and can lead to false negative results 
especially in patients with HIV [91, 101]. The inability of this technique to confirm TB 
in patients with symptoms can lead to delayed or missed diagnosis. In view of the low 
sensitivity of sputum smear microscopy, Xpert MTB/RIF was introduced and it has a 
higher sensitivity [102] and a shorter turn-around-time [103] compared to smear 
microscopy. The use of Xpert MTB/RIF is intended to reduce missed diagnosis and 
improve TB case detection. Several studies have shown that Xpert MTB/RIF is a robust, 
sensitive and specific test for accurate diagnosis of TB as compared to conventional 
tests like sputum smear microscopy [104-108]. A systematic review conducted in 2014 
on Xpert MTB/RIF assay for pulmonary TB and rifampicin resistance in adults had 
among other objectives to assess the diagnostic accuracy of Xpert MTB/RIF for 
pulmonary TB detection, where Xpert MTB/RIF was used as both an initial test replacing 
microscopy and an add-on test following a negative sputum smear microscopy result 
[109]. The review included 27 studies involving 9557 participants. Sixteen studies (59%) 
were conducted in LMICs. The authors found that as an initial test replacing sputum 
smear microscopy, Xpert MTB/RIF pooled sensitivity was 89% [95% credible interval 
(CrI) 85% to 92%] and pooled specificity 99% (95% CrI 98% to 99%). As an add-on test 
following a negative smear microscopy result, Xpert MTB/RIF pooled sensitivity was 
67% (95% CrI 60% to 74%) and pooled specificity 99% (95% CrI 98% to 99%). They also 
found that in comparison with sputum smear microscopy, Xpert MTB/RIF increased TB 
detection among culture-confirmed cases by 23% (95% CrI 15% to 32%). In addition, 
the authors reported that if pooled sensitivity estimates for Xpert MTB/RIF and smear 
microscopy were applied to a hypothetical cohort of 1000 patients where 10% of those 
with symptoms had TB, Xpert MTB/RIF would diagnose 88 cases and miss 12 cases, 
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whereas sputum smear microscopy would diagnose 65 cases and miss 35 cases  [109]. 
 
Studies have also evaluated the effect of using Xpert MTB/RIF on time to TB treatment 
initiation compared to smear microscopy. Auld et at conducted a narrative review of 
Xpert impact trials to summarize which patient-relevant outcomes Xpert had improved 
and explore reasons for no observed morbidity or mortality reductions [110]. Eight 
trials were included in the review, of which six were from sub-Saharan Africa, one 
from Brazil, and one from Indonesia. All eight trials were conducted in routine 
healthcare settings, with the potential for existing programmatic weaknesses to 
impact trial outcomes. The authors reported that in six of the eight trials, Xpert 
achieved higher diagnostic yield than microscopy and in these six trials, compared with 
microscopy, Xpert increased TB diagnostic yield by a factor of about 1.2-3.0. Four of 
the eight trials reported time from sample collection to result availability among drug-
sensitive TB positive patients, and they found Xpert reduced this time in three trials (0-
2 days for Xpert compared to 0-12 days for smear microscopy). Also, six trials reported 
median time from enrollment or sputum collection to TB treatment initiation among 
all patients who started TB treatment, regardless of reason for starting TB treatment; 
in four of the six trials there was either strong or weak evidence that the median time 
to treatment was shorter in the Xpert than microscopy arms. In these four trials, Xpert 
reduced median time to TB treatment by about 1 day in two of the trials, 3.3 days in 
one trial and 4 days in the other trial. However, reduction in time to treatment 
initiation might not necessarily influence treatment outcome as factors such as 
adherence to treatment also play a role. In addition, of two trials reporting the 
percentage of bacteriologically confirmed TB patients lost to follow-up before TB 
treatment initiation, one trial reported lower loss to follow-up in the Xpert arm (15 vs 
8%, p=0.03). However, among five trials that reported incidence of unfavourable 
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outcomes following TB treatment initiation, the percentage with unfavourable TB 
treatment outcomes was similar between microscopy and Xpert arms  [110]. 
 
The literature has shown that Xpert MTB/RIF has advanced TB diagnostic capability 
compared to smear microscopy. In some settings it has reduced time to treatment 
initiation, and it has also reduced pre-treatment loss to follow-up. However, Xpert has 
not yet demonstrated impact on reductions in patient morbidity and mortality as 
evidenced in recent trials. 
 
2.7.3 Laboratory turnaround times 
 
Several factors affect laboratory turnaround times and these include irregular supply 
of reagents and availability of technical staff to perform the test. The irregular supply 
of laboratory reagents in some health facilities for sputum testing can lead to delay in 
diagnosis [90, 91, 97, 103]. This is because patients might send their sputum sample to 
the laboratory but due to lack of reagents, the test cannot be performed. The patient 
might need to wait till reagents are supplied then they can return to the laboratory for 
the test to be done. Also, in some health facilities there are few trained technical staff 
who can perform smear microscopy test [62, 87, 91]. Therefore, when these staff are 
not around, then the test cannot be done and patients with a request for sputum 
testing will have to wait till staff are available to perform the test. These factors may 
result in loss to follow-up since some patients might not return to have the test done. 
If such patients turn out to have TB, then they will continue transmitting the disease 






2.8 Receiving test results 
 
In the TB testing pathway, usually patients are required to visit the health facility for a 
second or third time to receive a test result after submitting sputum for the test [85]. 
In Uganda, a cross sectional study among 392 patients showed a quarter (25.5%) of 
patients received test results after 3-5 working days while the national standard 
operating procedure states results should be reported within 24 hours  [96]. 
 
When a test result is positive for TB, the patient is referred to the TB treatment centre 
to commence treatment but if the result is negative, there should be some follow up 
tests. According to the International standards for tuberculosis care, a patient with 
smear negative result should be treated with broad spectrum antimicrobials and if 
there is no Improvement, the sputum microscopy test should be repeated. If the result 
is still negative, then a chest radiograph should be taken and a physician should make 
a judgement to either treat for TB or not [79]. In South Africa, a study evaluating 
adherence to TB diagnostic algorithms in primary health clinics for people with a 
negative test result as part of the XTEND trial showed that of 4,037 patients with a 
negative test result, 2,155 (53%) were HIV positive and 540 (13%) had unknown HIV 
status. Among HIV-positive patients, after 6 months of the index negative result, only 
507 (24%) had evidence of further investigation, while among those with unknown HIV 
status, there was no evidence of further investigation found in clinic records. This 
proved a lack of adherence to diagnostic algorithms which could lead to high mortality 
[111]. Other studies have shown that smear negative result was a determinant of 






2.9 Initiating TB treatment 
 
The final steps in the TB care cascade are initiating persons confirmed to have TB on 
treatment and ensuring they complete treatment. Delays or pre-treatment loss to 
follow-up do occur at this point just like the other steps in the care cascade. TB patients 
may be ‘lost’ after diagnosis and before treatment initiation. This is called initial or pre-
treatment loss to follow-up [113]. A systematic review and meta-analysis of pre-
treatment loss to follow-up in TB patients in LMICs and high-burden countries, that 
included 23 studies from 14 countries, reported a pre- treatment loss to follow-up 
range of 4 to 38%  [114]. This was common in studies from Africa and Asia. One study 
that reported minimal delays in treatment initiation was a retrospective, descriptive 
cohort study using routinely collected programmatic data from TB registers in 
Pakistan, where the authors reported that among 152 diagnosed TB patients, 66% 
initiated TB treatment on the day of TB diagnosis or the next day and a further 34% 
initiated TB treatment within a mean time of 7 days  [115].  
 
However, other retrospective cohort studies have reported high pre-treatment loss to 
follow- up proportions [116, 117]. A cohort study using secondary programme data 
was conducted in Zimbabwe to quantify and assess trends and risk factors for loss to 
follow-up and delays before treatment initiation among bacteriologically-confirmed 
pulmonary TB patients in 2012–16 [118]. The study reported that, of 2443 TB patients, 
508 (20.8%) were lost to follow-up after being diagnosed with TB and this included 252 
(10.3%) deaths. The mean delay from sputum receipt at the laboratory to testing was 
2.7 days and from testing to result dispatch was 8.8 days. Among 1935 patients 
registered for TB treatment, the mean delay was 29.1 days. This study revealed a 





In qualitative studies, HCWs have suggested some reasons for delays or pre-treatment 
loss to follow-up. They mentioned that, at times, results being transferred from the 
laboratory to the TB clinic go missing in transit [99]. When this happens, nurses at the 
TB clinic are not able to initiate treatment and patients might need to go back to the 
laboratory for a copy of the results before they initiate treatment. This was reported by 
Bulage et al in a qualitative study among 20 HCWs conducted in a rural district in Uganda 
[96]. Some HCWs also said the inability of patients to keep clinic appointments is a cause 
for delay in initiating treatment [96]. Though the staff at the TB clinic might have 
received a positive test result from the laboratory, the affected patient might not turn 
up on their appointment date and treatment cannot be initiated. At times too, delays 
are due to shortage of anti-TB drugs at the health facility [25, 73, 95] so patients are 
forced to wait till the drugs are available before they start treatment. In peripheral 
health facilities where they lack HCWs, irregular attendance of HCWs from other 
facilities from time to time to support, often led to inadequate counselling and poor 
adherence to treatment [62]. Delays or pre-treatment loss to follow-up leads to 




Review of literature has shown that delayed or missed diagnosis of TB occurs at different 
points in the diagnostic pathway. Figure 2.3 provides a summary of factors that are 
associated with delayed or missed diagnosis of TB. A combination of patient and health 
system related factors are associated with delay in the pre-diagnostic stage of the 
pathway. The low sensitivity of the diagnostic method and inadequate laboratory staff 
are causes of delay in the diagnostic stage of the pathway while inadequate staff at 
peripheral health facilities to initiate TB treatment is a cause of delay in the treatment 
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stage of the pathway. 
 
Few studies have looked at the entire diagnostic pathway to identify points at which 
these delays occur and why they occur. Of studies that look at the care cascade, many of 
these studies enrolled only people on TB treatment thus not exploring the experiences 
of people with TB symptoms who never started treatment. Also, many of these studies 
were cross-sectional rather than cohort so again not allowing any opportunity to trace 
people who were lost from the system. Thus, this PhD attempted to address these gaps 
by looking at various steps in the TB care pathway with focus on the steps in the health 
facility prior to a sputum being submitted to the laboratory for testing to identify points 
at which diagnosis can be delayed or missed using more robust study methods. 
 
Figure 2. 4: Summary of factors that can cause delayed or missed diagnosis 







Table 2.2 is a summary of 18 studies on health systems delay in TB diagnosis selected 
from the 72 papers reviewed based on their definition of health systems delay being 
first contact with a public or private health facility to diagnosis of TB or initiation of TB 
treatment. 
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Type of facility Important findings Comments 
   Adejumo et al, Nigeria, 2016  
[56] 
TB patients 
aged >14 years 
Cross-sectional study, 
470 
DOTS facilities Median HSD in public DOTS facilities was 14 days and 
12.5 days in private DOTS facilities. TB patients who 
first visited a non-hospital facility were over four times 
more likely (odds ratio 4.12; 95% confidence interval 
2.25–7.54) to have prolonged HSD than those who first 
visited the government hospital. 
Use of cross-sectional design and recruiting TB 
patients already on treatment implies those who 
never started treatment were not studied. 
Participants from private DOTS facilities could 
differ in characteristics from those in public 
DOTS facilities and could introduce bias 
    Adenager et al, Ethiopia, 2017 
[32] 
PTB patients 
aged ≥15 years 
Cross-sectional study, 
425 





Median HSD was 9 days and 54.8% experienced HSD. 
Hemoptysis and being unemployed were less likely to 
experience HSD 
Use of cross-sectional design and recruiting TB 
patients implies those who never started 
treatment were not studied. Participants from 
private DOTS facilities could differ in 
characteristics from those in public DOTS 
facilities and could introduce bias 
    Belay et al, Ethiopia, 2012 
[42] 
TB patients 
aged ≥18 years 
Cross-sectional study, 
216 
1 hospital and 1 
health centre 
Median HSD was 33.5 days. Extra-pulmonary TB (aOR. 
2.08, CI 1.08- 4.04), and first visit to health 
posts/clinics (aOR. 19.70, CI 6.18-62.79), health 
centres (aOR. 4.83, CI 2.23-10.43) and private health 
facilities (aOR. 2.49, CI 1.07-5.84) were found to be 
independent predictors 
of HSD 
The authors did not report on the number of 
health facilities in the study area out of which 
they chose two for the study but mentioned 
security threats in the area as the reason for not 
including more health facilities. This may affect 
the representativeness of the study findings 
Belkina et al, Uzbekistan, 2014 
[45] 
PTB patients 







hospitals and 1 
dispensary 
Median HSD was 7 days. Prescribed with OR: 2.19 (95% 
CI: 1.18 to 4.09) and visiting a private clinic OR: 2.87 
(95% CI: 1.83 to 4.54) were predictors of HSD 
Use of cross-sectional design and recruiting TB 
patients already on treatment implies those who 
never started treatment were not studied 
   Bogale et al, Ethiopia, 2017 
[25] 
TB patients 





Median HSD was 5 days (IQR = 4–7). Seeking care from 
>1 health care provider (β: 0.28, 95% CI: 0.23, 0.34) 
and seeking initial care from primary level health care 
facilities (β: 0.10, 95% CI: 0.07, 0.13) were positively 
associated with HSD. 
The use of cross-sectional design and patients 
already on treatment could have introduced 
recall bias since patients might not remember 
the exact date of symptoms onset and first visit 
to a public health facility 




patients aged ≥ 
16 years. China: 
smear positive 






designated TB clinic 
Median HSD were 12 and 11.5 days (p>0.05) in Malawi 
and China, respectively. Initial healthcare visits at 
village level led to longer HSD in both Malawi 
(aOR=2.055, 1.211–3.487) and China (aOR=5.627, 
2.218–14.276). 
Conducting the study in a LMIC and a HIC both 
with high TB burdens to share experience 
and lessons on TB case detection was relevant 
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Ebrahimi et al, Iran, 2018  
[52] 
TB patients 






Median HSD was 53 days. Factors associated with HSD 
were: ≥ 3 vs. < 3 visits to health facilities before correct 
diagnosis (OR = 9.44, 95% CI: 4.50 to 19.82), without 
vs. with access to TB diagnostic services (OR = 3.56, 
95% CI: 1.85 to 6.83), and misdiagnosis as cold or viral 
infection vs. not (OR = 2.62, 95% CI: 1.40 to 4.91). 
The presence of only one dedicated Tuberculosis 
and Lung Diseases Research Centre could have 
contributed to long HSD because all other 
facilities had to refer presumptive TB patients 
there for diagnosis and treatment 
Ekinci et al, Turkey, 2014  
[63] 
PTB patients 
aged ≥15 years 
(Group 1: smear 
negative and 




1 Hospital The median HSD was 41 days in group 1 and 16 days in 
group 2 (P < 0.0001). A low index of suspicion for TB by 
physicians and underutilized or delayed sputum 
examinations for acid-fast smears were the most 
common reason for doctor's delay. 
Separating smear positives and smear negatives 
patients was a good way to measure delay since 
the experiences might not be the same 
Gebreegziabher et al, Ethiopia, 
2016 [50] 
PTB patients 
aged ≥15 years 
Cross-sectional study, 
706 
30 Public health 
facilities 
Median HSD was 22 days (IQR: 4–88 days). Smear- 
negative TB (aOR, 1.88; 95 % CI, 1.32–2.68) and first 
visit to public health centres (aOR, 2.22; 95 % CI, 1.52– 
3.25) and health posts (aOR, 5.86; 95 % CI, 1.40–24.39) 
were found to be independent predictors of HSD. 
The inclusion of both smear negative and smear 
positive patients was useful in determining delay 
and factors associated with delay, but the use of 
a cross-sectional study design could have 
introduced some recall bias 










Median HSD was 15 days. Almost 30% of TB patients 
remained undiagnosed for more than 30 days after the 
initial health care visit. Female patients (p = 0.008), 
patients with a negative sputum smear (p = 0.003) and 
patients having symptoms other than the usual ones 
(0.037) were associated with HSD. 
Use of cross-sectional design and recruiting TB 
patients already on treatment implies those who 
never started treatment were not studied 
Kansiime et al, Uganda, 2013 
[73] 
PTB patients 
aged ≥18 years 
Cross-sectional study, 
266 
1 Referral hospital Median HSD was 9 days (IQR=8-19). 65.4% experienced 
HSD. Factors associated with HSD were: 1n-patient 
(OR= 4.68, 95% CI: 1.91-11.45), secondary as highest 
level of education attained (OR= 3.56, 95% CI: 1.18- 
10.74), primary as highest level of education attained 
(OR= 6.70, 95% CI: 2.13-21.02), presence of fever (OR= 
3.28, 95% CI: 1.05-10.79), and patient delay at health 
facility (OR= 5.01, 95% CI: 1.33-18.9). 
The inclusion of only one referral hospital in the 
study could possibly affect the generalizability of 
the study findings 
Osei et al, Ghana, 2015  
[26] 
TB patients 
aged ≥15 years 
Cross-sectional study, 
73 
1 Hospital Median HSD was 45 days (IQR: 38–128). Multiple 
healthcare contact following signs and symptoms (aOR 
= 10.26; 95 %CI: 2.95–35.72; P < 0.0001) was 
associated with prolonged HSD. 
The relatively small sample size makes it difficult 
to draw conclusions from the findings 
Peri et al, Italy, 2018  
[46] 
TB patients 
aged >18 years 
Cross-sectional study, 
137 
7 Referral hospitals Median HSD was 31 days (IQR: 7.25–85) Extra- 
pulmonary TB (OR 4.3; 95% CI 1.4–13.8) and first 
contact with general practitioner (OR 5.1; 95% CI 1.8– 
14.5) were independently associated with higher risk 
of HSD > 10 weeks. 
The exclusion from enrolment of patients due to 
language barriers and inability to sign informed 
consent could imply selection bias 
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Saifodine et al, Mozambique, 
2013  [54] 
PTB patients 
aged ≥18 years 
Cross-sectional study, 
622 
5 TB clinics Median HSD was 62 days (37–120). More than two 
visits to a health facility, farming and coexistence of a 
chronic disease were associated with increased HSD. 
Use of cross-sectional design and recruiting TB 
patients already on treatment implies those who 
never started treatment were not studied but 
the inclusion of both smear positive and smear 
negative patients made it relevant to measure 
delay and associated factors for these different 
groups 
Seid et al, Ethiopia, 2018  
[64] 
TB patients 





Median HSD was 6 (IQR: 4, 8) days. Initial visit to 
general practitioners (aOR: 2.57; 95% CI: 1.43–4.63) 
and >1 health care visit (aOR: 2.12; 95% CI: 1.30–3.46) 
were independent predictors of HSD. 
The use of the median value as cut-off for delay 
may limit comparability of study findings with 
national and international expected delay 
periods of TB control programme 
Shiferaw et al, Ethiopia, 2019  
[24] 




Mean HSD was 33.3 days (range: 1-51weeks). Average 
repeated visits to health facility was 3 times (SD+1.9). 
56% of patients asked about TB-related symptoms at 
first health facility visit. 47% of patients not asked to 
submit sputum at first health facility visit 
The aim of the study was to assess delay in TB 
diagnosis among patients taking TB treatment 
and the delay included both patient and health 
system delay and factors associated with these 
delays. Apart from descriptive findings on some 
health system factors, no associated factors for 
HSD were shown except for patient delay 
Yang et al, China, 2019 
[27] 
All TB patients Cross-sectional study, 
1342 
TB clinics 23.6% TB patients experienced delay in diagnosis. The 
time to reach a township hospital or the facility of a 
patient’s first consultation was significantly associated 
with delays in diagnosis. 
No mean or median HSD was reported and the 
use of cross-sectional design and recruiting TB 
patients already on treatment implies those who 
never started treatment were not studied 
Yimer et al, Ethiopia, 2014 
[43] 
TB patients 
aged >15 years 
Cross-sectional study, 
201 
1 Referral hospital Median HSD was 27 days (IQR 8-60). Patients who first 
visited health centres [(aOR) 5.1; 95% (CI 2.1, 12.5)], 
private facilities [(aOR) 3.5; 95% (CI 1.3, 9.7] and health 
posts [(aOR) 109; 95% (CI 12, 958], were more likely to 
experience an increase in HSD compared to those who 
visited hospitals. 
The use of only referral hospital may affect the 
representativeness of the findings 
HSD= health system delay, DOTS= directly observed treatment short course, TB= tuberculosis, OR= odds ratio, aOR= adjusted odds ratio, CI= confidence interval, 
IQR= interquartile range, SD= standard deviation 
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Chapter 3: Methods 
This chapter provides an overview of the different methodologies used in this thesis. 
It gives details of the study area, study designs, data collection, data handling, data 
analysis and ethics. Further details of each methodology used to answer each of the 
objectives are described in the research papers (chapters 5, 6 and 7 of this thesis). 
 
3.1 Overview of methods 
 
The thesis applied a mixed-method research commonly defined as research that 
focuses on collecting, analysing, and mixing both quantitative and qualitative data in a 
single study or a series of studies [121]. The reason for employing this type of research 
was that it could address the study research questions more comprehensively than 
using either quantitative or qualitative methods alone [121]. The use of both 
quantitative and qualitative methods provided a more complete analysis, and they 
complement each other where the quantitative results were explained in more detail 
through the qualitative data [122]. Even though some researchers argue that it is 
neither possible nor desirable to combine quantitative and qualitative methods in a 
study as they represent essentially different and conflicting ways of viewing the world 
and how we collect information about it, others too believe that concerns about the 
incommensurability of world views can be set aside if the combination of quantitative 
and qualitative methods addresses the research question effectively [123]. In health 
systems research, many of the areas explored are complex and multifaceted, therefore, 
combining quantitative and qualitative methods to address a research question is a 
useful way of addressing these complexities [124].  
 
The mixed-methods design employed was a convergent parallel design where data 
were collected parallelly from quantitative and qualitative components in a single 
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phase and the results from both components were considered together in the 
discussion for the purpose of corroboration and validation [121]. In this design, 
quantitative data were collected using a prospective cohort study and a cross-sectional 
study among patients; the qualitative data were collected using clinic observations and 
in-depth interviews with HCWs. The data collected from the different components 
were analysed separately and independently from each other using quantitative and 
qualitative analytic procedures. The results were then combined in the discussion and 
interpreted to provide a more complete understanding of gaps in the pathway to TB 
diagnosis in health facilities [121]. The rational for this approach was to obtain 
different but complementary data on steps in the diagnostic pathway where 
presumptive TB patients are missed and the barriers within the health system that 
could account for this, in order to create a better understanding of gaps in the pathway 
[125]. 
 
3.2 Study setting 
 
The study was conducted in Ketu South Municipality of the Volta region of Ghana. It is 
one of the 25 administrative districts/municipalities in the Volta region with a 
population of 202,406 based on extrapolation from the 2010 population census. It is 
located in the south-eastern part of Ghana and shares boundaries with the Republic of 
Togo to the east, Ketu North district to the north, Keta municipal to the south-west and 
the Gulf of Guinea to the south. The main occupations are fishing and trading with 
majority of the inhabitants being traditional worshippers and Christians. The 
municipality has six health demarcated sub-municipalities with one government 
hospital, four private hospitals, two private clinics, eight health centres and 14 
Community Health Planning Services (CHPS) compounds which are the lowest level of 
care [126]. Community Health Planning Services compounds are community-based 
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health service delivery points. The primary focus is communities in deprived sub-
districts and bringing health services close to the communities  [127]. 
 
With reference to TB diagnosis and treatment, there is only one TB diagnostic 
laboratory at the municipal hospital. At the time of planning the study in 2017, the 
main diagnostic method for TB was sputum smear microscopy but by the time we 
started the study in 2018, the main diagnostic method was Xpert MTB/RIF (Cepheid, 
Sunnyvale CA, USA). There is also one TB treatment centre (chest clinic) located at the 
municipal hospital. All other health facilities in the municipality refer patients with 
symptoms of TB to the municipal hospital for testing. Also, all patients diagnosed as 
having TB receive their treatment from the hospital and they make monthly visits to 
the hospital to collect their drugs. Supervision of treatment is by a treatment 
supporter (a person chosen by the patient whom they trust) at the community level. 
 
The research was conducted in the municipal hospital, which has a co-located 
laboratory, in an urban area, and four health centres without a laboratory, in rural 
areas. The health centres were located about 10-20 km from the municipal hospital 
and the mode of transportation between the health centres and the hospital was 
mainly by public buses, taxis or commercial motorbikes. Figure 3.1 shows the 
















3.3 Initial health facility assessment 
 
Initially, the study was planned to be conducted in the municipal hospital and one rural 
health facility. In order to familiarize myself with the study facilities and to find out the 
type of TB services offered; an initial site visit to the municipal hospital and selected 
health centre was made before the commencement of the study. This initial site visit 
led to a protocol amendment to include three additional rural health centres for the 
study. After the approval by the ethics committees for the inclusion of the three 
additional rural health centres, site visits were made to these additional facilities before 
the commencement of the study. The findings of this assessment are described in 
chapter 4 of this thesis. 
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3.4 Study components 
 
The study comprised of three components using different methods to investigate the 
various aspects of the diagnostic pathway. Two of the components used quantitative 
methods while the third component used qualitative methods. As stated earlier, details 
of methods used in the different components are described in result chapters 5, 6 and 
7 of this thesis. 
 
The first component was a cross-sectional study using exit interviews and addressed 
objective 1 which was to determine the proportion of health facility attendees eligible 
for sputum test according to national guidelines who were asked to do a sputum test 
by HCW, and the prevalence of having sputum positive on Xpert MTB/RIF among 
health facility attendees who met study criteria for having a sputum test. This was 
conducted among patients exiting the health facility after seeking care for their own 
health and reported at least one TB-related symptom to the study team. A 
standardized questionnaire was used to collect information from patients who 
consented to take part in the study. 
 
The second component was a prospective observational cohort study addressing 
objectives 2 and 3 which were to determine the proportion of patients with a request 
for sputum test who submitted a sputum for testing, the time from test request to 
submitting sputum, and factors contributing to non-submission of sputum for testing; 
and to compare the time from test request to submitting sputum among patients 
attending a health facility with vs. without a co-located laboratory. The study 
participants were patients presumed to have TB by a HCW and given a request for a 
sputum test as part of routine care. At enrolment, participants were interviewed using 
a standardized questionnaire. Participants were followed up for two months using 
68 
 
two-weekly phone calls or for those who had no telephone contact, a home visit was 
made once every month for the duration of follow up to find out if sputum had been 
submitted. The use of mobile phones for follow up for participants was inspired by my 
primary supervisor’s experience of high loss to follow-up by two months after 
enrolment among people being investigated for TB if no contact calls were made and 
using mobile phones for follow ups in a previous randomized control trials evaluating 
the effectiveness of Xpert MTB/RIF in South Africa. Moreover, ownership of mobile 
phones in Ghana was about 80% [128] so it was a more convenient and cost-effective 
way to follow up on participants. 
 
The third component was a qualitative study using clinic observations and in-depth 
interviews addressing objective 4 which was to explore HCWs’ perspectives concerning 
barriers to TB case finding in health facilities, their experiences, practices and 
suggested solutions for improvement. Participants interviewed were HCWs involved in 
TB case finding at both urban and rural health facilities. Participants were interviewed 
using an interview guide and clinic observations were conducted at OPDs of the health 
facilities using a check list. 
 
 
Figure 3.2 shows the TB diagnostic cascade and the steps covered by each component 
of the study. 
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3.5 Data collection and management 
 
Data collection started in May 2018 and ended in January 2019. Six research assistants 
who were first degree holders in Public Health were recruited and trained for two 
weeks on all the study tools prior to commencement of the study. Clinic observations 
were the first to be conducted from May 9 to May 18, 2018 (figure 3.3) and this was 
done by myself and another colleague from the School of Public Health, University of 
Health and Allied Sciences in Hohoe, Ghana. Clinic observations were conducted first 
to ensure that the introduction of the other components of the study did not influence 
HCWs’ practices in screening for symptoms of TB and requesting for a sputum test. On 
21st May 2018, the TB-symptom screening tool was introduced to HCWs who attend 
to patients in the consulting room of the study rural health facilities. The prospective 
cohort study was then rolled out on May 28th because it had an element of follow-up 
of study participants and required more time. The cross-sectional study was the third 
to be rolled out and this was followed by the in-depth interviews with HCWs (figure 
3.3). Most of the HCWs interviewed from rural health facilities were the ones the TB-
symptom screening tool was introduced to at the beginning phase of the project. 
 
All quantitative data were collected electronically using open data kit (ODK). 
Questionnaires for the quantitative data were piloted prior to commencement of the 
study. Data generated were stored on a secure server hosted by the London School of 
Hygiene & Tropical Medicine. Daily, data collected were checked for inconsistencies 
and missing data before uploading onto the server. Dashboards in Microsoft (MS) Excel 
were created for both the cross-sectional study and prospective cohort study to enable 
tracking of the numbers being recruited. To ensure data security, all study tablets were 
password protected and were stored in locked cabinets in an office at the municipal 
hospital during the period of data collection. 
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A check list was used for clinic observations and observations were done in the OPD of 
all the study health facilities including the laboratory and chest clinic of the municipal 
hospital. Findings from the clinic observations were used to modify the in-depth 
interview guide to seek explanation from HCWs on some findings during the 
observations. In-depth interviews were conducted in the health facilities and at times 
that were convenient for the HCWs. All interviews were audio-recorded. The audio 
records were stored in a locked cabinet to ensure data security. 
 
Data from the quantitative components were intended to quantify progress through 
and losses from different components of the patient pathway. The quantitative data 
were used to inform questions that were asked during in-depth interviews with HCWs. 
Likewise, data from the qualitative component was intended to provide a more 
complete understanding of findings from the cross-sectional study on TB symptom 
screening and sputum test requesting practices of HCWs. The qualitative data was also 
to provide understanding of health system factors that could prevent presumptive TB 
patients who have been asked to submit a sputum for TB testing from submitting 
sputum.  The qualitative data was then triangulated with the quantitative data in 
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In qualitative research, researchers need to increasingly focus on self-knowledge and 
sensitivity; better understand the role of the self in the creation of knowledge; 
carefully self-monitor the impact of their biases, beliefs, and personal experiences on 
their research; and maintain the balance between the personal and the universal 
[129]. In this regard, during the research process, I was continually reflective and 
ensuring that my presence during data collection and as facilitator of in-depth 
interviews did not influence responses given by the HCWs, but this could not be entirely 
eliminated. The type of relationship I had with the HCWs formed an important 
component of the study. Prior to conducting the in-depth interviews with HCWs, I had 
been living in the municipality for seven months conducting the other components of 
this PhD study in the selected health facilities. Therefore, by the time the in-depth 
interviews were conducted, the HCWs were familiar with me and used to seeing me in 
the health facilities on a daily basis. Also, as a Ghanaian woman who was familiar with 
the culture of the people and could converse with them in the local dialects made me 
acceptable and made it easy for me to develop rapport with HCWs. Participants were 
therefore comfortable talking to me about their experiences. I was mostly seen as a 
researcher from the London School of Hygiene & Tropical Medicine and not seen as a 
representative of the NTP or the Ghana Health Service who was there to find faults 
with their work, so participants felt relaxed and talked openly during interviews. 
However, it is still possible they modified some responses because I was an outsider. 
Moreover, as a former biomedical laboratory scientist who had worked in a TB 
laboratory in a regional hospital setting in Ghana, I could easily relate with some of the 
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issues on TB case finding raised by the HCWs during the interviews. This previous 
experience, coupled with what HCWs said, at times influenced the follow-up questions 
I asked during the interviews. 
 
Once  HCWs had the sense that I could relate with what they were saying, they became 
more open and shared their experiences. However, I was continuously reflexive about 
how my identity as a middle-aged woman doing a PhD and interviewing HCWs who 
were mostly younger than me could influence the data produced. This is because 
culturally, a woman studying for a higher degree is perceived to be very intelligent and 
this could have made participants conscious of how they expressed themselves. In 
addition, I recognise that my experience with previously working in a hospital setting 
and my views on how HCWs should conduct TB case finding in health facilities could 
influence the data collection, analysis, and interpretation. 
 
3.6 Data analysis 
 
Descriptive analysis, univariable and multivariable analysis using logistic regression 
were conducted for the quantitative data. In addition causal effect was assessed for 
the prospective cohort study data. Quantitative data were analysed using STATA v15 
(Stata Corp, College Station TX, USA). All qualitative data were analysed manually. 
Clinic observations were summarized in MS Excel and used to describe the flow of 
presumptive TB patients in the health facilities and practices of HCWs. Audio-
recordings were transcribed and analysed to generate themes relating to barriers in 
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3.7 Ethical Considerations 
 
The study received approval from the Ghana Health Service Ethics Review Committee 
(GHS- ERC:003/09/17) and the Ethics Committee of the London School of Hygiene & 
Tropical Medicine (LSHTM Ethics Ref: 14504).  Permission to conduct the study in the 
health facilities was obtained from the regional and municipal health directorates. 
Written informed consent was obtained from literate participants and for those who 
could not read and write, consent was documented with a thumbprint in the presence 
of a literate  witness. 
 
Table 3.1 provides a summary of study objectives, methods used and expected outcomes. 
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2. To determine the proportion 
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sputum test who submitted a 
sputum for testing, the time from 
test request to submitting 
sputum, and factors contributing 
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Chapter 4: Situation assessment at health facilities 
This chapter describes the findings of the situation assessment on TB case finding at 
health facilities prior to the commencement of the study. 
 
4.1 Municipal hospital 
 
At the municipal hospital, we were introduced to the senior hospital administrator by 
the municipal director of health services.  After explaining our mission, he in turn 
introduced us to the in-charge of the TB unit (chest clinic) with whom we had the 
discussion. 
 
All TB services were provided at the hospital and these included screening of patients 
for TB- related symptoms, requesting of sputum test, laboratory testing of sputum 
specimen using Xpert MTB/RIF and providing treatment for all diagnosed TB patients. 
The in-charge explained that there was a designated HCW at the OPD called the task-
shifting officer whose duty was to screen patients for TB-related symptoms and request 
for a sputum test if patient was eligible for the test. In addition to the task-shifting 
officer, all other HCWs in all departments of the hospital also screened patients for TB-
related symptoms and requested for a sputum test when necessary. All TB care activities 
were provided according to the national  guidelines. 
 
4.2 Initial rural health centre selected for study 
 
At the initial health centre selected for the study, we met with the in-charge of the 
facility and through the discussions, we found that no TB services were provided in the 
facility even though according to the national guidelines they were supposed to screen 
patients for TB-related symptoms and request for a sputum test if patient was eligible. 
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The in-charge explained that the facility’s laboratory was only used to run test for 
malaria, haemoglobin and blood sugar levels and the laboratory had no capacity for 
sputum testing for TB.  She mentioned that since she took over as the in-charge and 
clinician of the facility about a year ago, she had not referred any patient to the 
municipal hospital for TB testing and the reason was that she had not presumed TB in 
any patient to warrant referral to the municipal hospital. 
 
4.3 Initial actions taken by the study team 
 
After the discussions with the in-charge of the health facility, it was apparent that we 
needed to include other rural health facilities in the study to be able to recruit the 
required number of participants (patients routinely asked by a HCW to submit sputum 
for a TB test) for the prospective cohort study from rural health facilities. After 
consultations with the municipal director of health services and the municipal TB 
coordinator, six rural health centres were suggested, and the study team selected 
three based on high OPD attendance, representativeness of the sub-municipalities and 
being in rural areas of the municipality. A request for protocol amendment was 
submitted to the Ghana Health Service Ethics Review Committee and the London 
School of Hygiene & Tropical Medicine Ethics Committee for approval. Upon approval 
of the amendment, a visit was made to the three additional health facilities to assess 
the situation on TB services provided. 
 
4.4 Findings from three additional rural health centres 
 
At all the three health centres, we met with the in-charges of the facilities and through 
discussions, we found no TB services were provided in one of the facilities, however, 
in two of the facilities they did refer clients once in a while to the municipal hospital 
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for further assessment for TB but this was done without using the recommended TB 
symptom screening tool. The screening tool was not used because it was not available 
and HCWs had not been trained on how to use it. On average in a year about five 
patients were referred to the municipal hospital on suspicion of TB. 
 
4.5 Actions taken by study team after situation assessment 
 
It was agreed among investigators to introduce the TB-symptom screening tool to 
HCWs at the rural health facilities and explain to them how it was used. In all the four 
health centres, HCWs who attended to patients in the consulting room were trained 
on how to use the screening tool. It was necessary to do this so these facilities could 
start screening patients accessing care so we could identify eligible patients to recruit 
for the prospective cohort study. The study population for the prospective cohort study 
was presumptive TB patients who had a sputum test requested or were referred to the 
municipal hospital for further assessment for TB by a HCW through routine practice. If 
this intervention was not put in place, it would have taken a longer time period to 
recruit the required number of participants for the prospective cohort study based on 
the current numbers at the health facilities being referred for a sputum test. It might 
not have even been possible to do the study if action was not taken. Due to logistical 
challenges, the element of two months follow-up for the prospective cohort study and 
the timelines for this PhD study, we could not afford to have a very long recruitment 
period for the prospective cohort study. 
The clinic observations component of the qualitative study was conducted before the 
TB- symptoms screening tool was introduced to nurse prescribers and in-charges of the 
rural health facilities. This was done to ensure that the findings of the clinic 
observations were not biased by the introduction of the TB-screening tool but rather 
to capture the true picture of the practices of HCWs relating to TB case finding.
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Chapter 5: Research paper 1: Missed opportunities for 
tuberculosis investigation in a municipal hospital in Ghana: 
evidence from patient exit interviews 
 
This chapter provides details on the TB symptom screening practices of HCWs in the 
municipal hospital and gives details on the proportion of health facility attendees 
eligible for sputum test according to national guidelines who were asked to do a 
sputum test by a HCW (objective 1). The methodology used to achieve the objective is 
outlined. Characteristics of study participants and predictive factors for requesting a 
sputum test for eligible participants by HCWs are also provided in this chapter. 
 
This chapter was published on 24th August 2020 in Transactions of The Royal Society 
of Tropical Medicine & Hygiene [130]. The published manuscript is included in full 
below. The copyright is held by Oxford University Press and permission to reproduce 
the contents is included in appendix 10.3. 
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Background: We assessed coverage of symptom screening and sputum testing for tuberculosis (TB) in hospital 
outpatient clinics in  Ghana. 
Methods: In a cross-sectional study, we enrolled adults (≥18 years) exiting the clinics reporting 1 TB 
symptom (cough, fever, night sweats or weight loss). Participants reporting a cough ≥2 weeks or a 
cough of any duration plus ≥2 other TB symptoms  (per national criteria) and those self-reporting HIV-
positive status were asked to give sputum for testing with Xpert MTB/RIF. 
Results: We  enrolled 581 participants (median age 33 years [IQR: 24–48], 510/581 [87.8%] female). The most 
common symptoms were fever (348, 59.9%),  chest pain (282, 48.5%)  and cough (270, 46.5%).  386/581 
participants (66.4%) reported symptoms to a healthcare worker, of which 157/386 (40.7%) were eligible for a 
sputum test per national criteria. Only 31/157 (19.7%) had a sputum test requested. Thirty-two additional 
participants gave sputum among 41 eligible based on positive HIV status. In multivariable analysis, symptom 
duration ≥2 weeks (adjusted odds ratio [aOR] 6.99, 95% confidence interval [CI] 2.08–23.51) and previous TB 
treatment  (aOR:6.25, 95% CI: 2.24–17.48) were  the strongest predictors of having a sputum test requested.  6/189 
(3.2%)  sputum samples had a positive Xpert MTB/RIF result. 
Conclusion: Opportunities for early identification of people with TB are being missed in health facilities in Ghana. 
 
Keywords: Ghana, healthcare workers, missed diagnosis, screening practices, sputum request, tuberculosis 
 
Introduction 
According to the World Health Organization (WHO), in 2018, an 
estimated 3 million TB cases were missed globally.1 Missed or 
delayed diagnosis of TB can have negative implications for 
patients and the community. Treatment delays increase the 
duration of infectiousness among people with TB, which can lead 
to ongoing transmission in the community.2,3 Patients may also 
suffer increased ill-health, increased costs or mortality.2 
The 2013 national TB prevalence survey in Ghana showed a 
higher prevalence than anticipated (253/100 000 measured vs. 
72/100 000 previously estimated), suggesting more missing cases 
than previously thought.4,5 The goal of the National TB Control 
Program (NTP) is to reduce TB prevalence by 25% by 2020 
 
compared to the 2013 baseline level of 253/100 000 population.6 
To achieve this goal, it is necessary to promptly identify people 
with active TB accessing care from health facilities and put them 
on treatment to reduce transmission. Moreover, Ghana’s national 
standard operating procedures for TB case detection state that all 
adult patients attending outpatient departments and consulting 
rooms in clinics and hospitals, regardless of presenting symptoms, 
should be asked about cough by healthcare workers;7 and the 
criteria for requesting a sputum for TB testing is a cough longer 
than two weeks or a cough of any duration with at least two other 
TB-related symptoms (chest pain, weight loss, night sweat and 
fever). Patients who are HIV positive with a cough of any duration, 
fever, weight loss or night sweat should also be asked to submit 
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Studies in Ghana have measured patient and health system 
delay in TB care, but these recruited TB patients who were 
already on treatment.9,10 Much less is known about losses from 
the cascade of TB care prior to treatment in Ghana. We 
hypothesized suboptimal adherence to the national standard 
operating procedures for TB case detection in health facilities. 
We aimed to assess the coverage of TB symptom screening and 
sputum test-requesting practices among healthcare workers in 





The study was conducted at outpatient clinics at the hospital 
in Ketu South Municipality of the Volta region, Ghana. In 2018, 
the municipality notified 172 TB cases out of a target of 546 
estimated based on the 2013 national TB prevalence survey.11 
The municipality has eight health centres and one hospital. The 
hospital outpatient clinics provide several primary health care 
services. Persons identified in peripheral health centres as 
requiring further assessment or TB testing are referred to the 
hospital.12 The hospital was chosen as the study site because it 
is the only testing centre for TB in the municipality with a 
laboratory that performs TB testing using Xpert MTB/RIF 
(Cepheid, Sunnyvale CA, USA). Tuberculosis diagnostic services 
are provided according to the national standard operating 
procedures for TB case detection. 
 
Study design 
We carried out a cross-sectional study using exit interviews. 
 
Study population 
We recruited adults aged 18 years and above with at least one 
symptom suggestive of TB defined according to WHO criteria 
(cough, fever, night sweats or weight loss),13 exiting the health 
facility after seeking care for their own health. 
 
Sampling strategy and data collection procedure 
Adults exiting the health facility on weekdays from September 
to November 2018, between 8am and 3pm, were approached 
by trained research assistants. Research staff attempted to 
approach consecutive adults; if the number of exiting adults 
exceeded the capacity of the research team to approach them, 
staff approached the closest individual. Those who reported 
seeking care for themselves were screened with a TB symptom 
questionnaire. Those who reported at least one symptom 
suggestive of TB were invited to be part of the study and those 
consenting were consecutively enrolled. A standardised 
questionnaire was used to collect data, including socio-
demographic characteristics, reason for clinic visit, TB-related 
symptoms, whether these symptoms were reported to the 
healthcare worker and whether a sputum test was requested. In 
line with national criteria, study staff requested participants who 
reported a cough longer than two weeks, or a cough of any 
duration plus at least two other TB-related symptoms, to 
produce a single spot sputum sample for testing in the hospital 
laboratory using the Xpert MTB/RIF assay. In addition, those  self-
reporting HIV-positive status  with  any TB-related symptom were 
asked to produce sputum for laboratory testing. Research 
assistants coached participants who were eligible for a sputum 
test on how to produce quality sputum before a sputum container 
was given to them. Participants then went into a sputum booth 
to produce sputum on their own. Those who produced a sputum 
sample were informed of their test result and those with a 
positive test result were referred to the chest clinic for TB 
treatment. We crosschecked with the TB laboratory register at 
the hospital to find out if participants who reported having a 
sputum test requested by a healthcare worker did submit a 
sputum for testing. All data were collected electronically using 
Open Data Kit (ODK) and uploaded onto a secure server hosted 




The primary outcome was the proportion of participants who 
had a sputum test requested by a healthcare worker in the 
outpatient clinic, among individuals who met the criteria for a 
sputum test according to Ghana’s national standard operating 
procedures for TB case detection. 
 
Sample size 
We assumed that 25% of patients reporting a cough >2 weeks 
to a healthcare worker would be asked to submit sputum for a TB 
test;4 to estimate the 95% confidence interval with 8% precision, 
the minimum target sample size was 450 participants. 
 
Data management and statistical analysis 
Characteristics of study participants were described, and 
comparisons made using a chi-square test for categorical 
variables and a t-test for continuous variables. Logistic regression 
analysis was used to identify associations between being asked to 
give a sputum sample as the outcome variable and explanatory 
variables. Variables with likelihood ratio p-value <0.2 in univariable 
analysis were considered for inclusion in a multivariable model. 
However, adjusted analysis was limited by the relatively small 
number of outcomes and the multivariable model therefore 
included only covariates most strongly associated with the 
outcome. Data were analysed using Stata v15 (Stata Corp, College 
Station TX, USA). 
 
Results 
A total of 2516 people exiting the health facility were approached: 
1652 (65.7%) of them had sought care at the hospital, of which 
653/1652 (39.5%) were eligible for the study (Figure 1). The main 
reasons for ineligibility were not having any of the TB-related 
symptoms (865, 86.6%), being below 18 years (96, 9.6%) or being 
already on TB treatment (32, 3.2%). Among these 653 eligible 
individuals, 581 (89.0%) consented and were recruited. The main 
reasons for non-consent were not having time for the interview 
(53, 73.6%) and not being interested in the study (19, 26.4%). 
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Figure 1. Flowchart of study recruitment of participants, reporting of symptoms and being asked to do a sputum test by HCW. HF: health facility; 
HCW: healthcare worker. a Symptoms considered suggestive of TB, i.e. cough, fever, weight loss, night sweats. b Criteria for eligibility for sputum test 
= cough >2 weeks or cough of any duration plus at least two other TB-related symptoms (fever, weight loss, night sweats). 
 
Characteristics of study participants 
The median age of the 581 recruited participants was 33 years 
(interquartile range [IQR] 24–48), most were women (510/581, 
87.8%) and the majority had attained primary-level education 
(312/581, 53.7%) (Table 1). The most common TB-related 
symptoms were fever (348, 59.9%), chest pain (282, 48.5%) and 
cough (270, 46.5%). The main reason for visiting the hospital for 
most participants was for general medical care (237/581, 40.8%). 
There was strong evidence that those who reported symptoms to 
a healthcare worker had more TB-related symptoms (p<0.001) 
and longer duration of symptoms (p=0.01) compared to those 
who did not report their symptoms (Table 1). 
 
 
Practices of healthcare workers 
Of the 581 recruited participants, 386/581 (66.4%) had reported 
their symptoms to a healthcare worker. Among those who 
reported their symptoms, 333/386 (86.0%) had spontaneously 
reported their symptoms while 53/386 (14.0%) only reported 
their symptoms when elicited by a healthcare worker (Figure 1). 
Overall, 195 (33.6%) participants of the 581 recruited were 
eligible for a sputum test according to Ghana’s national standard 
operating procedures for TB case detection, but only 31/195 
(15.9%) had a sputum test requested by a healthcare worker. 
Among those who spontaneously reported their TB-related 
symptoms, 135/333 (40.5%) were eligible for a sputum test; 
however, only 29/135 (21.5%) had a sputum test requested 
(Figure 1). Among the 53 participants whose symptoms were 
elicited by a healthcare worker, 22 (41.5%) were eligible for a 
sputum test, yet only 2/22 (9.1%) had a sputum test requested. 
Also, among participants who did not report their symptoms 
at all to a healthcare worker, 38/311 (19.5%) were eligible for 
a sputum test: none of them had a sputum test requested 
(Figure 1). All participants who had a sputum test requested by 
a healthcare worker were confirmed in the laboratory register to 
have submitted sputum for the test. 
 
Reasons for not reporting symptoms to a healthcare 
worker 
For participants (195/581, 33.6%) who did not report their TB-
related symptoms to the healthcare worker, the reasons given 
were that the TB-related symptoms were not the reason they 
visited the hospital (156/195, 80.0%), they did not think it was 
important to report (32, 16.4%) and other reasons such as 
forgetting to report (7, 3.6%). 
 
Factors associated with having a sputum test 
requested by a healthcare worker 
In univariable analysis, there was a higher odds of having a 
sputum test requested by a healthcare worker among people with 
a longer duration of symptoms (≥2 weeks vs <2 weeks, OR: 9.71, 
95% CI 2.94–32.06), previous TB treatment (OR 8.52, 95% 
Approached 
2516 (100.0%) 
Did not seek care 
from HF 
864 (34.3%) 











53 (73.6%) did not have time for interview 
19 (26.4%) were not interested in the study Consented & recruited 
581 (89.0%) 
865 (86.6%) did not meet symptom 
criteriaa 
96 (9.6%) were <18yrs 
32 (3.2%) were on TB treatment 
Reported symptomsa to 
HCW 
386 (66.4%) 








Not eligible for 
sputum testb 
198 (59.5%) 
Not eligible for 
sputum testb 
31 (58.5%) 












































n (column %) 
 Reported symptoms to  HCW n=386  
Spontaneously HCW elicited 
reported n=333  n=53 
n (row %) n (row %) 
Did not report symptoms 
to HCW n=195 
 
n (row %) 
 
ap-value 
Age, years (IQR) 33 (24–48) 37 (25–51) 34 (22–48) 29 (22–39) <0.001 
Gender     0.28 
Male 71 (12.2) 45 (63.4) 8 (11.3) 18 (25.4)  
Female 510 (87.8) 288 (56.5) 45 (8.8) 177 (34.7)  
Educational level     0.12 
No formal education 148 (25.5) 97 (65.5) 8 (5.4) 43 (29.1)  
Primary/JHS 312 (53.7) 171 (54.8) 30 (9.6) 111 (35.6)  
Secondary/tertiary 121 (20.8) 65 (53.7) 15 (12.4) 41 (33.9)  
Symptoms (yes)b      
Cough 270 (46.5) 180 (66.7) 28 (10.4) 62 (23.0) <0.001 
Fever 348 (59.9) 220 (63.2) 32 (9.2) 96 (27.6) 0.001 
Chest pain 282 (48.5) 186 (66.0) 29 (10.3) 67 (23.8) <0.001 
Excessive night sweat 163 (28.1) 88 (54.0) 14 (8.6) 61 (37.4) 0.47 
Weight loss 214 (36.8) 113 (52.8) 28 (13.1) 73 (34.1) 0.03 
Number of symptoms     <0.001 
1 208 (35.8) 98 (47.1) 16 (7.7) 94 (45.2)  
2 165 (28.4) 99 (60.0) 13 (7.9) 53 (32.1)  
3 116 (20.0) 71 (61.2) 11 (9.5) 34 (29.3)  
≥4 92 (15.8) 65 (70.7) 13 (14.1) 14 (15.2)  
Duration of symptoms     0.01 
<2 weeks 252 (44.4) 155 (61.5) 13 (5.2) 84 (33.3)  
≥2 weeks 315 (55.6) 174 (55.2) 39 (12.4) 102 (32.4)  
HIV status     0.19 
Positive 63 (10.8) 40 (63.5) 3 (4.8) 20 (31.8)  
Negative 307 (52.8) 163 (53.1) 30 (9.8) 114 (37.1)  
Don’t know 211 (36.3) 130 (61.6) 20 (9.5) 61 (28.9)  
Health histories (yes)b      
Diabetes 29 (5.0) 15 (51.7) 3 (10.3) 11 (37.9) 0.82 
Hypertension 145 (25.0) 91 (62.8) 17 (11.7) 37 (25.5) 0.05 
Ever treated for TB 22 (3.8) 13 (59.1) 3 (13.6) 6 (27.3) 0.67 
Main reason for visit     <0.001 
TB symptoms 96 (16.5) 92 (95.8) 4 (4.2) 0 (0.0)  
Routine ART clinic 40 (6.9) 26 (65.0) 3 (7.5) 11 (27.5)  
Antenatal care 129 (22.2) 54 (41.9) 10 (7.8) 65 (50.4)  
General medical care 237 (40.8) 133 (56.1) 30 (12.7) 74 (31.2)  
Otherc 79 (13.6) 28 (35.4) 6 (7.6) 45 (57.0)  
Number of times ever     0.37 
   sought care for TB      
   symptoms      
0 106 (18.2) 52 (49.1) 11 (10.4) 43 (40.6)  
1–2 408 (70.2) 240 (58.8) 35 (8.6) 133 (32.6)  
≥5 67 (11.8) 41 (61.2) 7 (10.5) 19 (28.4)  
ART: antiretroviral therapy; HCW: healthcare worker; HIV: human immunodeficiency virus; JHS (12–14 years): Junior High School; TB: tuberculosis. 
a p-value is for the comparison between those who reported their symptoms spontaneously, those whose symptoms were elicited by a health- 
care worker and those who did not report their symptoms at all. 
b Response is not mutually exclusive. 










Table 2. Factors associated with being asked to submit sputum by a healthcare worker, Ketu South Municipality, Ghana 
 
  N=581  
Submitted 
 Total (n) sputum (n) % Univariable analysis Multivariable analysis 












Male 71 11 15.5 3.56 (1.67–7.59) <0.01  











40–60 143 11 7.7 1.74 (0.79–3.80) 0.17  
>60 67 8 11.9 2.82 (1.17–6.84) 0.02  
Educational level 










Primary/JHS 312 16 5.1 0.52 (0.25–1.09) 0.08  
Secondary/tertiary 121 6 5.0 0.50 (0.19–1.34) 0.17  
 
Reference 












Duration of symptoms 
208 25 12.0 4.50 (2.16–9.34) <0.001 
a<0.001 
b3.14 (1.47–6.71) <0.01 
<2 weeks 252 3 1.2 Reference Reference 
≥2 weeks 315 33 10.5 9.71 (2.94–32.06) <0.001 b6.99 (2.08–23.51) <0.01 
HIV status     a0.54   
Negative 307 16 5.2 Reference  
Positive 63 5 7.9 1.56 (0.55–4.45) 0.40  
Don’t know 211 15 7.1 1.39 (0.67–2.88) 0.37  
Ever treated for TB     a<0.001 
No 559 29 5.2 Reference Reference 
Yes 
Diabetes 
22 7 31.8 8.52 (3.23–22.54) <0.001 
a0.50 
b6.25 (2.24–17.46) <0.001 
No 552 35 6.3 Reference  
Yes 29 1 3.5 0.53 (0.07–3.99) 0.54  
Main reason for visit     a<0.001 
General medical care 237 14 5.9 Reference  
TB symptoms 96 16 16.7 3.12 (1.49–6.82) <0.01  
Routine ART clinic 40 3 7.5 1.29 (0.35–4.71) 0.70  
Antenatal care 129 1 0.8 0.12 (0.02–0.96) 0.05  
Otherc 
Number of times sought 
care for TB symptoms 
79 2 2.5 0.41 (0.92–1.86) 0.25 
a0.02 
 
0 106 7 6.6 Reference  
1–2 408 19 4.7 0.69 (0.28–1.69) 0.42  
≥3 67 10 14.9 2.48 (0.90–6.88) 0.08  
ART: antiretroviral therapy; HIV: human immunodeficiency virus; JHS (12–14 years): Junior High School; P: p-value; TB: tuberculosis. 
a Log likelihood p-value. 
b In order to prevent overfitting of the adjusted model, it was restricted to the three covariates with the strongest association with the outcome. 
c Diabetic clinic, hypertension clinic, mental health clinic, eye clinic and family planning unit. 
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Figure 2. Flowchart for laboratory testing (Xpert MTB/RIF) using study 
criteria. a Eligibility for sputum test by study criteria = cough >2 weeks 
or cough of any duration plus at least two other TB-related symptoms 
(fever, weight loss, night sweats) or self-reporting HIV-positive status 
with any TB-related symptom. 
 
 
CI 3.23–22.54), an increasing number of symptoms (≥3 vs 1–2, 
OR 4.50, 95% CI 2.16–9.34), males (OR 3.56, 95% CI 1.67–7.59), 
attending for TB-related symptoms vs general medical care (OR 
3.12, 95% CI 1.49–6.82) and older age (OR 2.82, 95% CI 1.17–6.84 
and 1.74, 95% CI 0.79–3.80 for >60 and 40–60 vs 18–39 years 
respectively, Table 2). After adjusting for confounders in multi- 
variable analysis, there remained strong associations between 
sputum being requested and duration of symptoms (adjusted OR 
[aOR] 6.99, 95% CI 2.08–23.51), previous TB treatment (aOR 
6.25, 95% CI 2.24–17.46) and increasing number of symptoms 
(aOR 3.14, 95% CI 1.47–6.71) (Table 2). In addition, to explore 
any potential confounding effect of age and gender, a separate 
model was developed to assess the association of duration of 
symptoms with having a sputum test requested after adjusting 
for age and gender (data not shown). The strength of association 
was similar to that presented in Table 2, thus not suggesting 
confounding by age or gender. Similar models were run for 
previous TB treatment and number of symptoms, and similarly 




A total of 236/581 (40.6%) participants were eligible according to 
study criteria to produce a spot sputum sample for laboratory 
testing using Xpert MTB/RIF (Figure 2). Among these, 195 met 
the national criteria for sputum testing, and an additional 41 met 
study criteria based on self-reporting HIV-positive status who did 
not meet national criteria but reported any of cough, weight loss, 
fever or night sweats. Of those eligible, 189/236 (80.1%) 
produced a sputum sample for the test. The majority of the 
sputum samples (125/189, 66.1%) were salivary and 64/189 
(33.9%) were mucopurulent. Test results showed 174/189 
(92.1%) were negative, 6/189 (3.2%) were positive and 9/189 
(4.8%) were invalid probably due to laboratory error (Figure 2). 
All positive results were without rifampicin resistance. 
Discussion 
Findings from this study show that patients with TB-related 
symptoms visiting outpatient departments for primary health- 
care services were not optimally screened for symptoms of TB, 
even though the national standard operating procedure for TB 
case detection specifies that people attending outpatient 
departments of health facilities should be asked about TB-related 
symptoms. Even among patients who reported symptoms and 
were eligible for a sputum test, a large proportion never had the 
test requested by a healthcare worker. This shows that there are 
missed opportunities for TB diagnosis in the health facility. 
A study in Cape Town, South Africa in 2013 also showed that 
people with respiratory symptoms exiting primary health facilities 
were not asked about their symptoms and did not have a sputum 
test requested.14 They recommended that intensified case finding 
should not be limited to only those who report their respiratory 
symptoms. Other studies have demonstrated missed 
opportunities for early TB diagnosis in health facilities due to non-
adherence to diagnostic guidelines.15–17 In a sub- study using exit 
interviews at clinics participating in a pragmatic cluster 
randomised trial evaluating programmatic roll-out of Xpert 
MTB/RIF in South Africa (XTEND), the change from sputum 
microscopy to Xpert MTB/RIF did not substantially influence 
healthcare workers’ suboptimal practices in requesting sputum 
tests among patients presenting with TB symptoms.18 
The main reason patients did not report their symptoms to a 
healthcare worker in our study was because they were not 
seeking care for these symptoms or did not find it important to 
report. The study in Cape Town conducted in primary health 
facilities also found that among study participants who tested 
positive for TB, none of them reported their symptoms to a 
healthcare worker when they visited the clinic.14 Several other 
studies have shown that patients delay in seeking care for their 
TB-related symptoms.3,19–21 It is imperative that we find ways to 
encourage patients to seek care early and to report all their 
symptoms when they visit a health facility. 
Our study showed that persons with a longer duration of 
symptoms or prior TB treatment were more likely to be asked to 
submit sputum for a test. Studies in Uganda and South Africa 
have all shown that healthcare workers tend to request sputum 
tests in persons with longer duration of symptoms.18,22 However, 
a study conducted in the Greater Accra region of Ghana from 
2010 to 2013 showed that more TB cases were identified when 
screening was done using the new diagnostic guidelines of a 
cough of any duration (>24 hours) and any other TB-related 
symptom compared to using just a cough >2 weeks.23 This 
confirms that using longer duration of symptoms to investigate 
for TB could lead to missed opportunities for early diagnosis. This, 
however, has high cost implications for diagnosis. Therefore, there 
is the need to find efficient and cost-effective strategies for 
diagnosis. 
In this study, the majority of participants were females, and 
this reflects the true outpatient department attendance where 
more women visit the outpatient department for care than 
men. This is supported by data from the district health  
information management system showing that from 2016 to 









Cannot produce sputum 
45 (95.7%) 
Eligible for sputum 









Invalid test results 
9 (4.8%) 
89  




There are some limitations to this study. We depended on 
participants’ self-report of having reported or not reported their 
symptoms to a healthcare worker, which we could not verify 
from clinic records. For those who said that they had had a 
sputum test requested, we crosschecked from the laboratory 
register to see if they had submitted a sputum sample. However, 
the use of exit interviews was a robust way to reduce recall bias 
since patients were interviewed immediately after consultation 
with a healthcare worker. The low yield of TB cases among 
participants submitting a sputum sample to the study team 
could be as a result of poor quality of sputum samples since 
most of the samples were salivary. This highlights the need for 
staff to supervise patients to ensure good quality sputum 
samples. In addition, the study was conducted in only the 
municipal hospital, and only during working hours, so findings 





Opportunities to identify people with TB were missed in this 
health facility; both coverage of TB symptom screening and 
testing of those fulfilling criteria for testing were low. This shows 
suboptimal adherence to national guidelines by healthcare 
workers in the study setting. There is the need to improve the 
system to maximise early detection of TB among people attending 
health facilities. 
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Chapter 6: Research paper 2: Where are patients missed in 
the tuberculosis diagnostic cascade? A prospective cohort 
study in Ghana 
 
This chapter provides in-depth analysis of data to determine the proportion of patients 
with a request for sputum test who submitted a sputum for testing, the time from test 
request to submitting sputum, and factors contributing to non-submission of sputum 
for testing (objective 2). It also provides analysis of data to compare the time from test 
request to submitting sputum among patients attending a health facility with vs. 
without a co-located laboratory (objective 3). The methodology used, causal analysis 
and predictive analysis are also described in this chapter. This chapter was published 
on 19th March 2020 in PloS One [131]. The manuscript was published under a Creative 
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Ghana’s national prevalence survey showed higher than expected tuberculosis (TB) 
prevalence, indicating that many people with TB are not identified and treated. This study 
aimed to identify gaps in the TB diagnostic cascade prior to starting treatment. 
 
Methods 
A prospective cohort study was conducted in urban and rural health facilities in south-east 
Ghana. Consecutive patients routinely identified as needing a TB test were followed up for 
two months to find out if sputum was submitted and/or treatment started. The causal effect 
of health facility location on submitting sputum was assessed before risk factors were 
investigated using logistic regression. 
 
Results 
A total of 428 persons (mean age 48 years, 67.3% female) were recruited, 285 (66.6%) from 
urban and 143 (33.4%) from rural facilities. Of 410 (96%) individuals followed up, 290 
(70.7%) submitted sputum, among which 27 (14.1%) had a positive result and started 
treatment. Among those who visited an urban facility, 245/267(91.8%) submitted sputum, 
compared to 45/143 (31.5%) who visited a rural facility. Participants recruited at the urban 
facility were far more likely to submit a sputum sample (odds ratio (OR) 24.24, 95%CI 
13.84– 42.51). After adjustment for confounding, there was still a strong association 
between attending the urban facility and submitting sputum (adjusted OR (aOR) 9.52, 95%CI 
3.87– 23.40). Travel distance of >10 km to the laboratory was the strongest predictor of not 
submitting sputum (aOR 0.12, 95%CI 0.05–0.33). 
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and Tropical Medicine’s Data Compass and 
are accessible using the following DOI: 
https://doi.org/ 10.17037/DATA.00001529. 
Interested researchers wishing  to request access 
to the data can do by clicking the “request 
access” button to fill a form 
Conclusion 
The majority of presumptive TB patients attending a rural health facility did not submit 
sputum for testing, mainly due to the long travel distance to the laboratory. Bridging this gap 
in the diagnostic cascade may improve case detection. 
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Introduction 
Ghana is one of the tuberculosis (TB) and human immunodeficiency virus (HIV) high 
burden countries according to the World Health Organization (WHO) [1]. Ghana’s TB case 
notification rate has declined from 56/100,000 in 2014 [2] to 52/100,000 in 2017[3] 
compared to an estimated incidence of 152/100,000 based on the 2013 national TB prevalence 
survey [4]. Ghana’s national TB prevalence survey also highlighted weaknesses in the care 
cascade where of persons with prolonged cough who visited a health facility, only 25% 
submitted sputum for testing [4]. 
In Ghana, TB diagnosis and treatment is mainly done at government health facilities. Until 
recently, sputum smear microscopy was the main diagnostic method, but Xpert MTB/RIF has 
now been introduced with 105 GeneXpert machines installed nationwide by 2017 [3]. Most 
diagnostic laboratories are located at secondary and tertiary levels of care but not at peripheral 
levels such as health centres mostly in rural areas. Therefore, a person with symptoms of TB 
might be identified at a health centre but will have to travel themselves to the district hospital 
for a sputum test to confirm the diagnosis. This creates an obstacle to diagnosis and treatment 
and potential loss within the cascade of TB care. 
There is a wealth of literature on health facility contribution to delayed or missed diagnosis 
of TB and pre-treatment loss-to-follow up [5–9]; however, most are cross-sectional studies 
involving TB patients already on treatment, thus excluding those who never started treatment, 
or retrospective reviews of secondary data [10]. To better understand losses from the care 
cascade, we conducted a prospective observational cohort study to identify where and when 
potential TB patients are missed in the diagnostic cascade. We hypothesized that distance to 
the laboratory was a key determinant of whether sputum was submitted or not, therefore, per- 
sons with symptoms suggestive of TB (presumptive TB patients) were less likely to submit a 
sputum if they attended a rural health facility without a laboratory compared to those 
attending an urban facility with a co-located laboratory. Our aim was to determine if persons 
asked to submit sputum for testing for TB submitted sputum, and whether this was 
associated with urban vs. rural location of the facility; also whether they received test results, 
and if the results were positive, whether they started TB treatment. 
 
Materials and methods 
Study setting 
The study was conducted in Ketu South Municipality in the Volta region of Ghana, which 
shares boundaries with the Republic of Togo. The municipality has one government hospital 
and eight health centres. In 2017, the municipality notified 290 TB cases out of a target of 534 
estimated based on the 2013 national TB prevalence survey. In 2018, it notified 172 TB cases 
out of a target of 546, indicating a decreased case detection rate from 53.8% in 2017 to 31.5% 
in 2018 [11]. There is only one TB diagnostic laboratory in the municipality, located at the 
municipal hospital. All other health facilities in the municipality refer patients with symptoms 
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of TB to the municipal hospital for testing. The study was thus conducted in the municipal 
hospital, and four health centres without co-located TB diagnostic facilities in rural areas 
located 10 to 20 km from the municipal hospital. The four health centres were selected based 




This was a prospective observational cohort study among adults aged ≥18 years with or 
without symptoms suggesting TB, self-presenting at the health facility, who were identified 
routinely by a health worker as needing TB investigation and given a laboratory request to 
do a sputum test or referred to the municipal hospital. 
Sampling strategy. We consecutively invited eligible patients from the selected health 
facilities from May 2018 until the target study population had been enrolled in February 2019. 
 
Data collection 
At enrolment, trained research assistants collected baseline information on socio-demographic 
characteristics, symptoms of illness, health histories and date the sputum test was requested, 
using a standardised questionnaire. The questionnaire was pretested at the municipal hospital 
in a population similar to the study population. Following pretesting, revisions were made to 
improve comprehensibility and understanding. Participants were followed up for two months 
after the test request, via two-weekly phone calls to find out if sputum had been submitted, 
when and where it was submitted and the result of the test; and among those with a positive 
test result, to determine whether the patient had started TB treatment. Those without phones 
were visited at their homes once monthly for two months. Geographic positioning coordinates 
(GPS) of participant households and health facilities attended were collected. Coordinates 
were stored separately from participant information to ensure confidentiality. All data were 
collected electronically using Open Data Kit (ODK) and uploaded onto a secured server hosted 
by the London School of Hygiene & Tropical Medicine. 
 
Sample size 
Assuming 49% of participants attending an urban facility would submit sputum [7], we 
calculated that a sample size of 414 would provide 80% power to detect a difference of 15% 
in the proportion of participants who submitted a sputum in an urban versus a rural facility 
with alpha set to 5% and allowing 10% loss to follow up. 
 
Measures and definitions 
TB symptoms were defined as the four cardinal symptoms of TB (cough, fever, weight loss and 
night sweats) and/or other TB symptoms (chest pain, coughing up blood, tiredness, shortness 
of breath and/or lump in neck). Rural and urban residence was defined based on the municipal 
health directorate categorization. Socioeconomic status was generated using asset scores which 
included 33 items, based on methods used by demographic and health surveys [12]. 
Participants’ attitudes of stigma towards people with TB were measured using a tool 
developed by Van Rie et al, based on 12 questions measured on a five-point Likert scale, with 1 
being lowest score for stigma and 5 being the highest [13]. The mean score across the 12 
questions was calculated and dichotomized to represent high perceived or low perceived 
stigma. Distance from a participant’s residence to the TB diagnostic facility was generated 
from GPS coordinates. 
Body mass index (BMI) was categorized according to WHO guidelines [14]. A Karnofsky 
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score was estimated as a measure of illness severity [15]. Diabetes and HIV status were defined 
based on participant self-report. 
Primary outcome. This was the proportion of participants who submitted a sputum 
sample. 
 
Data management and statistical analysis 
Primary analysis assessed the causal effect of type of health facility attended (urban versus 
rural) on the probability of submitting sputum, using logistic regression. Any factor that 
changed the odds ratio by approximately 10% in bivariable analysis was considered a potential 
confounder and adjusted for in a final multivariable model. Kaplan-Meier analysis was used to 
compare the time to submitting sputum between urban and rural facility attendees. Predictive 
modelling was employed to assess risk factors associated with submitting sputum using logistic 
regression. Variables with likelihood ratio p-value <0.2 in univariable analysis were included 




Ethical approval was obtained from the Ghana Health Service Ethics Review Committee and 
London School of Hygiene & Tropical Medicine Ethics Committee. Written informed consent 
was obtained from literate participants and for those who could not read and write, consent 
was documented with a thumbprint in the presence of a literate witness. 
 
Results 
A total of 468 persons were approached: of this number 437 (93.4%) were eligible, 428/437 
(97.9%) consented and were recruited (285 from urban facility and 143 from rural facilities). 
The main reason for non-eligibility was being <18 years (28, 90.3%). Of the 428 recruited, 397 
(92.8%) completed follow-up for two months, 13 (3.0%) died at some point in time within the 
two-month follow-up period and 17 (4.0%) were lost to follow up (Fig 1). 
 
Baseline characteristics of study participants 
Among 428 participants, the mean age was 48 years (standard deviation [SD]18.8) and this 
was similar among urban and rural facilities (Table 1). The majority of participants (288, 
67.3%) were female and most (237, 55.4%) had attained primary level education. The median 
distance between participants’ home and the laboratory was 17.3 km (interquartile range 
[IQR]16.7–19.4) for rural facility attendees and 2.6 km (IQR 1.3–10.0) for urban facility 
attendees. Most participants attending rural facilities were in the lowest socioeconomic tertile 
(58, 40.6%) compared to those attending urban facilities (85, 29.8%) and more than half (255, 
59.6%) of study participants had a high perception of TB related stigma. 
 
Cascade of care 
Of 410 presumptive TB patients asked to do a sputum test who were followed up, 290 (70.7%) 
submitted sputum for the test; 194/290 (66.9%) received a test result; 27/194 (13.9%) had a 
positive test result and all 27 started TB treatment (Fig 2). Sixteen additional patients started 
treatment based on chest radiograph findings. Stratifying by type of health facility attended, 
245/ 267 (91.8%) submitted sputum among those attending the urban facility and 45/143 
(31.5%) among those attending rural health facilities (Fig 2). 
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Time to submitting sputum among rural and urban health facility 
attendees 
In Kaplan-Meier analysis, there was strong evidence for a difference in time to submitting 
sputum by location of health facility, where urban facility attendees submitted sputum earlier 
than rural facility attendees (P<0.001) (Fig 3). Of urban facility attendees, 229 (80.4%) 
submitted sputum on the day the test was requested, 10 (3.5%) submitted within 7 days and 6 
(2.1%) after 14 days. However, among rural facility attendees, only 6 (4.2%) submitted sputum 
on the day the test was requested, 18 (12.6%) within 7 days and 21 (14.7%) after 14 days (Fig 
3). 
 
Reasons for not submitting sputum 
The main reasons given by participants for not submitting sputum were being too busy to go 
to the laboratory (58/116, 50.0%), feeling well so not seeing the need to do the test (19, 16.4%), 
having no money to travel to do the test (17, 14.7%) and being unable to produce sputum (15, 
12.9%). 
 
Association between type of health facility attended and submitting 
sputum 
In causal analysis, participants recruited from the urban health facility had a much higher odds 
(unadjusted odds ratio [OR] 24.24, 95% CI 13.84–42.51) of submitting sputum compared to 
those recruited at a rural health facility. Adjusting for distance from participants’ residence to 
the laboratory resulted in the biggest reduction in the odds of submitting sputum, comparing 
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Table 1. Baseline characteristics of participants (people requested to give sputum for TB investigation) in Ketu South Municipality, Ghana. 
Characteristics Variable Urban health facility, n = 285 Rural health facility, n = 143 Total, N = 428 P-value 
n (%) n (%) n (%) 
Age (years) Mean ± SD 47.6±17.9 48.4±20.4 47.9±18.8 0.901 
Gender Male 99 (34.7) 41 (28.7) 140 (32.7) 0.207 
Female 186 (65.3) 102 (71.3) 288 (67.3) 
Educational level No formal education 70 (24.6) 34 (23.8) 104 (24.3) 0.982 
Primary/JHS 157 (55.1) 80 (55.9) 237 (55.4) 
Secondary/Tertiary 58 (20.4) 29 (20.3) 87 (20.3) 
Place of residence Urban 205 (71.9) 1 (0.7) 206 (48.1) <0.001 
Rural 80 (28.1) 142 (99.3) 222 (51.9) 
Distance to laboratory (km) Median (IQR) 2.6 (1.3–10.0) 17.3 (16.7–19.4) 10.0 (1.6–17.3) <0.001 
Socioeconomic status (tertiles) High 114 (40.0) 28 (19.6) 142 (33.2) <0.001 
Middle 86 (30.2) 57 (39.9) 143 (33.4) 
Low 85 (29.8) 58 (40.6) 143 (33.4) 
TB symptoms (yes) Cough 279 (97.9) 142 (99.3) 421 (98.4) 0.279 
Fever 204 (71.6) 115 (80.4) 319 (74.5) 0.048 
Night sweat 70 (24.6) 24 (16.8) 94 (22.0) 0.067 
Weight loss 79 (27.7) 22 (15.4) 101 (23.6) 0.005 
Symptoms duration (days) Median (IQR) 19 (7–31) 7 (7–14) 14 (7–28) <0.001 
HIV status Positive 32 (11.2) 0 (0.0) 32 (7.5) <0.001 
Negative 72 (25.3) 17 (11.9) 89 (20.8) 
Don’t know 181 (63.5) 126 (88.1) 307 (71.7) 
Diabetes No 273 (95.8) 142 (99.3) 415 (97.0) 0.046 
Yes 12 (4.2) 1 (0.7) 13 (3.0) 
BMI (kg/m2) Median (IQR) 24.6 (19.7–34.1) 25.1 (22.0–30.3) 24.8 (20.3–32.6) 0.077 
Severity of illness (Karnofsky score) Mean ± SD 81.2±10.8 86.1±6.4 82.9±9.8 <0.001 
Stigma Low perceived stigma 138 (48.4) 35 (24.5) 173 (40.4) <0.001 
High perceived stigma 147 (51.6) 108 (75.5) 255 (59.6) 
 
N = total number, n = number within facility, SD = standard deviation, IQR = interquartile range, BMI = body mass index, TB = tuberculosis, HIV = human 





urban and rural facility attendees (adjusted OR [aOR] 12.98, 95% CI 5.95–28.30) (Table 2). 
After adjusting for all other confounders, in the final adjusted model, a strong association 
between attending the urban versus rural health facilities and submitting sputum remained 
(aOR 9.52, 95% CI 3.87–23.40) (Table 2). 
 
Factors associated with submitting sputum among study participants 
attending an urban or rural health facility 
In univariable analysis (Table 3), rural versus urban residence (OR 0.08, 95% CI 0.05–0.15); 
longer travel distance to the laboratory (OR 0.06, 95% CI 0.03–0.11 for 10–20 km and OR 0.17, 
95% CI 0.07–0.41 for >20 km versus <10 km); and high versus low perception of TB-related 
stigma (OR 0.39, 95% CI 0.24–0.62) were associated with a lower odds of submitting sputum. 
Prior TB treatment (OR 4.00, 95%CI 1.19–13.460); more reported symptoms (OR 2.87, 95% 
CI 1.47–5.59 for >4 versus 1–2), longer symptom duration (OR 2.20, 95% CI 1.39–3.50 for 
>14 versus ≤14 days); and visit to at least one care providers prior to current clinic visit 
 (  OR 3.18, 95% CI 1.88–5.10) were predictors of submitting sputum. 
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In predictive multivariable analysis, longer travel distance to the laboratory and high 
perception of TB-related stigma remained associated with a lower odds of submitting 
sputum (Table 3). 
 
Discussion 
In south-east Ghana, more than a quarter of presumptive TB patients never submitted a 
sputum, and non-submission of sputum was most strongly associated with longer distance to 
the laboratory. Studies from Zimbabwe, India and Tanzania have also reported high pre-
diagnosis loss-to-follow, 25%, 30.4% and 44% respectively [16–18], and some studies, 
including one from Ghana, showed that attending rural health clinics and long travel distance 
were risk fac- tors for delay or pre-diagnosis loss to follow-up [7, 10, 17, 19]. In contrast, pre-
diagnosis attrition was lower in South Africa and China (5% and 11% respectively) [20, 21], 
perhaps because in South Africa, sputum specimens are transported free to a central 
laboratory for diagnosis. 
TB-related stigma was independently associated with non-submission of sputum, 
consistent with findings from a study in India [22]. Several studies have reported high 
perception of TB-associated stigma [23–27], and specific actions are needed to counter this 
[28, 29]. 
An encouraging finding was that all patients with a positive TB result on their sputum were 
promptly put on treatment. This contrasts with a study of routine data from a regional hospital 
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in Ghana in 2011 where pre-treatment loss-to-follow up was 38% [30], and a systematic review 
which found an 18% pre-treatment loss to follow-up in Africa [31]. The difference could be 
due to the presence of a “task-shifting officer”, dedicated to TB screening and follow-up in our 
study hospital’s main outpatient department, supporting the value of this role. 
 
Table 2. Causal analysis showing association between the type of health facility attended and submitting a sputum 
for a TB test, Ketu South Municipal—Ghana. 
Association between type of health facility attended and submitting sputum OR CI P 
Univariable+ 24.25 13.84–42.51 P<0.001 
Confounder adjustment    
Adjusted for longer distance from residence to laboratory 12.98 5.95–28.30 P<0.001 
Adjusted for rural residence 18.25 8.08–41.21 P<0.001 
Adjusted for negative HIV status 22.07 12.35–39.44 P<0.001 
Adjusted for high perceived stigma 22.46 12.73–39.61 P<0.001 
Adjusted for increasing number of symptoms 22.64 12.85–39.88 P<0.001 
Final: adjusted for all of above 9.52 3.87–23.40 P<0.001 
 
†bivariate analysis between type of health facility (rural or urban) and sputum submission as an outcome. 
OR = odds ratio, CI = 95% confidence interval, P = p-value 
https://doi.org/10.1371/journal.pone.0230604.t002 
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Table 3. Factors associated with submitting sputum among study participants attending rural and urban health facilities in Ketu South Municipality, Ghana. 
 N = 410 
Variable Number submitting sputum (%) OR (95% CI) P aOR (95%CI) P 
Age group (years)   ∗0.689   
18–38 99/145 (68.3) 1    
39–59 107/150 (71.3) 1.15 (0.70–1.90) 0.567   
≥60 84/115 (73.0) 1.26 (0.73–2.16) 0.403   
Gender   ∗0.177   
Male 102/136 (75.0) 1  1  
Female 188/274 (68.6) 0.73 (0.46–1.16) 0.182 0.90 (0.48–1.69) 0.739 
Educational level   ∗0.706   
No formal education 65/96 (67.7) 1    
Primary/JHS 162/228 (71.1) 1.17 (0.70–1.96) 0.549   
Secondary/Tertiary 63/86 (73.3) 1.31 (0.69–2.48) 0.414   
Place of residence   ∗<0.001   
Urban 182/197 (92.4) 1  1  
Rural 108/213 (50.7) 0.08 (0.05-.015) <0.001 0.41 (0.16–1.03) 0.058 
Distance to laboratory (Km)   ∗<0.001   
<10 184/197 (93.4) 1  1  
10–20 74/168 (44.1) 0.06 (0.03–0.11) <0.001 0.12 (0.05–0.33) <0.001 
>20 32/45 (71.1) 0.17 (0.07–0.41) <0.001 0.29 (0.10–0.86) 0.025 
Socioeconomic status (tertiles)   ∗0.002   
Low 92/134 (68.7) 1  1  
Middle 86/138 (62.3) 0.76 (0.46–1.25) 0.272 0.59 (0.30–1.13) 0.113 
High 112/138 (81.2) 1.97 (1.12–3.45) 0.018 1.03 (0.47–2.24) 0.945 
Ever treated for TB   ∗0.008   
No 263/380 (69.2) 1  1  
Yes 27/30 (90.0) 4.00 (1.19–13.46) 0.025 2.02 (0.45–9.07) 0.359 
Number of symptoms   ∗<0.001   
1–2 34/56 (60.7) 1  1  
3–4 123/191 (64.4) 1.17 (0.63–2.16) 0.615 1.33 (0.60–2.96) 0.488 
>4 133/163 (81.6) 2.87 (1.47–5.59) 0.002 2.00 (0.83–4.80) 0.12 
Duration of symptoms (days)   ∗<0.001   
≤14 158/245 (64.5) 1  1  
>14 132/165 (80.0) 2.20 (1.39–3.50) 0.001 0.83 (0.43–1.62) 0.589 
HIV status   ∗0.037   
Positive 28/28 (100.0) 1  1  
Negative 66/85 (77.7) 1.79 (1.02–3.15) 0.043 0.85 (0.40–1.83) 0.678 
Don’t know+ 196/297 (66.0) - - - - 
Severity of illness (Karnofsky score)   ∗0.024   
Less severe (≥90) 136/217 (62.7) 1  1  
Moderately severe (70–80) 133/167 (79.6) 2.70 (1.24–5.92) 0.013 1.84 (0.68–4.98) 0.228 
Severe (≤60) 21/26 (80.8) 0.92 (0.17–5.10) 0.924 0.14 (0.01–2.28) 0.165 
Number of previous care providers visited   ∗<0.001   
0 173/272 (63.6) 1  1  
≥1 117/138 (84.8) 3.18 (1.88–5.40) <0.001 2.05 (1.02–4.13) 0.045 
Stigma   ∗<0.001   
Low perception 134/164 (81.7) 1  1  
(Continued) 
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Table 3. (Continued) 
 
 N = 410 
Variable Number submitting sputum (%) OR (95% CI) P aOR (95%CI) P 
High perception 156/246 (63.4) 0.39 (0.24–0.62) <0.001 0.54 (0.30–0.98) 0.043 
∗Log likelihood P-value, 
+Omitted from model due to collinearity, 
OR = odds ratio, aOR = adjusted odds ratio, P = p-value, JHS (13–15 years) = Junior high school 
https://doi.org/10.1371/journal.pone.0230604.t003 
 
Mortality among study participants was high, with 3% documented to have died within two 
months of enrolment, which is high for a population of presumptive TB patients but supports 
data from Zimbabwe [32]. An additional, 4% of participants recruited were lost to follow-up, if 
all these had died, two-month mortality would have been 7%. This further emphasizes the 
need for better access to prompt diagnosis and treatment for TB and other conditions. 
Findings from this study have both programmatic and health system implications. This 
study clearly shows there is a gap in the cascade between a sputum test being requested and 
sputum being submitted, particularly among persons attending rural health facilities, and this 
can be attributed to the distance people need to travel to submit a sputum. An effective 
specimen transport system might bridge the gap in the diagnostic cascade. 
 
Limitations 
The study was designed to be observational rather than interventional and so the follow-up 
calls aimed to find out whether the participant had given a specimen and/or started TB 
treatment rather than motivating them to give a specimen; however, follow-up calls could 
have prompted some participants to give a sputum specimen, and thus we may have 
underestimated the true pre-diagnostic delays or losses. 
 
Strengths 
The prospective cohort design of our study allowed us to determine pre-diagnostic losses 
directly and explore the reasons for losses, whereas previous studies have been based on 
secondary data analysis, or recruited patients already on TB treatment, thus excluding those 
who never started treatment. 
 
Conclusion 
Almost 30% of patients asked to give a sputum specimen for TB testing in Ketu South 
municipality, Ghana, did not submit sputum: this was primarily determined by longer distance 
to the TB diagnostic laboratory. Closing this gap in the TB diagnostic cascade is an important 
step in reducing treatment delay and reducing TB transmission. 
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Additional material for chapters 5 and 6 
Additional material for chapters 5 and 6 is presented in this section to provide more 




There are several strategies that can be used to determine factors or potential 
confounders that should be included in a multivariable model.  No single one of these 
strategies is best in all situations. Every strategy has limitations and defects that 
depend on the context in which it is applied [132]. In the quantitative studies 
presented in chapters 5 and 6 of this thesis, factors/potential confounders for inclusion 
in the multivariable models were selected using change-in-estimate and p-values. The 
advantage of using these is that they show the size and strength of an association 
between an outcome and an exposure. However, this strategy has several limitations 
compared to other methods such as the use of causal diagrams or directed acyclic 
graphs (DAG). A causal diagram or DAG is a visual representation of the causal 
relationships believed to exist between the variables of interest, including the 
exposure, outcome and potential confounding variables [133]. One of the advantages 
of using DAGs is that they help to differentiate between confounders, mediators 
(intermediate variables on the causal path between exposure and outcome), and 
colliders (variables influenced by both the exposure and the outcome) and therefore 
makes it easier to select which variables need to be controlled for [134]. Colliders are 
not to be adjusted for as doing that will introduce bias and mediators are rarely 
adjusted for unless the interest is to quantify different causal pathways between the 
exposure and the outcome [133, 135]. 
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Therefore, the limitation of using change-in-estimate and p-values for confounder 
selection is that colliders and mediators might be included in the multivariable model 
because they meet the set criteria for change-in-estimate or p-value for inclusion 
whereas important confounders might not be included in the multivariable model 
because they do not meet the inclusion criteria. The potential impact of this on the 
study findings is that the associations or causal relationship between study outcomes 
and exposures reported might be distorted or biased. For example, we could have 
overestimated or underestimated the causal relationship between attending a rural 
health facility and not submitting sputum just by using change-in-estimate in selecting 
potential confounders to control for.   
 
On the other hand, specifying a DAG to use as the basis for which variables to control 
for requires specialist knowledge of the causal question. This may or may not be easy 
to do and misspecification of the causal DAG can also lead to a biased or miss specified 
causal effect estimate. For instance, given that we were exploring factors that could 
influence whether a healthcare worker requested a sputum test or not and because 
we did not know what these factors were, it would have been difficult to correctly 
specify a DAG for this analysis.  
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Chapter 5: Research paper 1: Missed opportunities for tuberculosis investigation in 
a municipal hospital in Ghana: evidence from patient exit interviews 
 
Evidence of association  
Initially it was reported in Chapter 5 from table 1 that there was strong evidence that 
persons who reported their symptoms to a healthcare worker had longer duration of 
symptoms compared to those who did not report their symptoms, however upon 
review, that statement only holds for those whose symptoms were elicited by a HCW 













<2 weeks 155/333 (47.1) 13/53 (25.0) 84/195 (45.2) 0.01 
>2 weeks 174/333 (52.9) 39/53 (75.0) 102/195 (54.8)  
HCW= healthcare worker 
 
Multivariable models 
In the results section of chapter 5, it was mentioned that to prevent overfitting of the 
multivariable model due to the small number of outcomes, only three covariates with 
the strongest association with the outcome were adjusted for; that model was 
presented in table 2. It was also mentioned in the text that to explore for any potential 
confounding effect by age and sex, separate models were developed to assess the 
association of duration of symptoms, number of symptoms and ever treated for TB 
with having a sputum test being requested by a healthcare worker after adjusting for 







Model 1: Multivariable model showing the association between number of symptoms, 




Variable Total (n) 
Submitted 
sputum (n) % Multivariable analysis 
    aOR (95% CI) P-value 
Number of symptoms      
1-2 373 11 3.0 Reference  
≥3 208 25 12.0 3.14 (1.47-6.71) <0.01 
Duration of symptoms      
<2 weeks 252 3 1.2 Reference  
≥2 weeks 315 33 10.5 6.99 (2.08-23.51) <0.01 
Ever treated for TB      
No 559 29 5.2 Reference  
Yes 22 7 31.8 6.25 (2.24-17.46) <0.001 
 
In model 1, persons with increasing number of symptoms, longer duration of 
symptoms and those ever treated for TB were more likely to have a sputum test 
requested by a HCW.  
 
 
Model 2: Multivariable model showing the association between duration of 
symptoms and having a sputum test requested, after adjusting for age and sex 
N=581 
Variable Total (n) 
Submitted 
sputum (n) % Multivariable analysis 
    aOR (95% CI) P-value 
Gender      
Female 510 25 4.9 Reference  
Male 71 11 15.5 3.10 (1.41-6.83) <0.01 
Age group (years)      
18-39 371 17 4.6 Reference  
40-60 143 11 7.7 1.62 (0.72-3.63) 0.24 
>60 67 8 11.9 2.40 (0.95-6.03) 0.06 
Duration of symptoms      
<2 weeks 252 3 1.2 Reference  
≥2 weeks 315 33 10.5 8.94 (2.69-29.68) <0.001 
 
In model 2, after adjusting for age and sex, persons with longer duration of symptoms 
were more likely to have a sputum test requested by a HCW.  
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Model 3: Multivariable model showing the association between number of symptoms and 
having a sputum test requested, after adjusting for age and sex 
 
N=581 
Variable Total (n) 
Submitted 
sputum (n) % Multivariable analysis 
    aOR (95% CI) P-value 
Gender      
Female 510 25 4.9 Reference  
Male 71 11 15.5 2.98 (1.36-6.55) <0.01 
Age group (years)      
18-39 371 17 4.6 Reference  
40-60 143 11 7.7 1.77 (0.79-3.97) 0.16 
>60 67 8 11.9 2.96 (1.17-7.47) 0.02 
Number of symptoms      
1-2 373 11 3.0 Reference  
≥3 208 25 12 4.35 (2.07-9.16) <0.001 
 
In model 3, after adjusting for age and sex, persons with increasing number of symptoms 
were more likely to have a sputum test requested by a HCW. 
 
Model 4: Multivariable model showing the association between whether ever treated 
for TB and having a sputum requested, after adjusting for age and sex 
 
N=581 
Variable Total (n) 
Submitted 
sputum (n) % Multivariable analysis 
    aOR (95% CI) P-value 
Gender      
Female 510 25 4.9 Reference  
Male 71 11 15.5 3.06 (1.39-6.76) <0.01 
Age group (years)      
18-39 371 17 4.6 Reference  
40-60 143 11 7.7 1.66 (0.74-3.72) 0.22 
>60 67 8 11.9 2.40 (0.95-6.05) 0.06 
Ever treated for TB      
No 559 29 5.2 Reference  
Yes 22 7 31.8 6.80 (2.48-18.71) <0.001 
 
In model 4, after adjusting for age and sex, persons who had ever been treated for TB 
were more likely to have a sputum test requested by a HCW.  
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The number of parameters that could be included in the multivariable model was 
limited by the number of outcomes (36), to prevent overfitting of the model. The 
choice of using p-values for selection of variables to be moved to a multivariable level 
could have led to some variables that might be associated with the outcome to be 
excluded in the final model. Not including these variables could imply the true 
association between the outcome and factors in the multivariable model could be 
masked. 
 
Chapter 6: Research paper 2: Where are patients missed in the tuberculosis diagnostic 




In calculating the sample size for the cohort study presented in chapter 6, the aim was 
to detect an absolute difference of 15% in the proportion of participants who submit 




In the analysis even though we recruited from four rural health facilities, we did not 
adjust for clustering because of the small number of participants recruited from some 
of the rural health facilities. The small numbers could produce biased estimates in 
adjusting for clustering. Out of a total of 428 participants enrolled, 285 where from the 
urban facility and 143 were from the four rural facilities. Of the number recruited from 
the rural health facilities, 105, 6, 5 and 27 were recruited from the four respective rural 




Limitations of multivariable model 
There could be potential limitations to the multivariable model in table 2. As explained 
earlier in this additional material, the choice of using the change-in-estimate method 
for selection of variables to be included in the multivariable model could have led to 
other potential confounders being excluded in the final model. For example, socio-
economic status could be a potential confounder for the association between type of 
health facility attended and submitting a sputum sample for a TB test (figure 6.1). This 
is because people with a low socio-economic status may be the ones living in rural 
areas and therefore will visit a rural health facility (table 1 of published paper 
presented in chapter 6). Also because of their low socio-economic status they might 
not have money to travel to the municipal hospital to submit a sputum. Likewise, a 
person’s educational level could determine the type of health facility they attend and 
also whether they will submit a sputum specimen. For instance, people with a low 
educational level are likely to reside in rural areas and will attend a rural health facility. 
Due to their low educational level, they might not see the need to travel to the 
municipal hospital to submit a sputum for the test. Other factors such as age, gender, 
severity of illness etc which could be potential confounders are shown in the causal 
diagram in figure 6.1. All these potential confounders were not included in the 
multivariable model because they did not meet the 10% change-in-estimate and this 
could have led to an over- or underestimation of the association between the type of 
health facility attended and submitting a sputum sample for a TB test. There could be 









Figure 6.1: Causal diagram showing relationship between the type of health facility 





 adjusted variable 
 causal path 
 biasing path 
 
Figure 6.1 shows the potential confounders of the relationship between the type of 
health facility attended by a presumptive TB patient and submitting sputum for a TB 
test.  
 
Interpretation of findings 
In as much as distance seems to be the main determinant of patients not submitting 
sputum for a test, it is important to note that other factors relating to travel distance 
could account for this, for example, people of low socio-economic status may not have 
money to travel a long distance to the municipal hospital to submit a sputum. Also, 
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people who are severely ill or in the older age category may not be able to travel a long 
distance to submit a sputum for a test. In addition, the size of the odds ratio does not 
necessarily mean that longer distance of travel is the main cause of patients not 
submitting a sputum, it only shows there is a strong relationship between travel 
distance and submitting sputum, but other factors could influence this association.  
 
Limitations of follow up methods used 
Even though it has been stated as part of the limitations in chapter 6 that the frequency 
of follow up might have influenced people to submit a sputum, it is worth mentioning 
that this could be more prominent among those with mobile phones since they were 
followed up four times compared to those without mobile phones who were followed 
up twice in their homes during the two months follow up period. Moreover, the effect 
size for participants in the high wealth tertile could have been overestimated since this 
category of people were more likely to own phones and therefore were followed up 























Chapter 7: Research paper 3: Barriers to tuberculosis case 
finding in health facilities in Ghana: perceptions, experiences 
and practices of healthcare workers 
This chapter provides in-depth analysis of qualitative data to explore barriers to TB 
case finding in health facilities (objective 4). It provides details of the experiences and 
practices of HCWs. 
This chapter is prepared as a manuscript to be submitted to BMC Health Services 
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Background: Ghana’s national tuberculosis (TB) prevalence survey conducted in 2013 
showed higher than expected prevalence indicating that many people with TB were 
not being identified and treated. Responding to this, we assessed barriers to TB case 
finding from the perspective, experiences and practices of healthcare workers (HCWs) 
in rural and urban health facilities in south eastern Volta region, Ghana. 
Methods: We conducted clinic observations and in-depth interviews with 12 HCWs 
(including five trained in TB) in four rural health facilities and a municipal hospital. 
Interviews were transcribed. Transcripts and clinic observations summaries were 
manually analysed, triangulated and organised by health system-related and HCW-
related barriers.  
Results: The key health system barriers identified included lack of TB diagnostic 
laboratories in rural health facilities and no standard referral system to the municipal 
hospital for further assessment and TB testing. In addition, missed opportunities for 
early diagnosis of TB were driven by suboptimal screening practices of HCWs linked to 
not adhering to the national standard operating procedures (SOP) for TB case 
detection. Infection prevention and control measures in health facilities were not 
implemented as recommended by the same SOP. HCW-related barriers were mainly 
lack of training on case detection guidelines, fear of infection (exacerbated by lack of 
appropriate personal protective equipment) and apathy among HCWs for TB work. 
Solutions to these barriers suggested by HCWs included provision of at least one 
diagnostic facility in each sub-municipality, laboratory staff going round to collect 
sputum samples from rural health facilities and training of newly recruited staff on 
case detection guidelines. 
 Conclusion: Findings portray the complexity of barriers within the health system that 
affects TB case finding. There is the need for efforts from the national TB control 
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programme and health facility managers to ensure continuous quality monitoring of 
TB diagnosis and treatment with focus on patient-centred care. An effective specimen 





Tuberculosis (TB) is a major global public health threat and in 2018, an estimated ten 
million people developed the disease with 1.2 million deaths among human 
immunodeficiency virus (HIV) negative people (1). It was also estimated that three 
million TB cases were missed globally in the same year and this could be due to under-
reporting of detected cases or under-diagnosis. Under-diagnosis could arise from 
people with TB not accessing health care and/or being missed by the health system 
when they seek care (1). Prompt diagnosis and treatment of TB is essential to prevent 
spread of infection. 
 
Ghana is among the 30 TB and HIV high burden countries according to the World 
Health Organization (WHO) (1). A national TB prevalence survey conducted in 2013 
showed higher than expected TB prevalence. The survey also revealed that a large 
number of people with TB had visited public health facilities but only 5% had been 
diagnosed with TB (2). The national standard operating procedures (SOP) developed in 
2010 for TB case detection, outlines what health facilities and healthcare workers 
(HCW) should practice to ensure clients with symptoms of TB who access care are 
identified promptly and initiated on treatment (3). However, HCWs may encounter 
barriers that hinder their ability to detect people with TB promptly when they seek 
care from health facilities. 
 
Qualitative studies in Africa and other low- and middle-income countries have evaluated 
barriers to TB diagnosis and treatment in health facilities that can be classified as health 
system-related or patient-related barriers (4-8). Several quantitative studies have 
assessed reasons for health systems delay in diagnosing TB such as first seeking care 
from private health providers (9), primary healthcare facilities (10) or general 
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practitioners (11) and multiple healthcare contacts (12, 13). In our study setting, no 
qualitative study has been conducted to assess barriers to TB case finding in health 
facilities. This study was part of a larger project where qualitative research activities 
were conducted before and after quantitative components. Specifically, clinic 
observations were carried out before cohort and cross-sectional studies (14, 15) and in-
depth interviews were carried out as the final research activity of the project. Some 
findings from these quantitative studies showed gaps which were health system- and 
HCW-related. We conducted this qualitative study to assess barriers to TB case finding 
from the perspective, experiences and practices of HCWs and explore their suggestions 






The study was conducted in the south eastern part of the Volta region, Ghana, in a 
municipality that has one of the highest burdens of TB in the region (16). In 2018, the 
municipality notified 172 TB cases out of a target of 546 estimated based on the 2013 
national TB prevalence survey (17). We selected for the study four of the municipality’s 
eight rural health facilities that were geographically spread and had the highest 
outpatient department (OPD) attendance, along with the OPD of the municipal 
hospital, where the only TB diagnostic laboratory and chest clinic were based. 
 
Study design and population 
 
We employed qualitative methods using clinic observations and in-depth interviews. 
Participants were HCWs involved with TB case finding in the selected health facilities. 
The participants were purposefully chosen and included one medical doctor, two 
physician assistants, eight nurses and one task-shifting officer. There were four women 
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and eight men participants. Their ages ranged from 27-42 with a mean age of 32 
(standard deviation: 4.8) years. Four of the participants were from rural health 
facilities. The number of years of experience in TB work ranged from six months to 
three  years. 
 
Data collection and procedure 
Clinic observations were conducted in May 2018. The observations were done by JBD 
and CTN at the OPD waiting area, triage area, consulting rooms of the study health 
facilities including the laboratory and chest clinic of the municipal hospital. 
Observations were done using a checklist and included: waiting time of clients at the 
OPD waiting area; procedures at the triage area; interaction between HCW and clients 
in the consulting room; waiting time and dropping samples at the laboratory; and 
procedures at the chest clinic (supplementary table 1). These observations were done 
between 7am and 12pm on days that the health facilities were very busy (usually 
market days). Two days were spent at each facility and on each of the days, two 
researchers followed client flow by observing clients as they moved from one area to 
the other. The researchers dressed casually and were introduced to HCWs at the 
facilities before they started the observations. 
 
Based on an initial assessment of health facilities in April 2018 before the start of data 
collection, we found that there were no TB case finding activities in the rural health 
facilities. This made it necessary to introduce the screening tool to HCWs who 
attended to patients in the consulting rooms of the study rural health facilities to 
facilitate enrolment for the cohort study (15) and also as an ethical obligation to help 
improve TB services. The TB symptom screening tool was introduced just after the 
clinic observations at the beginning of May 2018, the quantitative studies were then 
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conducted from May to December 2018 followed by the in-depth interviews that were 
conducted in January 2019.  
 
 In-depth interviews were held in the health facilities at a time that was convenient for 
the HCW and lasted on average 50 minutes. Some of the HCWs in the rural health 
facilities to whom the TB symptom screening tool was introduced were among those 
interviewed. Interviews were led by JBD, and a trained research assistant observed and 
took notes. All interviews were conducted in English and audio recorded. An interview 
guide based on findings from clinic observations was used and included training in TB 
control, practices in TB diagnosis and treatment, experiences in TB case finding, 
barriers to TB diagnosis and treatment and suggested solutions by the HCWs. 
 
Data analysis 
Data from clinic observations were entered in Excel spreadsheet by JBD with columns 
representing observations done per area of the health facility and rows representing 
each health facility. This was done immediately after the observations were carried 
out. Data were organized by the type of health facility and patterns across the different 
areas of the health facilities observed were noted. Narrative data based on the 
observed patterns were used to show the workflow and practices of HCWS when 
clients reported to the health facility. Also, frequencies on number of patients 
screened for TB symptoms, numbers reporting a cough and numbers asked to submit 
a sputum for TB test were computed. Subsequently, with the data presented in this 
manner, the observations from the facilities could be used to validate the findings 
from the in-depth interviews and to thus triangulate, enrich and deepen the 
understanding of the data. All audio recordings were transcribed by JBD and reviewed 
by listening to the recordings as a quality control step. The transcripts were also 
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reviewed by VB who was the senior qualitative expert on the team. Transcripts and 
field notes were summarized and read over to identify emerging themes. JBD and VD 
then discussed and agreed on the themes. Summaries from clinic observations and 
transcripts were triangulated to generate the final analytical themes. Themes were 
organized in a framework that categorized barriers into two main areas: (i) health 
system-related factors, which are factors relating to the operations of the health 
system; and (ii) HCW-related factors relating to attitudes of HCWs. These categories 
were adopted from models used by Cattamanchi et al and Chimbatata et al (4, 18). 
 
Ethical approval 
Ethical approval was obtained from the Ghana Health Service Ethics Review 
Committee and London School of Hygiene & Tropical Medicine Ethics Committee. 
Permission to conduct the study in the health facilities was obtained from the regional 





We first present the TB client flow and standard TB management in the two types of 
health facilities, before presenting findings about barriers that were categorized as 
health system- related and HCW-related barriers. A summary of barriers to TB case 
detection in health facilities is shown in figure 2 and a table of illustrative quotes 
(supplementary table 2) is presented as supplementary material. 
 
TB client flow and standard TB management in health facilities 
 
In every health facility, the standard practice is that there should be a TB team made up 
of facility stakeholders that is responsible for planning, monitoring and evaluating 
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adherence to TB case detection protocols. The regional and district TB teams are 
supposed to visit health facilities quarterly to monitor case detection activities. 
 
The national SOP for TB case detection indicates that all clients attending OPDs should 
be asked about cough, irrespective of presenting symptoms. Those who report a cough 
should be screened with a TB symptom questionnaire (a screening tool) (3). Clients 
who report a cough of two weeks or more, or clients with cough of any duration plus 
two or more TB-related symptoms (fever, chest pain, weight loss and night sweats), 
should be asked to do a sputum TB test, and be recorded into a cough register. Also 
health talks on basics of TB and TB infection control should be given to clients at the 
OPD. 
 
Figure 1 shows the TB client flow and actions that are taken at each step of the 
pathway in rural health facilities and the municipal hospital. Client flow in all facilities 
is similar until after triaging where, in the municipal hospital, clients first see a task-
shifting officer before queuing to see a clinician. The task-shifting officer is a HCW 
designated to screen for symptoms of TB and request sputum tests. 
 
Rural health facilities 
 
Health system-related barriers 
 
Lack of diagnostic facilities in rural health facilities 
 
In the study setting, the only TB diagnostic facility was in the municipal hospital. 
Therefore, HCWs in rural health facilities had to refer all presumed TB clients to the 
municipal hospital for further assessment and testing. However, HCWs in all the four 
rural health facilities complained that most clients who are referred never reach the 
municipal hospital. In addition, there was no standard referral system for presumed 
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TB clients. Two facilities gave clients a referral letter to the chest clinic at the municipal 
hospital, one facility referred clients to the task-shifting officer and the other facility 
referred clients to the general OPD at the municipal hospital. Study observations 
documented that clients who are referred to either the chest clinic or the task- shifting 
officer are attended to more quickly than those referred to the general OPD. In one 
facility, a HCW said at times they need to threaten clients to go and do the test. 
“I have experienced that, most of them don’t go [….] unless we tell them that maybe 
they will die before they will just rush to go and come”. (Male HCW, Rural health facility 
[RHF]) 
 
HCWs said some of the health system reasons that clients do not go to the municipal 
hospital when they are referred are extensive waiting times at the municipal hospital 
and being treated badly by staff at the municipal hospital.  
 
HCWs relayed how consequently sometimes people could die and/or some clients 
would suppress their cough or would not report their TB-related symptoms to the HCW 
because they do not want to be referred to the municipal hospital. 
“[…] sometimes patients want to suppress the symptoms because they know you will 
refer them and if you refer them, they won’t go because of financial constraints. So, 
when you start going deeper, they tend to refrain from answering you more and that 
way we don’t get to capture the whole history about the patient. A patient could be 
coughing like two weeks and will come and tell you it started three days ago […]”. 
(Female HCW, RHF) 
 
One reason for which HCWs might not refer clients for a TB test was lack of money for 
clients to travel to the municipal hospital for further assessment and/or to do a TB 
test. These rural facilities were about 10 to 20 km from the municipal hospital. 
“[…] if they hear the name X (municipal hospital) they will start crying because they 




Another reason especially in fishing communities was migration. During the peak of 
the fishing season, most fisherfolk migrate to Benin, Togo, or Ivory Coast where there 
are big fishing vessels. They go to work on these fishing vessels for better income and 
only return after several months. If they have symptoms of TB and are referred to the 
municipal hospital, they may never go and do the test but will rather migrate and 
cannot be traced. Therefore, HCWs are reluctant to refer such clients during the fishing 
season.  
“Some of them you will not see them again after you refer them […] they will travel to 
Benin, Togo or Ivory Coast. Those are the places they have been going because of the 
fishing, they will go to fish there and it makes follow up difficult”. (Female HCW, RHF) 
 
 
Suboptimal screening for TB symptoms and sputum test request 
 
Clinic observations showed that in three of the four rural health facilities, HCWs at the 
triage area were not asking clients about cough. In the consulting rooms, clients were 
asked about cough as part of a routine set of symptoms asked to all clients. However, 
clients who reported a cough were not screened with the TB symptom questionnaire 
to determine their eligibility for a sputum test. Of 78 clients observed across the four 
rural health facilities in May 2018, 27 (34.5%) reported a cough to a HCW in the 
consulting room but none of them was screened with the screening tool. During HCW 
interviews conducted in January 2019, after the symptom screening tool that had been 
introduced, some of them said all clients in the consulting room are asked about cough 
and that the screening tool is used when appropriate.  However, no observations were 
conducted after to triangulate whether this change in practice had been made. Other 
HCWs shared that they do not ask all clients about a cough. 
“A patient could come with hypertension, we don’t ask for cough so I won’t say all 
patients, but I will say majority of patients, especially with the malaria cases […] but not 
all patients”. (Female HCW, RHF) 
 
Asked why HCWs were not asking about cough or using the screening tool, they 
responded that there was shortage of staff leading to heavy workload.   
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“We don’t have enough staff [..] Actually the one who was doing this is no longer in the 
facility”. (Female HCW, RHF)  
 
HCWs said they had never seen the screening tool until the study team introduced it 
to them. During clinic observations, the screening tool was not found in any of the 
consulting rooms of the health facilities. 
“I think the first time we had it (screening tool) was when you provided it, to be very 
frank. We never had any guideline (screening tool) for TB until you provided the TB 
guideline (screening tool)”. (Female HCW, RHF) 
 
 
Sub-optimal infection prevention and control practices 
 
In all the rural health facilities, we observed that health talks on TB and other health 
conditions were not given at the clients’ waiting area. When we interviewed HCWs, 
they said health talks are provided on one-on-one basis with clients who report a 
cough and they normally advise them to cover their mouths when they are coughing. 
Again, in all health facilities, we observed that clients in the waiting area who were 
visibly coughing were not isolated from the crowd and attended to as required by the 
national SOP for case detection. In one rural health facility, the HCW admitted that 
they did not have enough space to isolate clients with cough. Further, fast- tracking 
them through the process created misunderstanding with other clients already in the 
queue. 
“You only tell them to use their handkerchief to cover their mouth when they are 
coughing because this place is just too small so you can’t be isolating […] and 
sometimes too some came to meet others so if they are overpassing it will bring 
confusion”. (Female HCW, RHF) 
 
 
Insufficient monitoring and supervision of TB work 
 
None of the rural health facilities had a TB team or focal person to ensure HCWs were 
following protocols.  Also, there was poor documentation in cough registers at all the 
rural health facilities, and no supervision of TB case finding activities. The last record 
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of cough was entered more than a year ago prior to this research. HCWs explained this 
as due to “laziness”, not enough staff to do entries, heavy workloads and inadequate 
registers. 
“You see this place that we are working, the workload is too much for us, because you 
are the only person consulting, dispensing at the same time dressing wound and other 
things. So, most times doing recordings in the book is difficult. So if you take one client 




Healthcare worker-related barriers 
Gaps in TB knowledge and lack of training in case detection guidelines 
 
HCWs believed some of their colleagues might have less knowledge about TB, 
especially the signs and symptoms. Therefore, when they examine clients with 
symptoms of TB, they do not think of TB but rather other health conditions. To 
compound this problem, the majority (75%) of the HCWs interviewed had received no 
training on TB and had no idea about the national SOP for TB case detection. Indeed, 
prior to this study, the SOP was not available in any of the health facilities. HCWs 
believed the lack of training on the SOP led to majority of them not knowing what to 
do when they see a client with cough or TB-related symptoms. They believed that 
training should be done regularly because of the high turnover of staff. 
 
In addition, the lack of training on the SOP for case detection led to different criteria 
being used by different rural health facilities to refer a client to the municipal hospital 
for further assessment or for a TB test. In one facility, cough ≥2 weeks was used as 
criterion for referring clients for a TB test, in another facility, cough and weight loss 
were used. In the two other facilities, they used cough and other TB-related 
symptoms. A respondent at one rural health facility felt lack of training should not 




Health system-related barriers 
Suboptimal screening for TB symptoms and sputum test request 
At the municipal hospital, clients are supposed to be asked about cough during triaging 
and those who report a cough should be referred to the task-shifting officer to be 
screened for TB-related symptoms and if eligible be asked to submit sputum for a TB 
test.  However, clinic observations showed that after being triaged patients were not 
sent to the task-shifting officer to be screened for TB-related symptoms. Rather, the 
task-shifting officer either actively identified clients who were coughing in the waiting 
area and approached them to be screened and have a sputum test requested if they 
were eligible, or clients identified in consulting rooms of the municipal hospital who 
required screening were referred to the task-shifting officer. Some HCWs said the 
reasons they were not asking about cough or using the screening tool were that it was 
not their job, that it was extra work and at times they forget to ask about cough.  
“They are complaining that it’s not their job and they sometimes forget to ask. They 
cannot be checking the vital signs and at the same time remember to be asking about 
cough”. (Male HCW, Municipal hospital [MH]) 
 
All the clinicians at the municipal hospital said they had never seen the screening tool 
or sputum test request forms in the consulting room. However, HCWs at the chest 
clinic disagreed with their colleagues saying all HCWs were trained on how to use the 
screening tool and all forms needed were distributed to all the departments but they 
refused to use them. 
“They don’t ask about cough, but they are supposed to ask the clients, but they are not 
doing it, meanwhile they’ve been trained but yet still they are not doing it. Apart from 
the task- shifting officer asking about cough, the screening tool was sent to every unit, 
consulting rooms but now they are not doing it at all, […] now everything is on the task-
shifting officer and the TB unit”. (Male HCW, MH). 
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Many HCWs in the municipal hospital alluded that TB diagnosis would be more 
efficient if they were also screening for symptoms of TB and requesting for sputum 
test directly instead of referring to the task-shifting officer. 
 
Sub-optimal infection prevention and control practices 
HCWs from the chest clinic complained that when they try to let clients who are 
coughing see the doctor quickly to prevent potential spread of infection, they face 
opposition from their colleague HCWs at the OPD.  Also, entry to the isolation wards for 
TB clients was not restricted and the time spent in the ward by client relatives was not 
regulated. 
“[…] mostly I try my best to let them see the doctor fast but sometimes it brings some 
kind of argument between I and the nurses because they will say they can’t allow me 
to jump the person over other people in the queue […], this person just came some few 
minutes ago […]”. (Male HCW, MH) 
 
In the municipal hospital, there was a TB team in theory, but it was described by some 
key HCWs as non-functional for the past two years. HCWs with TB responsibilities 
felt that the ineffectiveness of the team was what was causing other HCWs not to 
adhere to the SOP for TB case detection. 
“Previous minutes from the files show the team used to meet […] and discuss the 
challenges and find some ways of resolving them but since I joined the team in 2016, 
frankly speaking the team is not working well, is not working, it was working previously 
but now is not working since they had different administration [….], it is no more 
effective again”. (Male HCW, MH) 
 
Shortage of staff 
Some HCWs said they could not adequately and effectively screen for symptoms of 
TB because they did not have enough staff. 
“Fair enough! We are supposed to be asking every patient about cough but I mean 
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sometimes too the workload I mean you can’t be asking every patient whether the 
patient is coughing”. (Male HCW, MH) 
 
Shortage of staff led laboratory staff to batch sputum specimen for the day and 
perform the test at the end of the day. Therefore, patients who submitted a sputum at 
the laboratory had to return the following day to the hospital for their test results. This 
caused some patients not to return for their results.  Some HCWs reported that 
laboratory staff did not give priority to TB work. 
“[...]sometimes the samples delay so you get the test results late [...] sometimes they 
even misplace the samples [...] we are having a problem with the lab in terms of human 
resource. If you look at the number of cases I mean we see at the lab and even in the 
day the number of people working there are not enough, I mean it’s a human resource 
challenge”. (Male HCW, MH) 
 
Also, because laboratory results were not given to patients on the day of sputum 
submission, the task-shifting officer on a daily basis at the start of work would go to the 
laboratory and collect all sputum test results from the previous day. The task-shifting 
officer then called all patients with a positive test result immediately and asked them 
to come and start TB treatment. He reported that at times he had difficulty convincing 
patients with positive result to return to the hospital to start TB treatment. Also, when 
he could not reach patients with a positive test result on phone, he traced them to 
their homes using the contact address provided during screening. HCWs at the chest 
clinic reported that availability of a vehicle to trace some patients with positive test 
result who cannot be reached via telephone was often a challenge. 
“[…] most of them […] if you call them […] they come but some of them you have to 
keep on calling them convincing them, talking to them and they will say, they don’t have 
money to come or their place is far they cannot come. Sometimes you have to walk to 
the house because you took their address, you have to make sure you go to the house 
and look for them and tell them that please you have to come for the medication […]” 
(HCW, MH). 
 
Those with a negative test result were not called to inform them of their result, and 
the reason given was that no call credit was given to the task-shifting officer to call 
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patients and inform them of their test result. 
“Those who are negative […] I don’t call them. I will not call them but we tell them to 
come back for the results the following day and they themselves will come or later on 
if they come back for review and they will come to me for the result […] because there 
is no money given for calling, but I just sacrifice my own money to buy the credit and be 
calling the positive ones”. (Male HCW, MH). 
 
 
Shortage of diagnostic logistics 
 
HCWs at the chest clinic of the municipal hospital complained that there were 
intermittent shortage of sputum containers or Xpert MTB/RIF cartridges. When this 
happened it affected the diagnosis of TB because once the presumed patient leaves 
the hospital, it is normally difficult to get them to return to do the test. The main reason 
attributed for these shortages was that the laboratory staff were not proactive in 
requesting for these items when their stock levels were low. Therefore, to prevent 
shortage of sputum containers, the containers were usually kept with the task-shifting 
officer at the OPD or kept at the chest clinic. When containers were kept at the chest 
clinic, it was inconvenient for patients as the chest clinic was quite a distance from the 
OPD. 
 
Healthcare worker-related barriers 
Fear of infection and attitude towards TB work 
 
Fear of infection was one of the main barriers affecting TB case detection in the 
municipal hospital. Nurses in the wards were reluctant to attend to TB clients admitted 
to the isolation wards of the hospital because they were worried about getting 
infected. This fear also prevented other HCWs from being interested in TB work. The 
fear was attributed to the lack of essential personal protective equipment (PPE) like 
N95 respirators. HCWs claimed the hospital management said N95 respirators were 
expensive and not readily available. This had led to some HCWs refusing to see clients 
with productive cough or TB   clients. 
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“So everybody is on the alert, I don’t want to be infected, I don’t want to get infected 
and that thing has brought in some reluctancy in getting closer to TB clients or TB unit 
[…]” (Male HCW, MH) 
 
HCWs at the chest clinic said the presence of a task-shifting officer, coupled with lack 
of motivation, had undermined the interest of other HCWs in TB work. Perceived 
incentives for the task-shifting officer and other staff of the chest clinic from the 
national TB control programme reinforced that they should be the only ones screening 
for symptoms of TB and requesting for sputum test. It was reported that at times that 
the task-shifting officer was not available, for instance on sick leave, no one did his job. 
They also said this responsibility shifting could lead to delay in diagnosis and more 
inconvenience and cost for presumed TB clients. 
“[…] I’ve heard statements whereby somebody is coughing, and they will say they 
should call the task-shifting officer because he is being paid to do that work, that one 
I’ve heard it several times”. (Male HCW, MH) 
 
 
Solutions suggested by healthcare workers 
 
In rural health facilities, some HCWs mentioned that if there could be a diagnostic 
facility in each sub-municipality, then clients would not have to travel to the municipal 
hospital for the TB test. Other HCWs thought that laboratory personnel going round 
the rural facilities and collecting sputum specimen from presumed TB clients would 
also help to reduce the loss to follow-up due to referrals to the municipal hospital. 
 
Most of the HCWs in both rural and urban facilities mentioned sensitization and training 
of HCWs on SOP for TB case detection. They recommended that training should be 
routinely held because of the high turnover of staff.  Providing logistics such as N95 




HCWs felt that there should be a functional TB team or focal person in every health 
facility to monitor TB case detection activities and to ensure HCWs adhere to the 
guidelines. Apart from a functional TB team, there should be regular monitoring and 
supervisory visits from the national, regional and district TB teams to ensure that 
guidelines are followed and also to serve as motivation for the HCWs to know that 
their work is appreciated. Other HCWs suggested directors from the national level 
should come to the health facilities and talk to HCWs and let them know TB case 
detection is part of their work and that this would let HCWs adhere to the guidelines. 
Provision of funds to health facilities to support patients with their transportation cost 




This study explored HCW perceptions and experiences in TB case detection in rural 
and urban health facilities in south eastern Volta region, Ghana. These perceptions 
and experiences were supplemented with findings from observations in these health 
facilities. We found there were barriers to TB case detection, presented using a 
framework of health system-related and HCW- related barriers. 
 
The main health system-related barrier was the lack of TB diagnostic laboratories in 
rural health facilities. This caused HCWs in rural health facilities to refer presumed TB 
clients to the municipal hospital for further assessment and testing. This system could 
contribute to high pre-treatment loss to follow-up since these facilities are mostly 
located far from the municipal hospital and, according to the HCWs, most clients are 
not able to afford the cost of transportation to the municipal hospital. This was 
substantiated by our linked quantitative study in the same facilities (15). Ereso et al in 
their study in Ethiopia also demonstrated that the absence of TB diagnostic 
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laboratories in facilities and subsequent referral of clients often led to delayed care 
seeking by these clients (5). Limited access to diagnostic facilities, mostly in rural 
settings, and long travel distance were similar barriers experienced by presumed TB 
clients in other parts of the world (6, 18-22). Rural health facilities in this study referred 
clients either to the chest clinic, task-shifting officer or to the general OPD. The lack of 
a standard referral system in our rural study facilities also led to extensive waiting 
times for some referred clients at the municipal hospital and this further underscored 
their reluctance to go to the municipal hospital for further assessment and testing. 
 
Suboptimal TB screening practices in both rural health facilities and the municipal 
hospital imply non-adherence to national SOP for TB case detection. This was a barrier 
in this study as related by HCWs and from clinic observations. This can result in missed 
opportunities for early identification of clients with TB that could further impact on 
the spread of TB in the community. The lack of training and absence of the screening 
tool that we observed in this study could account for the HCWs not asking clients about 
cough as required by the national SOP for case detection. Harper et al in their study 
in The Gambia also revealed through observations that HCWs did not adhere to the 
stated health policy on asking about cough and referral of presumed TB patients to 
the national TB control programme (NTP) for further assessment (19). Similarly, in 
China, Xu et al found that HCWs were not alert to symptoms of TB and did not screen 
for other TB-related symptoms or request for a sputum test (23). The “Stop TB 
partnership’s” “Action framework for higher and earlier TB case detection” 
recommends training of all HCWs and not just HCWs in the TB unit to ensure 
comprehensive implementation of existing diagnostic algorithms in health facilities to 
improve TB case detection (24). Both this study and other research identified HCWs 
not being appropriately trained as a barrier to TB case detection (6, 18).  Shortage of 
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staff and heavy workload were mentioned by HCWs as explanations for this non-
adherence to TB case detection SOP, similar to other studies (4, 18, 25, 26). 
 
The absence of a dedicated TB team could be one of the reasons for the non-
adherence to the SOP. We found insufficient monitoring and supervision of TB work in 
the health facilities because there were no TB teams or focal persons in any of the rural 
health facilities and the one in the municipal hospital was described as non-
functional. HCWs in the rural health facilities and those in the chest clinic of the 
municipal hospital perceived that if there was a team regularly supervising and 
monitoring the activities of HCWs then that would prompt them to ask about cough 
and request for sputum test where necessary. Lisboa et al in their study in 
Mozambique found that the lack of a motivated TB taskforce to supervise and monitor 
TB control activities in the health facility was a potential factor contributing to poor 
quality TB care (22). In addition, HCWs in our study were of  the view that if TB teams 
from the district, regional or national levels regularly visited the health facilities to 
monitor and encourage staff, this appreciation of their efforts combined with knowing 
their activities are going to be monitored would serve as a motivation for them to pay 
attention to TB case detection.  HCWs in another region in Ghana expressed similar 
sentiments (27). Moreover, in our study, HCWs were not putting into practice the 
recommended infection control measures which could lead to transmission of 
infection within the health facility. Comparably, in Nigeria, Tobin-West et al found 
poor TB infection control practices in both rural and urban health facilities (28). 
 
The  main  HCW-related barrier identified in this study was fear of infection that affected 
attitudes to TB work and undermined effective screening for symptoms of TB. A study 
from Malawi in 2015 also reported that fear of infection by HCW led to underassessment 
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of clients for symptoms of TB (4). The lack of PPE for HCWs compounds this fear. This 
same challenge was reported by Dordor et al in Ghana and Lisboa et al in Mozambique 
(22, 27). In some rural health facilities, clients who were coughing at the OPD could not 
be isolated due to lack of space. This creates a complex barrier because the SOP states 
that it has to be done but no provisions are made. In the municipal hospital, the lack of 
interest in TB work led to all the work being left to the task-shifting officer and HCWs at 
the chest clinic. This could lead to clients with symptoms of TB going through the health 
system without being identified by other categories of staff. Contrarily, in the 
Mozambican study, HCWs were advocating for task shifting in TB work where auxiliary 
staff can be trained to screen for symptoms of TB and believed that this would solve the 
problem of TB case detection (22). In addition, HCWs’ perceptions that some incentives 
were given to the task-shifting officer and chest clinic staff meant that they were not 
responsible to screen for symptoms of TB and request for sputum test. These findings 
conformed to findings from other parts of Ghana where perceived incentives for 
frontline TB staff and lack of interest in TB work by clinicians were identified as barriers 
to TB control (29). HCWs need to be provided with the right PPE to alleviate their fear 
of infection when dealing with presumed or TB clients and motivated to implement TB 
case detection activities in health facilities. This could subsequently lead to improved TB 
case detection. 
 
Many health care organizations have embraced patient-centred care as central to their 
strategic missions and values (30). Patient-centred care involves providing care that is 
compassionate, empathetic, and responsive to the needs, values, and expressed 
preferences of each individual patient (31). The care providers must understand the 
patient’s context and provide services to meet their needs. TB case finding in health 
facilities is impeded by complex barriers, and solutions should be patient centred. For 
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instance in rural health facilities, a specimen transport system should be implemented 
where presumptive TB patients will be asked to produce sputum at the rural health 
facility. The sputum specimen is then transported to the diagnostic laboratory for 
testing instead of referring patients to travel to the diagnostic laboratory to submit 
sputum. In South Africa, Naidoo et al found only 5% of TB patients could not access 
testing (32). The authors suggested that the effective sputum specimen transport 
system in South Africa could have accounted for the low proportion of patients not 
accessing testing. Ghana’s NTP could adopt such patient-centred strategies to improve 
TB case finding in rural facilities. Also, implementation of a standard patient referral 
system between rural health facilities and the municipal hospital might improve TB 
case finding. 
 
 Our study had potential limitations. HCWs might have been more comfortable 
highlighting some barriers than others. The dominance of one health professional 
category (nurses) in the study population might affect the diversity of the information 
obtained. However, the strength of this study was the use of both interviews and 




In south eastern Volta region, Ghana, the main health system barriers to TB case 
detection reported by HCW were lack of TB diagnostic laboratories in rural health 
facilities, fear of infection and suboptimal adherence to case detection protocols. 
These barriers likely contribute to poor TB case detection rates in the municipality. The 
barriers identified portray a complicated health system with no “one size fits all” 
solution. There is a need for appropriate interventions that focus on patient-centred 
care such as to improve TB symptom screening, an effective sputum transport system 
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and standard referral linkage to bridge the gap between rural health facilities and 
laboratories so that people with TB are not lost even before diagnosis. Also, hospital 
management especially in the municipal hospital should provide the appropriate PPE 

























































Figure 1: TB client flow and management in rural health facilities and the municipal hospital.  
Ideally, in the municipal hospital, after triaging, clients should be referred to the TSO but this is not done in practice. Also, the TSO is not supposed to go to the ward to screen clients, but this is done 
in practice. 
Person in community 
with symptoms of TB 
Rural Health Centre Municipal Hospital 
Triage and client waiting area 
• Clients arrive, records retrieved or 
generated if first visit to the facility 
• Vital signs checked 
• Clients join queue to see a clinician 
Consulting room 
• Clinician assesses client 
• Clinician may prescribe drugs, or refer 
client to the municipal hospital for 
further assessment or testing for TB  
Health records unit and client waiting 
area 
• Clients arrive, records retrieved or 
generated if first visit 
• Clients wait in a queue to be called 
for triaging 
Triage area 
• Vital signs are checked 
• Clients referred to TSO to 
screen for symptoms of TB  
• Clients then join a queue to see 
a clinician 
Consulting rooms 
• Clinician assesses clients 
• If TB is suspected, client is 
referred to the TSO to screen for 
symptoms and request a sputum 
test if eligible 
 
Laboratory 
• Clients submit sputum for testing 
• Sputum is tested using Xpert MTB/RIF 
Chest clinic 
• Presumed TB clients are referred 
to the laboratory for testing 
• Clients with positive test results 
are counselled and given 
treatment 
Wards 
• Clients admitted who are 
presumed to have TB 
referred to the laboratory 
• TSO called to screen 
clients in the ward  
TSO’s desk 
• Screens clients for symptoms 
of TB 
• Request a sputum test if 
eligible 
• Retrieves laboratory results 
and refers clients with positive 
test result to chest clinic 
•  
Movement of clients outlined in national SOP 
Movement of clients observed in health facilities 
TSO= task-shifting officer 
Movement of clients described by healthcare workers  
SOP= standard operating procedures 
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Figure 2: Summary of barriers to TB case detection in health facilities in south 




























The diagram shows that health system-related and healthcare-worker related barriers lead to missed 









Health system-related barriers 
1. No diagnostic facilities in rural health 
centres 
2. Suboptimal screening for TB symptoms 
& sputum test requests  
3. Suboptimal infection prevention and 
control practices 
4. Insufficient monitoring and supervision 
5. Shortage of staff 
6. Shortage of diagnostic logistics 
Healthcare worker-related barriers 
1. Gaps in TB knowledge and lack of 
training on case detection guidelines 
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OPD waiting area 
Presence of TB posters, whether health talks were held, 
waiting time of clients, behaviour of clients as they waited, 
whether visibly coughing clients were separated from other 









Number of HCWs present, HCWs asking clients about cough 
and other TB related symptoms, use of TB symptom 
screening tool, number of clients who reported a cough, 
recording of cough in a cough register, requesting/referral 
for sputum test, providing education on cough etiquette and 
how to produce sputum samples, escorting clients to the 
laboratory for sputum test or allowing them to go on their 










Number of HCWs present, HCWs asking clients about cough 
and other TB related symptoms, use of TB symptom screening 
tool, number of clients who reported a cough, recording of 
cough in a cough register, requesting/referral for sputum test, 
providing education on cough etiquette and how to produce 
sputum sample, escorting clients to the laboratory for sputum 
test or allowing them to go on their own, behaviour and 
communication 






Number of HCWs present, providing education on cough 
etiquette and how to produce sputum samples, waiting 
time to submit sputum, handling of sputum sample by 
client and how laboratory staff collected sputum from 
client, behaviour and communication style of laboratory 






Number of HCWs present, clients escorted to chest clinic by 
HCW or arriving alone, providing education on cough 
etiquette, counselling of clients with positive test results, 
explaining treatment procedure to clients, serving of 





General facility layout and workflow, whether any 
significant event was happening at the health facility on 
the day of observation 
OPD= outpatient department, TB=tuberculosis, HCW= healthcare worker, RHF= rural health facility,  









Supplementary Table 2: Illustrative quotes on barriers to TB case detection 
 
Study results Illustrative quotes 
Health system related barriers 
Suboptimal 




“Every client whether the person is a BP (blood pressure) client, […] because 
sometimes they easily forget something unless you remind them before they will 






“[...] sometime sputum container will get finish, cartridge will get finish and 
sometimes what marvels me is that on days containers are in the lab they will be 
giving the containers out without checking their stock levels but will wait when I 
send a patient to them for sputum test before they will tell me that containers are 
finished. Sometimes containers will get finish and because the clients are coming 
plenty and everybody is at risk, so I have to go and […] have to give me some money 





“We don’t have enough staff to record cough in the register. Actually the one who 





“Here the relatives can enter anytime they want, maybe in the night that I don’t know 
but for daytime the relatives enter the isolation ward anytime they want […], that’s 




TB work by TB 
team 
“There is a name to that effect, yes in quote a TB Team, but we don’t conduct any 
meetings I mean nothing really happens so I really don’t know if that team is 
functional or not but it’s just a name [..]”. (Male HCW, MH) 
Healthcare worker related barriers 
 
 
Gaps in TB 
knowledge and 
lack of training in 
case detection 
guidelines 
“The nurses at the hospital here we are many and if all of us we know something 
about tuberculosis and about tuberculosis detection, if all of us we are aware and we 
know much about it, we will be able to identify more cases but because most of us 
don’t know anything about tuberculosis when a person is even coughing they will 
ignore the person until those experience ones capture the person”. (Male HCW, MH) 
“Not all the health workers have gone for the training, but TB is a common thing [..], 
we have been learning about it so even if you don’t go for training at least you have to 





Fear of infection 
“If the health worker doesn’t have so much knowledge about TB and has just this 
knowledge that TB is infectious, […] then getting closer to the person and even 
how to handle yourself before the person so that you will not also get infected is 
one issue. 
Also, if the nurse doesn’t have much knowledge then stigmatization then comes in 
and fear of infection comes in too so you will not be able to assess the client very 
well”. (Female HCW, RHF) 
“[…] so, the ones who are not coughing I mean we can do our normal examination 
but most of the time I mean we don’t wear any PPEs. There have been few times 
which I have declined to see TB patients […]”. (Male HCW, MH) 





“Some of our laboratory staff, who show much concern for this screening issue, 
sometimes if accidentally they are not there and those who are around are the less 
concerned ones, sometimes we don’t get test result. [Therefore we] sometimes have 
to recall the clients to come and reproduce the sputum, sometimes you have to pay 





“If we get laboratory in any of the four facilities in the sub-district, it will solve the 
referral problem”. (Female HCW, RHF) 
“[…] instead of we referring directly to the laboratory at the municipal hospital, 
there could be a focal person at the laboratory who could come and take the sample 
and then when the person is diagnosed positive, the person can now go to the 
bigger facility for treatment […]”. (Female HCW, RHF) 
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Chapter 8: Discussion 
This chapter provides a synthesis of this thesis. It presents a summary of the key 
findings, reflections on the findings in relation to literature and the implications of the 
findings to TB case detection in health facilities. It also presents the strengths and 
limitations of the research and lastly it gives the conclusions and recommendations. 
 
8.1 Summary of key findings 
 
8.1.1 Situation assessment at health facilities 
 
Findings from a situation assessment at health facilities prior to the start of the study 
(chapter 4) revealed that some rural health facilities were not screening patients for 
symptoms of TB or requesting sputum tests. Also, in the facilities that were screening 
for TB-related symptoms, this was not done regularly. The reasons given for not 
screening for TB-related symptoms and requesting a sputum test were that HCWs were 
not trained on the use of the screening tool and the tool was not available in the health 
facilities. Since the prospective cohort component of this PhD study required patients 
who had a sputum test requested routinely by a HCW, the screening tool was 
introduced and HCWs at the rural health facilities selected for the study were trained 
by the study team on how to use it. This action likely influenced HCWs to screen for 
TB-related symptoms and request a sputum test. The likely impact on the results of 
the study is that, had the study not happened, there would have been even less TB 
case finding at these rural health facilities. 
 
8.1.2 Objective 1 
 
To determine the proportion of health facility attendees eligible for sputum test 
according to national guidelines who were asked to do a sputum test by a HCW and the 
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prevalence of having sputum positive on Xpert MTB/RIF among health facility 
attendees who met the criteria for sputum test according to study criteria. 
The findings of this objective are detailed in chapter 5. The key findings were that 
among patients attending outpatient clinics at the municipal hospital and had at least 
one symptom of TB and did not report these symptoms to a HCW, most were not asked 
about TB-related symptoms even though the national SOP for TB case detection states 
they should be asked. In addition, among patients who reported their TB-related 
symptoms to a HCW and were eligible for a sputum test, only about a fifth (21.5%) of 
them were asked to submit sputum for a TB test. Likewise, among patients whose TB-
related symptoms were elicited by a HCW and were eligible for a sputum test, only 
9.1% were asked to submit a sputum. Some patients did not report their TB-related 
symptoms at all to a HCW and among this category, 20% were eligible for a sputum 
test but none was asked to submit a sputum. The factors positively associated with 
being asked to submit a sputum by a HCW were increasing number and longer duration 
of symptoms as well as having been previously treated for TB. The prevalence of TB 
among patients who were eligible for a sputum test according to the study criteria was 
3.2% which was surprisingly low. 
 
8.1.3 Objective 2 
 
To determine the proportion of patients with a request for sputum test who submitted 
a sputum for testing, the time from test request to submitting sputum, and factors 
contributing to non- submission of sputum for testing. 
Findings for this objective are detailed in chapter 6. In summary, about 70% of patients 
with a request for a sputum test submitted a sputum for the test. Stratifying by the 
type of health facility attended, only 31.5% of rural facility attendees submitted 
sputum compared to 91.8% of urban facility attendees who submitted a sputum. The 
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main predictors of not submitting a sputum were travel distance greater than 10 km 
and a high perception of TB  stigma. 
 
8.1.4 Objective 3 
 
To compare the time from test request to submitting sputum among patients attending 
a health facility with vs. without a co-located laboratory. 
The majority of urban facility attendees submitted sputum earlier than rural facility 
attendees. In rural facilities where there was no co-located laboratory, only 4.2% 
submitted sputum to the laboratory on the day the test was requested compared to 
80.4% of urban facility attendees who submitted sputum on the day the test was 
requested. 
 
8.1.5 Objective 4 
 
To explore HCWs’ perspectives concerning barriers to TB case finding in health facilities, 
their experiences, practices and suggested solutions for improvement. 
The findings of this objective are detailed in chapter 7. Barriers to TB case finding in 
health facilities were classified into two thematic areas: health system-related and HCW-
related barriers. The main health system-related barriers were lack of access to 
diagnostic laboratories for patients attending rural health facilities, suboptimal screening 
for TB-related symptoms and sputum test request, lack of implementation of infection 
control measures according to the standard guidelines and insufficient monitoring of TB 
case detection activities in health facilities. The main HCW-related symptoms were lack 
of training on case detection guidelines and fear of infection causing a lack of motivation 
to carry out TB work. HCWs interviewed suggested that provision of diagnostic facilities 
in sub-municipalities, training on case detection guidelines and intensified supervision 
would help improve TB case detection in health facilities.  
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In summary, findings from this thesis show there are gaps in the pre-diagnostic steps 
of the TB care cascade. These gaps need to be closed to ensure patients with active TB 
accessing health facilities for care are promptly identified and initiated on treatment. 
 
8.2 Reflections on findings 
 
I have organised the discussion of these findings using a framework modelled around 
the steps of the TB care cascade. The framework was adapted from the conceptual 
framework of Bitton et al [136] and is shown in figure 8.1. It shows the gaps identified 
using the different components of the study, best practices from other countries to 
address similar gaps and what Ghana’s national TB control program can adapt from 
these best practices. The gaps identified, best practices from other countries, 
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Screening for TB 
symptoms by 
HCW 
Gap 1 Gap 2 
• Clinic observations: HCWs were not asking 
about TB-related symptoms; screening tool 
was not used 
• Exit interviews: HCWs in municipal hospital 
were not screening for TB-related symptoms 
and not requesting a sputum test 
• In-depth interviews: high workload, fear of 
infection, concept of task-shifting and 
shortage of staff were reasons given by 
HCWs for not screening for TB symptoms 
 
• Prospective cohort study: majority of rural 
facility attendees did not submit sputum 
• Main reasons: distance to laboratory and 
stigma 
• In-depth interviews: HCWs confirmed 
patients referred for test do not go. 
• Main reasons: no diagnostic facilities in rural 
settings, stock-outs of logistics, batch testing 
of samples leading to multiday visits and 
long waiting times at diagnostic facility  
Use of programme quality and efficiency (PQE) 
models 
• Tanzania: PQE model that included a tool kit 
for quality improvement, training package, 
tools/jobs aid, comprehensive screening, and 
intense monitoring  
• Kenya: training of hospital managers/senior 
doctors and appointment of TB focal clinician 
Use of specimen referral systems 
• Zimbabwe: use of motorcycle couriers to 
transport sputum specimen from urban and 
rural clinics to diagnostic facility 
• Uganda: use of postal services and motor 
riders to transport specimen from peripheral 
facilities to diagnostic facility 
• Inputs: training of HCWs, management 
support at facility level, leadership 
commitment at national level and intense 
monitoring at facility level 
• Output: informed and motivated HCWs who 
screen for TB symptoms and request sputum 
test 
• Outcome: improved TB case finding 
• Inputs: specimen referral systems from rural 
facilities to diagnostic facility, logistics for 
testing, increase laboratory staff  
• Output: increased access to diagnosis for 
patients by reducing the burden of travelling to 
the diagnostic facility 
• Outcome: improved TB case finding 
• All patients with 
positive TB test 
received a result 
• However, one 
third of patients 
did not receive a 
test result 




and patients with 
negative results 
All patients with a 
positive test result 
started TB 
treatment 
Suboptimal TB symptom screening and sputum 
requesting practices of HCWs 











Ghana from best 
practices 
Abbreviations  
HF = health facility 
HCW = healthcare worker 
TB = tuberculosis 
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Two main gaps were identified mainly in the pre-diagnostic steps of the TB care 
cascade. The gaps identified are: 
 
8.2.1  Gap 1: Suboptimal TB symptom screening and sputum requesting   
practices of HCWs 
 
Screening for symptoms of TB is the first important step required to identify people with 
TB. The WHO’s principles and recommendations for systematic screening for active TB 
states that the primary objective of screening for active TB is to ensure early detection 
of active TB and prompt initiation of treatment, with the ultimate aim of reducing the 
risk of poor treatment outcomes, health sequelae and the adverse social and economic 
consequences of TB, as well as helping to reduce TB transmission [38]. The WHO’s 
document outlines different recommendations for systematic screening for different 
risk groups. Different countries have adapted the WHO’s recommendations to suit 
their local context. In Ghana, the SOP for TB case detection states that all adult patients 
visiting OPD of health facilities should be asked about cough and those reporting a 
cough should be screened for TB-related systems, if eligible they should have a sputum 
test requested. Findings from the cross-sectional study using exit interviews showed 
that HCWs in the municipal hospital were not screening for TB-related symptoms and 
not requesting a sputum test among persons who spontaneously reported their 
symptoms and were eligible for a sputum test. Studies in South Africa and Zimbabwe 
using similar methodologies also reported that patients with TB symptoms seeking 
care in health facilities were not screened and sputum was not requested [82, 137-
141]. The details of how some of these studies compare with our study are discussed 
in chapter 5. In one of these studies [140], the authors found through exit interviews 
that, of patients reporting a history of cough of two weeks or more only 21% were 
asked to submit a sputum for testing. This was comparable to our study where we 
reported a similar proportion of 21.5% asked to submit a sputum among those eligible 
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for the test. Kweza et al in their exit interview study in South Africa, also reported that 
of 5% of patients exiting the facility who tested positive for TB by study team, 38.5% 
were never screened for TB-related symptoms by clinic staff and 61.5% were 
screened but not tested for TB [139]. Others similarly reported that HCWs were only 
prompted to request a sputum test if symptoms were obvious as TB related such as 
prolonged cough  [137, 141]. 
 
These findings from the cross-sectional study were supported by findings from the 
clinic observations in health facilities where we noticed HCWs were not systematically 
screening for symptoms of TB and requesting sputum tests. During the in-depth 
interviews in the qualitative study of this thesis, HCWs reported that shortage of staff 
leading to heavy workload were some of the reasons they do not screen for symptoms 
of TB. Others too felt screening for TB symptoms was extra work and not their duty. 
HCWs not screening for TB clearly showed non-adherence to standard guidelines and 
typically meant missed opportunities for identifying patients with TB.  In 2010 when 
the NTP introduced systematic screening of patients attending OPDs for TB-related 
symptoms as part of routine practices, HCWs started complaining of heavy workload 
leading to non-adherence to the guidelines. In response to this complaint, the NTP 
introduced the concept of “task-shifting” in some selected health facilities where a 
designated HCW is assigned and stationed at the OPD to support in the screening of 
patients for TB-related symptoms and request for a sputum test [142]. In 2016, task-
shifting officers were employed and posted to all district/municipal and regional 
hospitals. Findings from clinic observations and in-depth interviews in this study 
showed the presence of the task-shifting officer was helpful in identifying patients with 
TB, but the main challenge was that the presence of the task-shifting officer caused 
other HCWs not to screen for TB-related symptoms, because they felt it was not their 
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job leading to lack of attention to TB case finding. This made it difficult for the task-
shifting officer to take leave from work. We found during the clinic observations that 
at any point in time that the task-shifting officer fell sick, no one took over their role 
and this could lead to missed TB diagnoses. In a qualitative study among HCWs in the 
northern part of Ghana on barriers and facilitators to bidirectional screening of TB and 
diabetes (TB-DM), HCWs said the presence of a task-shifting officer had increased TB 
case finding compared to the low case detection they had prior to the institution of 
this position [143]. However, similar to what was found in our study, the task-shifting 
officer said the main challenge was that even though it was mandatory to screen all 
patients at the OPD for TB, other HCWs were not doing it, because the screening had 
not been fully incorporated in the triage routines at the OPD [143]. Despite the fact 
that the NTP has tried to solve the problem of non-adherence to screening guidelines 
by introducing the task-shifting concept, the challenges still exist as evidenced by our 
study and the TB-DM study. Project planners need to be aware that task shifting 
programmes are limited by the health system of which they are a part. Therefore, 
there is the need to consider the entire health system in the implementation of such 
programs most especially the professions affected by these programs [144]. These 
professions must be an active component of the change process rather than being 
alienated from it, such that they can provide the needed support for successful 
implementation. When they are excluded, then challenges such as those observed in 
our study arise.  Based on the experiences of HCWs on the concept of task shifting in 
sub-Saharan Africa reported in a systematic qualitative review [144], Ghana’s NTP 
needs to provide training for all HCWs at OPDs of health facilities on the concept of 
task shifting in TB case finding.  HCWs should be educated on the limitations of the 
concept and made to know that it is a complimentary practice hence, the need for 
them to all be supportive instead of leaving the work for the task-shifting officer. The 
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training of HCWs should be accompanied by strong supervision of the TB screening 
practices of HCWs and the task-shifting officer. 
 
Moreover, among HCWs we interviewed, most of them were not trained on the SOP 
for TB case detection. They acknowledged that lack of training led to poor knowledge 
of TB and a low index of suspicion. In chapter two, I detailed in the literature review 
several studies that also identified poor knowledge and low index of suspicion as 
factors causing delayed or missed diagnosis of TB [33, 39, 51, 63, 145]. Fear of infection 
was another reason for which HCWs did not screen for symptoms of TB or were 
reluctant to attend to TB patients admitted to the TB ward. HCWs need to be educated 
on the fact that TB patients on treatment and admitted in wards are unlikely to be 
infectious especially after two weeks of anti-TB treatment [146, 147] but rather it is 
the unidentified, untreated TB patient who is most likely to be infectious. Therefore, it 
will be in their interest to rather screen for symptoms of TB among patients so that 
those with the disease can be identified early and put on treatment to reduce the 
infectiousness of the disease and keep everyone safe. 
 
In Tanzania and Kenya, after their national prevalence surveys were conducted in 2013 
and 2015 respectively, they found higher than expected TB prevalence, showing that 
their case detection rates were low indicating persons with TB were missed, similar to 
what was found in Ghana [148]. In order to solve the problem, they conducted national 
assessments to identify the barriers and best practices in TB case finding. In Tanzania, 
the barriers included low index of suspicion among HCWs, low usage of diagnostic 
algorithms and unequal distribution of laboratory diagnostic services; and in Kenya, 
limited hospital managers’ and HCWs’ involvement in TB case detection and treatment 
were their main barriers. Both countries developed programme quality and efficiency 
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(PQE) models to solve the challenges. In Tanzania, the PQE included a toolkit for quality 
improvement in TB case detection, training package, tools and job aids, comprehensive 
screening and intense monitoring of health facilities. Training of hospital managers and 
senior doctors and the appointment of a TB  focal clinician whose duty was to keep TB 
on the agenda of discussions and meetings where components of the PQE 
implemented in Kenya. In addition, the Minister of Health sent a memo directing the 
practice of active TB case finding in all health facilities and this was a significant action 
that changed things. Peer mentorship visits were also carried out. After 18 months of 
implementation in Tanzania, the key results of the intervention were increased 
notification in facilities that implemented PQE compared with the control facilities; 
and increased index of suspicion of TB among HCWs. In Kenya, after a year of 
implementation, there was an increase of 158 percent in case detection in the 13 
country hospitals that benefitted from the intervention [148]. The key lessons learnt 
were that management support at the facility level and leadership commitment at the 
national level were essential in changing HCWs’ practices in TB case finding [148]. 
These were success stories shared at a workshop organized as part of a collaborative 
initiative designed to bring countries together to share experiences and support their 
efforts to reach the common goal of ending TB by 2030, in line with the WHO End TB 
strategy [148]. During our qualitative study, some HCWs mentioned that if leadership 
from the NTP and regional health directorate could come to the facility and talk to 
HCWs then they would comply with TB case finding guidelines in the facility, 
emphasizing the role of leadership, as demonstrated in Kenya. Ghana’s NTP could 
adapt some of these strategies based on what is feasible and meets the country’s need 
to improve TB case finding in health facilities. However, there is the need to bear in 
mind that these programme quality and efficiency models may not be sustainable 
[149]. Thus, an understanding of how to ensure sustainability and the factors that 
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affect it is of fundamental importance to prevent wasted effort [150]. These should be 
incorporated into the project design at the earliest stage of its development. It 
requires a supportive management structure from national, regional, district and 
facility level as well as a robust, transparent feedback systems to make it work [150]. 
 
As mentioned above in the summary of findings, the action taken after the situation 
assessment of health facilities was to ensure that the recruitment period for the 
prospective cohort study was not extended or the study could not be done. The 
assessment also portrayed the magnitude of the challenges with TB case finding in rural 
health facilities in the study setting. If prior to the study rural health facilities were not 
regularly referring presumptive TB patients for a sputum test, then the potential 
number of missed diagnoses of TB could be huge and this has implications for patient 
outcomes, transmission of disease in the community and national programme goals. 
This finding from the initial situation assessment was confirmed by findings from the 
clinic observations in the qualitative study where we found that even though HCWs in 
the consulting rooms of rural health facilities asked a routine set of symptoms 
questions to all patients, they did not continue to ask about other TB-related 
symptoms when a patient responded they had cough. Even though they asked about 
duration of cough, there were instances when patients reported durations of two 
weeks or more but they were not referred to the municipal hospital to submit a sputum 
for a TB test. This showed a gap in TB symptom screening practices of HCWs. Several 
reasons were given for why HCWs did not screen for TB-related symptoms as part of 
routine practices and these were discussed in detail in chapter 7. One of the reasons 
was that they had not been trained on the SOP for TB case detection and did not know 
there was a TB-symptom screening tool they needed to use. This was evident during 
in-depth interviews when some HCWs alluded to the fact that the first time they saw 
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the screening tool was when the study team introduced it to them. One-off training of 
HCWs on the SOP might not necessarily change their behaviour in screening for 
symptoms and requesting for sputum test. Ghana’s NTP could consider adapting one 
of the many programme quality and efficiency models used by other countries 
especially one that incorporates involvement of high level management and 
leadership, as was done in Kenya (discussed above) [148], to motivate HCWs to show 
more interest in TB case finding activities. This also implies the district TB 
management team should monitor closely the data that is reported by health facilities. 
This would enable them to know which facilities are screening for symptoms of TB and 
requesting sputum tests. If there is close monitoring of the data, once a facility is not 
reporting or the numbers are decreasing, they can intervene early to determine what 
the challenges are and resolve them. 
 
8.2.2 Gap 2: Non-submission of sputum for a TB test by patients 
 
In the TB care cascade, once a person is eligible for a sputum test, the HCW normally 
gives a request for a sputum test. The patient needs to produce a sputum sample and 
the sample submitted to the laboratory to be tested to confirm if the patient has TB or 
not. Submitting a sputum for testing is an essential step in the care cascade; however, 
it is not always easy to submit a sputum to the laboratory depending on where a 
patient accessed care. In our study setting, there was only one TB diagnostic laboratory 
at the municipal hospital and all patients with a request for a sputum test had to travel 
to the municipal hospital to submit a sputum for a TB test. In the prospective cohort 
study of this thesis, we followed up on patients to find out if they did submit a sputum 
after it was requested by a HCW and we found that the majority of rural health facility 
attendees did not submit a sputum for the test. In our qualitative study, HCWs in rural 
health facilities reported that when they referred patients to the municipal hospital 
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for a sputum test, most of them did not go to submit a sputum, leading to losses from 
the care cascade. The main predictor of patients not submitting a sputum was longer 
distance to the diagnostic laboratory. In the study setting, most of the rural areas were 
located about 10- 20 km from the municipal hospital and so patients need to reach the 
hospital either by using commercial motorbikes or public transport which they must 
pay for. As part of findings in the prospective cohort study, most study participants 
attending rural health facilities were in the lower wealth tertile. This implied they did 
not have money to pay for the transportation to the diagnostic laboratory for the test. 
In fact, one of the reasons mentioned by participants in the prospective cohort study 
as to why they did not submit a sputum was that they did not have money to travel to 
the hospital for the test. This also came out strongly during the qualitative study 
where HCWs said most patients were constrained financially and that is the reason 
why when they refer them for a sputum test, they do not go. On some occasions, HCWs 
had to pay the transportation cost for patients to go and submit a sputum at the 
municipal hospital. HCWs also mentioned that patients at times think they need to pay 
for services at the municipal hospital even though the TB test is free and for this 
reason, they are reluctant to go to the hospital. Studies in Ghana and Zimbabwe have 
reported long travel distance and its associated cost as risk factors for pre-diagnosis 
loss to follow-up [26, 28, 151]. 
 
Aside the direct out of pocket cost that prevented rural facility attendees from 
submitting sputum, there was also the opportunity cost. In the qualitative study, HCWs 
mentioned long waiting times at the municipal hospital as a reason for which patients 
they referred did not go. This was because patients felt they would waste time at the 
hospital and would rather prefer to do their work than to go to the hospital and lose 
income. This was also evident in the prospective cohort study where some patients who 
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did not submit sputum said the reason was because they did not have time to go to the 
hospital. In the literature review (Chapter 2), I detailed studies that reported how 
patients would prioritize their work over going to the hospital to seek health care [53, 
58, 62, 152]. During the qualitative study, we found that there was no standard referral 
system used at rural health facilities to refer presumptive TB patients to go for a 
sputum test or for further assessment at the municipal hospital. Presumptive TB 
patients were referred to different departments at the municipal hospital, and 
depending on the department the patient was referred to, it could lead to long waiting 
times. For instance, patients who were referred to the OPD of the municipal hospital 
had long waiting times compared to those referred to the chest clinic or directly to the 
task-shifting officer. A standard referral system could reduce the waiting time which 
might motivate patients to submit a sputum when they are referred.  In Tanzania and 
Kenya, during national assessment of barriers to TB case detection, they found weak 
referral systems as a reason for missed diagnosis of TB  [148]. 
 
Rather than asking patients to travel to the laboratory to submit a sputum, there could 
be innovative ways of transporting the sputum specimen to the laboratory. For 
instance in Zimbabwe, the NTP with the support of the United States Agency for 
International Development (USAID) and the International Union Against Tuberculosis 
and Lung Disease (The Union) initiated a medical specimen transport system in 2010 
to ensure universal and early access to TB diagnosis, care, and treatment [153]. The 
mainstay of the innovation was that it used a cadre of motorcycle couriers, enlisted to 
conduct specimen transport full-time. The couriers picked up sputum specimens from 
clinics and sent them to the laboratory for testing and they picked up the test results 
and delivered them back to the clinics. Clinics were visited on a daily basis in urban 
areas, and on a weekly basis in rural areas. The couriers used logbooks to track 
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specimens and results transported and HCWs and laboratory staff endorsed the 
logbooks daily, which fostered a high level of accountability for the couriers and 
implementers alike. In 2014, when they evaluated the programme, they found that the 
specimen transport system had strengthened TB diagnosis by decentralizing diagnostic 
services from district to peripheral health facilities. This increased access to diagnosis 
for patients by reducing the burden of traveling to district facilities to receive services. 
It also empowered HCWs to collect sputum specimens regularly instead of referring 
patients to district facilities and resulted in increased patient trust in the health system 
[153]. 
 
In Uganda, they also implemented an innovation to strengthen the TB specimen referral 
network for diagnosis of multi-drug resistant TB between 2008–2011 [154]. In their 
programme they used the postal services where on a daily basis, sputum specimens 
were transported from TB units to the local post office and the post office in turn 
transported the specimen to the national TB reference laboratory for testing. They 
found that the system led to increased numbers of patients receiving the necessary 
diagnostic testing and substantial reductions in transport delays [154]. Transport of 
sputum specimen which is an infectious material may require specific regulations and 
permits to be transported through the post office in most countries and specimen will 
require special packaging [155]. The authors mentioned that all the necessary 
consultations and permits were obtained from the relevant institutions before 
implementation of the intervention. HCWs and post office staff were trained on how 
to safely package specimen and the specimen transport containers used were the ones 
with triple packaging capacity which were validated by South African national 
standards [154].  
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Again, between 2015-2018, when Uganda realized there remained significant gaps 
along the cascade of care for patients undergoing TB diagnostic evaluation at 
peripheral health centres (i.e. considerable costs and time required to complete health 
centre visits), they initiated a system similar to the one implemented in Zimbabwe 
using motor riders [156]. They found it significantly improved the provision of high-
quality care for patients undergoing TB diagnostic evaluation. 
 
Specimen referral systems play a critical role in ensuring access to laboratory services 
by allowing patients to receive care and treatment at one location, while their 
specimens are transferred to various levels of a tiered laboratory system for testing 
[155]. Referral systems can efficiently increase access to diagnostics in areas where 
testing is not available, prevent the need and associated costs for patients to travel, 
and lead to equity in access to health care [155]. It is time Ghana’s NTP took a cue from 
these success stories in other countries and adopt a specimen referral system instead 
of asking patients to travel all the way to district or municipal hospitals to submit a 
sputum. There is no doubt that these innovations do have limitations and some of the 
limitations include getting to hard-to-reach areas in rural communities especially 
during the rainy season when roads are unmotorable [154] but these innovations still 
have the potential to reduce losses in the care cascade than asking patients to travel 
to the diagnostic laboratory to submit a sputum. Other factors in our study which 
contributed to pre-diagnostic delay or loss to follow-up such as rural facility attendance 
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Other findings from the diagnostic and post-diagnostic steps of the TB care cascade 
are discussed below: 
8.2.3 Laboratory testing of sputum samples 
 
Laboratory testing is another important step in the TB care cascade. During clinic 
observations in our qualitative study, we observed at the municipal hospital that 
patients who were given a request for a sputum sample had to either collect a sputum 
container from the task-shifting officer or the laboratory or the chest clinic. The 
location of containers kept changing because HCWs at the chest clinic claimed when 
the containers were given out at the laboratory, laboratory staff did not monitor the 
usage and this at times led to stock-outs. When this happened, patients who travelled 
in from rural health facilities to submit sputum would return home without submitting 
the sputum and some never returned to the hospital to submit a sputum. This added 
to the financial cost to the patients as was mentioned by HCWs of the chest clinic during 
in-depth interviews. Some of these inconveniences caused to patients could also be the 
reason for their reluctance to travel to the municipal hospital to submit a sputum. Also, 
when the sputum containers were kept at the chest clinic, it increased the time 
patients spent in the hospital and caused more inconvenience. This is because the chest 
clinic was located about 200-300 metres from the OPD and patients had to walk all the 
way to the chest clinic to collect a container, produce sputum and returned to the OPD 
to submit it at the laboratory. This made the whole process of sputum submission very 
cumbersome for patients. Allowing the task-shifting officer to keep the containers 
would make it simpler for patients to submit sputum. 
 
At the time of planning the study, the main diagnostic method was smear microscopy 
but by the time we were executing the study, the main diagnostic method had changed 
to Xpert MTB/RIF. At the planning stage of the study, we considered the fact that 
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presumed TB patients needed to submit a sputum the first day and return the next day 
to submit a second specimen, so we anticipated more loses than observed from the 
testing cascade in our prospective cohort study. However, the change to Xpert 
MTB/RIF did not affect this because presumptive TB patients submitting a sputum at 
the laboratory still needed to visit the hospital a second time to receive their results. 
The reason for this multi-day visit was because the laboratory batched all sputum 
specimen and performed the testing towards the end of the working day. In order not 
to let patients wait a long time to receive their results on the day of sputum 
submission, they were asked to return the next day for the results or told they would 
be called by the hospital to inform them of their results. The reason for which sputum 
specimens were batched and the test performed at the end of the day was because of 
heavy workload and few laboratory staff as reported during in-depth interviews with 
HCWs. The laboratory doubled as the main laboratory for performing all laboratory 
tests for all other diseases with the same staff performing all the tests. Laboratory staff 
did not give priority to performing sputum test as reported by some HCWs during in-
depth interviews and this at times led to delay in the release of test results. This reflects 
the tension between laboratory organization and patient-centred care. These multi-
day visits contribute to loses from the care cascade as has been shown by several 
studies [97, 99]. Davids et al in their cross-sectional survey of primary healthcare 
providers on use of rapid tests and TB diagnostic practices in South Africa reported that 
despite implementation of Xpert MTB/RIF there was still long turnaround times to 
receiving TB test results (median: 3 days) [99]. This was similar to our qualitative finding 
where patients had to visit the hospital a second time after sputum submission to 
receive a test result even though Xpert MTB/RIF was the main diagnostic tool. Davids 
et al explained that the long turnaround time was due to backlogs created by the 
centralized testing system and that primary healthcare facilities required the 
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appointment of additional staff to ensure same-day results  [99]. 
 
In the cross-sectional exit interview study, we asked patients who were eligible for a 
sputum test according to our study criteria to submit one spot sputum specimen for 
laboratory testing to determine the prevalence of TB among patients exiting the 
hospital after seeking care for themselves and reporting at least one TB-related 
symptom. The yield of TB was low (3.2%), and several reasons could account for this 
but one of the reasons could be because most of the sputum specimen submitted were 
salivary. At the municipal hospital there was a sputum booth for sputum collection 
and although routinely patients were educated on how to produce a sputum 
specimen, there was no direct supervision of sputum production. The study team too 
did not supervise sputum collection though education on how to produce quality 
sputum was provided to patients. The study criteria used for eligibility for sputum 
submission was the same as the national criteria being used by the hospital except that 
the study criteria included patients self-reporting to be HIV-positive. Since study staff 
did not supervise patients to produce sputum which could have resulted in a lot of 
salivary specimen then it could be that since routinely in the hospital patients are 
equally not supervised to produce sputum then it is possible most of the specimen 
submitted to the laboratory for routine testing might also be salivary. This could result 
in missed diagnosis of TB. We would advise that patients should be supervised to 
produce quality sputum for testing. In Botswana, Mathebula et al conducted a study 
in 2013 to improve sputum collection processes to increase TB case finding among HIV-
positive persons by introducing sputum collection job aids and assisting patients to 
produce sputum [157]. They found that enhanced sputum collection significantly 
improved the quality of sputum collected. The number of salivary sputa decreased 
significantly, and the proportion of mucoid and muco-purulent sputum specimen 
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increased. The rates of TB diagnosis also increased from 9.7% to 12.5% but the 
evidence for this difference was weak (P=0.143) [157]. The authors however, did not 
comment on sustainability of the intervention strategies, although they mentioned that 
they did not assess the cost-effectiveness of the intervention strategies, but they 
believed it would be a low-cost intervention [157]. 
 
8.2.4 Receiving test results and initiating TB treatment 
 
In the prospective cohort study of this thesis, we found that about 33% of study 
participants who submitted a sputum for a TB test did not receive a test result. During 
clinic observations and in-depth interviews, we discovered that in the municipal 
hospital, the task-shifting officer on a daily basis picked up the test results from the 
laboratory of all patients who submitted sputum the previous day. He then called 
those with positive test results to inform them of the results and asked them to come 
to the hospital to start TB treatment. Those with a negative test result had to visit the 
hospital to pick up their results. It is possible that some of those who did not return to 
the hospital were those who had not received their results. This implied there was no 
further follow up of these patients with negative test results. In the SOP for TB case 
detection, the TB diagnosis and treatment algorithm outlines that patients with a 
negative TB result should be treated with broad spectrum antibiotics and if they did not 
get better, the sputum test should be repeated and chest radiograph taken and if both 
are negative then the clinician should make a clinical judgement to treat or not treat 
for TB. During follow-up calls as part of the prospective cohort study, when we asked 
participants why they had not received their test results, some said they felt better 
from their symptoms and did not see the need to return for the results but others said 
they were told by the task-shifting officer they will be called to inform them of the 
results but no one had called them. Some of them were quite upset that they had not 
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heard anything from the hospital about their results. This lack of communication from 
the hospital reduced their trust in the health system. When the task-shifting officer 
was asked during in-depth interviews why the hospital did not call patients to inform 
them of their test result as communicated to them, the task-shifting officer said no call 
credit was provided by the hospital or district management to call patients to inform 
them of their test results. In a study in South Africa where they used standardized 
patients’ analysis to measure the quality of TB screening at primary healthcare 
facilities, they found only 28% of standardized patients were effectively communicated 
to on receiving their results [158]. This showed a lack of information-sharing, 
particularly in terms of continuity of care.  
 
A positive finding however was that all patients with a positive test result were 
initiated on TB treatment promptly, usually within a day or two. This could be 
attributed to the commitment of the task-shifting officer in calling those with positive 
test results using his own call credit to come and start treatment. If the laboratory 
confirmed a positive test result and the task-shifting officer was not available, staff at 
the chest clinic were notified of the positive results and they would call the patient to 
come for treatment. In instances where a patient with a positive TB test result had 
no telephone number or could not be reached on the telephone number provided, the 
task-shifting officer traced them to their homes using the contact address they 
provided to inform them of the results and asked them to come and start treatment. 
At times, he used his own resources to do this but at other times he informed the staff 
at the chest clinic who would request for a vehicle from the hospital administration to 
follow up on the patient with positive test result and bring them in for treatment. 
Unfortunately, sometimes they were informed by the hospital administrator that there 
is no vehicle available. This highlights the institutional challenges HCWs sometimes 
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encounter in carrying out TB case finding activities. There is the need for facility 
management commitment to TB case finding in health facilities. 
 
Also, the task-shifting officer accompanied positive TB patients to the chest clinic for 
them to start treatment. A challenge was that at times patients with positive test result 
were not told to come with a treatment supporter and in such instances, they had to 
go and find a treatment supporter before they were initiated on treatment.  A 
treatment supporter was a person chosen by the TB patient whose main role was to 
make sure that the patient took the TB drugs regularly, on schedule, for the full duration 
of the treatment [159]. A TB patient having to go and look for a treatment supporter 
before TB treatment is initiated can lead to loss to follow-up. Since pre-treatment loss 
to follow-up was not the main focus of this study, we did not explore this further, but it 
could be an area for future research. 
 
The time between a positive test result and treatment being started in this thesis was 
comparable to a cross-sectional study in Italy on determinants of patient and health 
care services delays for TB diagnosis where the authors found the median treatment 
delay was zero days with an interquartile range of zero to three days [46]. Also, a 
systematic review and meta-analysis involving 78 countries on empirical evidence of 
delays in diagnosis and treatment of pulmonary TB showed that the pooled mean 
treatment delay was 7.9 days compared to pooled mean patient delay of 81 day [34]. 
Although most studies on delay define health system delay as the time a patient first 
contacts a health facility to the time TB treatment is initiated, there are few studies 
that sub-categorize health system delay into diagnostic delay and treatment delay as 
reported in this systematic review. The definitions for diagnostic delay and treatment 
delay were discussed in the literature review in chapter 2. The systematic review 
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showed that treatment delay was not the main contributor of delay in TB diagnosis and 
treatment but rather patients not accessing care early for their TB-related  symptoms. 
 
This PhD study was designed to focus on the pre-diagnostic steps and not the pre-
treatment step of the TB care cascade because we envisaged that the challenges in TB 
case finding in health facilities would be at the pre-diagnostic phase. Also, the pre-
diagnostic steps in health facilities are less often studied and perhaps less well 
understood. 
 




Some limitations of the different studies that make up this thesis are discussed in 
chapters 5, 6 and 7. Here I present some additional limitations. 
 
8.3.1.1 Potential biases in cross-sectional study using exit interviews 
 
Selection bias: in determining the prevalence of TB among patients with at least one 
TB-related symptom, we only asked patients who were eligible for a sputum test 
according to the study criteria (cough > 2 weeks or cough of any duration plus any two 
other TB-related symptoms or self-reported HIV positive status with any TB-related 
symptom) to submit one spot sputum sample for testing instead of asking all study 
participants. It is possible we missed out on some participants who were not eligible 
to submit a sputum but could have tested positive for TB. We restricted sputum testing 
to only those eligible because the study did not have sufficient funding to test all 
participants. It is also inevitable that the study would have missed out on subclinical 
TB patients (persons with active TB who do not report clinical TB-related symptoms 
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but have other abnormalities that can be detected using existing radiologic or 
microbiologic assays [9]) who would not have reported a TB-related symptom and 
therefore would not have been asked to take part in the cross-sectional study. 
 
Non-response bias: among symptomatic patients exiting the hospital who were 
eligible for the study, about 11% did not consent to take part in the study. If 
characteristics of these patients were different from those recruited in the study, then 
that could potentially affect the findings; for instance assuming all those who did not 
consent to be part of the study had reported their TB-related symptoms to a HCW and 
had a sputum test requested then the proportion of patients who had a sputum test 
requested by a HCW would have been higher than reported by the study. Research 
assistants did their best to encourage all eligible patients to take part in the study but 
because these were exit interviews and patients had already spent long hours at the 
hospital, they were in a hurry to leave the hospital. This is evident in the reasons for 
which consent was declined as 74% of eligible patients who declined said they did not 
have time for an interview. 
 
The cross-sectional study was only conducted at the municipal hospital due to logistical 
constraints. It is possible that the proportion of patients eligible for a sputum test who 
were not asked to submit a sputum would have been much higher if we had included 
the rural health facilities in this component of the study. 
 
8.3.1.2 Potential biases in prospective observational cohort study 
 
Loss to follow-up bias: some participants recruited were lost to follow up and this 
could have affected the outcome since we did not know whether they submitted a 
sputum sample or not, even though for most of them we cross-checked from the 
 175  
laboratory TB register to find out if they submitted a sputum sample. We did our best 
to minimize loss to follow-up by collecting two telephone numbers from study 
participants: their personal number and the number of another person they felt 
comfortable that we could call to check on them. For participants without telephone 
numbers, we collected a traceable home address using landmarks so we could visit 
them in their home for the follow up. We maintained participants’ interest in the study 
by letting them know that the follow up calls or visits were to check on their health 
condition rather than just soliciting for information. Participants were also given call 
credit of 0.50 pence (0.25p at recruitment and 0.25p at the last follow up call) of any 
mobile network of their choice to keep in touch with the study team. This was equally 
to maintain their interest in the study. The loss to follow-up for this study was 4% which 
was unlikely to affect the point estimate of the primary outcome. 
 
Response bias: since we kept calling participants regularly and each time asking 
whether they had submitted a sputum or received a test result, some of them could 
have responded yes to these questions without actually submitting sputum or 
receiving a test result. To minimize this, we cross-checked from the presumptive TB 
register and with the task-shifting officer to find out if a sputum had been submitted or 
a result collected. In instances where we found otherwise from the register or task-
shifting officer, at the next follow up we probed further the initial response given by 
the participant during the last follow up call or visit. 
 
8.3.1.3 Qualitative study 
 
An additional limitation in the qualitative study was that the study participants did not 
include a member of staff from the laboratory to give their experiences and 
perceptions since laboratory testing is an essential step in the TB care cascade. That 
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notwithstanding, HCWs interviewed were able to talk about barriers relating to 
laboratory testing for TB. We could not include a member of laboratory staff because 
during the period of the in-depth interviews, the laboratory staff operating the 
GeneXpert was not available. 
 
Also, having the national TB control programme manager as the local supervisor of the 
study, which was indicated on the study information sheet, could have influenced what 
HCWs said about their experiences and perceptions for fear of being victimized. To 
minimize any biases, participants were assured of confidentiality of their identity and 
information they provided. I acknowledge that my prior experience of working in a 
regional hospital laboratory and coordinating TB laboratory work at a regional level 
could have influenced my interpretation of the study findings. Because I have worked 
in a leadership role in TB control, my expectation was that, once guidelines are given 
to health facilities to follow, then HCWs will follow these guidelines but as study 
findings were contrary to this, I was tempted to blame HCWs. However, based on what 
I learnt during the study, I acknowledge that some of the challenges are health-system 
related where policies are made without making provision for the system to 
accommodate them. Also, being a middle-aged Christian woman going to conduct 
research in an area where many people hold traditional beliefs could have influenced how 
I perceived the study participants and their responses to some questions asked when 
these were contrary to my belief as a Christian. 
 
We did not do in-depth interviews with presumptive TB or TB patients to find out their 
experiences and perceptions of barriers to TB diagnosis and treatment. This was due 
to logistical challenges and time constraint for the study. Therefore, we could not get 
first-hand information on barriers TB patients encounter in getting a TB diagnosis and 
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initiating treatment, which is a limitation. However, in the prospective cohort study, 
we did get comments from patients on their perception of the TB diagnostic pathway. 
These are not qualitative data but at least gave some insight into their perspectives of 




The main strength of this thesis was the use of mixed methods to achieve the study 
objectives. Findings from the qualitative study were used to validate some of the 
findings in the quantitative studies. The different studies thus complemented each 
other to improve the validity of the study findings. 
 
The use of a prospective observational cohort design, as discussed in chapter 6, 
enabled us to measure the direct losses from the testing cascade and factors 
accounting for these losses. This was also quite novel since most studies on delayed or 
missed diagnosis of TB use retrospective cross-sectional designs or secondary data 
from TB patients already on treatment thus missing out on those who never got a 
diagnosis or started TB treatment. The prospective cohort design reduced selection 
bias, improved validity and provided unusual data since this approach is not often 
used. 
 
As previously discussed (chapter 5), the use of exit interviews in the cross-sectional 
study reduced recall bias since participants had just sought care and were more likely 
to remember what had happened in the clinic that day. The use of clinic observations 
and in-depth interviews in the qualitative study to triangulate findings was the main 
strength of the qualitative study as previously discussed in chapter 7. 
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8.4 Reflective commentary 
 
Prior to starting a PhD in 2016, I had been involved with research at different stages of 
the research process but this thesis gave me the opportunity to be involved at all 
stages of the research process: developing a protocol, seeking ethical approval, 
planning and executing data collection, coordinating fieldwork, data management and 
analysis, writing reports and manuscripts for publication. It has been a learning process 
where I learnt not only the challenges inherent in the research process but also the 
fulfilling moments when a major milestone was achieved. 
 
Throughout the process, I worked with different teams notably my supervisory, study 
and health facility teams, all of whom were very helpful. During fieldwork, I understood 
the importance of establishing good working relationships with members of the 
various teams including study participants. This was particularly important for the 
prospective cohort study because of the follow up element, as this made them more 
cooperative. Listening to stories told by study participants during interviews and 
relating to their circumstances was a good way to establish rapport and maintain their 
interest in the study. The follow up calls and home visits were novel to study participants 
as most of them said they never had people call them from the hospital to check on 
their health and they were very grateful. This gave the study team a sense of fulfilment. 
In Ghana and particularly in the study setting there was no formal address system so 
tracing participants without telephone numbers to their homes using landmarks 
during follow up was challenging. On numerous occasions we got lost in villages and 
there were times we needed to walk long distances because the roads were not 
accessible in a motor vehicle. But this made me appreciate better the challenges HCWs 
encounter in tracing TB patients and likewise the challenges faced by some patients in 
accessing health care services. 
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Despite all the challenges, the project was executed successfully. The whole process 
was a learning experience for me, and I learnt something new daily. I believe with the 
experience gained, module courses I took as well as different transferable skills I 
gained has made me a better researcher compared to the experience I had before the 




Ghana’s national TB control program can seek to bridge the gaps identified in this 
thesis by employing a systems thinking approach where the gaps can be viewed as part 
of a wider dynamic system. Systems thinking enables a deeper understanding of the 
linkages, relationships, interactions and approach to illuminate the full range of effects 
behaviours among the elements that characterize the entire system [160]. This will 
enable a better and realistic understanding of what works for whom and under what 
circumstances [161]. Health systems thinking can be modelled along the building 
blocks of the WHO’s health systems framework [160]. The WHO’s health systems 
framework has six building blocks that contribute to the strengthening of health 
systems in different ways [162]. Interventions implemented at systems level target one 
or multiple system building blocks directly or broadly rather than just one specific 
health problem [160]. A systems thinking approach to bridge the gaps in the TB care 
cascade within the health system should consider inputs, outputs, initial, intermediate 
and eventual outcomes that can strengthen the health system [161]. The 
recommendations from this thesis follow the concept of health systems thinking 
modelled along the building blocks as shown in figure 8.2 below: 
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Figure 8. 2: Recommended health systems framework building blocks for 

















TB= tuberculosis, HCW= healthcare worker, PPE= personal protective equipment 
Figure 8.2 shows the six building blocks, the activities that can be implemented to bridge the 
gaps and the possible outcomes. Recommendations for each gap are stated below: 
 
8.5.1 Recommendations for health system improvement 
 
8.5.1.1 Gap 1: Suboptimal TB symptom screening and sputum requesting practices 
of HCWs  
 
i. Service delivery: effective monitoring of TB case finding activities in health 
facilities should be carried out regularly by TB teams to ensure screening for 
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consistent activity carried out in all departments of the facility. Peer mentorship 
programs can be instituted in health facilities to motivate HCWs to screen for 
symptoms of TB and request for sputum test where necessary. The concept of 
task shifting should be fully integrated in the triaging process at the OPD of health 
facilities being mindful of existing professional identities. 
ii. Governance/leadership: health facility managers should be involved in TB case 
finding activities so they can provide the necessary logistics and high-level 
leadership that will ensure HCWs adhere to the standard guidelines for TB case 
detection. Teams from the national, regional and district levels should pay 
regular visits to health facilities to encourage HCWs to screen for symptoms of 
TB. 
iii. Human resource: all HCWs in all units of health facilities should be adequately 
trained on the standard guidelines for TB case finding. Functional TB teams 
should be formed, or TB focal persons appointed in health facilities and they 
should develop a plan outlining activities that should be carried out, sensitize 
HCWs on the plan, screening tool and sputum request form, and encourage 
them to comply and use the tools. The team should meet on a regular basis to 
review progress of implementation of the plan. 
iv. Medical supplies: health facility managements should provide N95 respirators 
for HCWs to alleviate their fears of infection and encourage screening for 
symptoms of TB. 
 
The different programme quality and efficiency models employed by Tanzania and 
Kenya to improve TB case detection discussed in section 8.2.1 could be adapted and 
modified by Ghana depending on the local needs to improve TB case finding in health 
facilities. 
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8.5.1.2 Gap 2: Non-submission of sputum for a TB test by patients  
 
i. Service delivery: Ghana’s NTP should possibly institute a specimen referral 
system so that presumptive TB patients identified in rural health facilities will 
not have to travel to the municipal hospital to submit a sputum for a TB test. 
Several success stories of implementing specimen referral systems have been 
shared by LMICs as discussed in section 8.2.2. Ghana could adapt one of the 
innovations that is feasible and suits the local needs. 
ii. Governance/leadership: high level support from the NTP by periodic evaluation 
of the system will enable them to identify challenges early which can be 
addressed to ensure the system is effective. 
iii. Human resource: more laboratory staff should be employed to handle the 
increase in sputum submission for testing to ensure timely release of test 
results.  
iv. Medical supplies: with an expected increase in sputum submission, the NTP 
should ensure adequate supply of sputum containers and GeneXpert cartridges 
to prevent stock outs and ensure the specimen referral system remains 
functional.  
v. Health information: an implementation of an efficient system for feedback of 
test results to the rural health facilities will be essential. Once HCWs get 
feedback from specimen they refer for testing, they will probably be motivated 
to screen for symptoms of TB and request for sputum test. Presumptive TB 
patients might also be encouraged to submit sputum for testing once they know 
they will receive a test result timely.  
vi. Financing: Ghana’s ministry of health and the NTP should commit funding to the 
implementation of a specimen referral system to reduce losses in the diagnostic 
cascade.  
 183  
 
The possible outcomes from these recommendations could be adequately trained 
HCWs who are motivated to screen for symptoms of TB and request for sputum test 
when a patient is eligible, increased access to testing for presumptive patients who 
seek care from rural health facilities, and all these could lead to increased case 
detection rates (figure 8.2).  
 
8.5.2 Recommendations for future research 
 
Since we could not conduct in-depth interviews with patients to explore their 
experiences and perceptions on barriers to TB case finding in health facilities, this 
could be an area for further research. Findings from this research could be used to 
inform patient-centred interventions for improved case finding. 
 
In this PhD study, we found that newly diagnosed TB patients being initiated on 
treatment needed to have a treatment supporter before treatment can be initiated. 
Since this area was not the main focus of our study, we could not explore more the 
usefulness of treatment supporters. Further research is needed to answer the research 
question: does having a treatment supporter improve treatment outcomes? It will also 
be worth exploring whether chest clinics rigidly enforce the requirements for a 
treatment supporter. If they do, does this mean that some people do not start 
treatment? Findings will justify or refute the insistence of chest clinic staff on TB 
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8.6 General conclusion 
 
This thesis highlights the gaps in the pre-diagnostic steps of the TB care cascade in 
health facilities in Ghana. HCWs’ suboptimal adherence to the national SOP for TB case 
detection is one of the causes of gaps in the pre-diagnostic cascade. Also, the majority 
of presumptive TB patients attending rural health facilities not submitting sputum for 
testing due to lack of a specimen transport system to facilitate sputum testing is 
another cause of the gaps. The factors contributing to these gaps are multifaceted and 
require commitments from the NTP, health facility managers, HCWs and presumptive 
TB patients to address. High-level leadership endorsement of TB symptom screening 
in health facilities will motivate HCWs to adhere to the SOP for TB case detection and 
a system to facilitate referral of specimen from rural health facilities to the diagnostic 
laboratory may bridge the gaps and possibly improve TB case detection. 
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include the URL reference and the date accessed. 
 
Translations of the Licensed Materials should be attributed as follows: 
 
"Translated with permission of the publisher from Publication title, Vol /edition 




4. Altering or Modifying the Licensed Materials. As part of the Licensed Use, 
you may minimally alter or adapt figures and tables in the Licensed Materials to 
match the style of your publication. Any other alteration or modification of the 
Licensed Materials (including abbreviations, additions, or deletions) may be made 
only with the prior written authorization of WHO. 
 
5. Appropriate and Prohibited Uses. You must use the Licensed Materials in a 
factual and appropriate context. You may not use the Licensed Materials in 
association with any product marketing, promotional, or commercial activities, 
including, without limitation, in advertisements, product brochures, company-
sponsored web sites, annual reports, or other non-educational publications or 
distributions. 
 
6. N o WHO endorsement. You shall not state or imply that WHO endorses or 
is affiliated with your publication or the Licensed Use, or that WHO endorses any 
entity, organization, company, or product. 
 
7. N o use of the WHO logo. In no case shall you use the WHO name or 
emblem, or any abbreviation thereof. Notwithstanding the foregoing, if the WHO 
name and/or emblem appear as an integral part of the Licensed Materials (e.g. on a 
map) you may use the name and/or emblem in your use of the License Materials, 
provided the name and/or logo is not used separately from the Licensed Materials. 
 
8. N o Warranties by WHO. All reasonable precautions have been taken by 
WHO to verify the information contained in the Licensed Materials. However, WHO 
provides the Licensed Materials to you without warranty of any kind, either 
expressed or implied, and you are entirely responsible for your use of the Licensed 
Materials. In no event shall WHO be liable for damages arising from your use of the 
Licensed Materials. 
 
9. Y our Indemnification of WHO. You agree to indemnify WHO for, and hold 
WHO harmless   against, any claim for damages, losses, and/or any costs, including 
attorneys' fees, arising in any manner whatsoever from your use of the Licensed 
Materials or for your breach of any of the terms of this Agreement. 
 
10. Termination. The licence and the rights granted under this Agreement shall 
terminate automatically upon any breach by you of the terms of this Agreement. 
Further, WHO may terminate this licence at any time with immediate effect for any 
reason by written notice to you. 
 
11. Entire Agreement, Amendment. This Agreement is the entire agreement 
between you and  WHO with respect to its subject matter. WHO is not bound by any 
additional terms that may appear in any communication from you. This Agreement 
may only be amended by mutual written agreement of you and WHO. 
 
12. Headings. Paragraph headings in this Agreement are for reference only. 
 
13. Dispute resolution. Any dispute relating to the interpretation or 
application of this Agreement shall, unless amicably settled, be subject to 
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conciliation. In the event of failure of the latter, the dispute shall be settled by 
arbitration. The arbitration shall be conducted in accordance with the modalities to 
be agreed upon by the parties or, in the absence of agreement, with the rules of 
arbitration of the International Chamber of Commerce. The parties shall accept the 
arbitral award as final. 
 
14. Privileges and immunities. Nothing in or relating to this Agreement shall be 
deemed a waiver of any of the privileges and immunities enjoyed by WHO under 

































Appendix 10.5 Permission from Ghana National TB Control 
Program to use prevalence survey reproduce TB 
care cascade  
 
Re: Permission to reproduce data in thesis 
Yaw Adusi-Poku <adusipokuyaw@gmail.com> 
Wed 12/23/2020 9:33 AM 
To: Joyce Der <joyce.der@lshtm.ac.uk> 
Cc: Zeleke Alebachew <zalebachew@gmail.com>; Rita Patricia Frimpong-Mansoh 
<ritapatriciafrimpongmansoh@gmail.com>; Kwami Afutu <kwami.afutu@ghsmail.org>; Bernard 
Wadie 
<nanawadie01@gmail.com> 
*** This message originated outside LSHTM *** 




From: Yaw Adusi-Poku <adusipokuyaw@gmail.com> 
Sent: Monday, November 16, 2020 7:25 PM 
To: Joyce Der <joyce.der@lshtm.ac.uk> 
 
Cc: Frank Bonsu <fabonsu@gmail.com>; Kwami Afutu <kwami.afutu@ghsmail.org>; 
Zeleke Alebachew 
<zalebachew@gmail.com>; Rita Patricia Frimpong-Mansoh 
<ritapatriciafrimpongmansoh@gmail.com>; Bernard Wadie 
<nanawadie01@gmail.com> 
Subject: Re: Permission to reproduce data in thesis 
 
*** This message originated outside LSHTM *** 
Dear Joyce, 
Glad to know that you started working 
with Dr Bonsu. I've put the rest of the 
team members in copy. 
We will discuss and 




Get O utlook for Android 
 
From: Joyce Der <joyce.der@lshtm.ac.uk> 
Sent: Monday, November 16, 2020 5:33:55 PM 
To: a dusipokuyaw@gmail.com <adusipokuyaw@gmail.com> 
Cc: Frank Bonsu <fabonsu@gmail.com> 





Dear Dr. Yaw Adusi-Poku, 
 
My name is Joyce Der, a lecturer at the University of Health and Allied Sciences, Ho 
but currently a PhD student at the London School of Hygiene and Tropical Medicine, 
UK. My PhD study is on the pathways to TB diagnosis and treatment in Ghana: 
identifying the gaps and seeking solutions. 
 
As part of the study, I followed patients who had routinely been given a sputum test 
request by a health worker in Ketu South Municipality to find out whether they 
submitted sputum for testing and determine factors associated with non-submission 
of sputum. I also used exit interviews of patients attending the municipal hospital to 
find out the TB symptom screening and sputum test requesting practices of health 
workers. This study was done based on findings of the 2013 national TB prevalence 
survey where they found among patients with prolonged cough who visited a 
government health facility and required a sputum test, only about 25% submitted a 
sputum. I therefore wanted to find out whether it is patients who do not submit 
sputum or health workers who do not screen for symptoms of TB and request a 
sputum test if patients are eligible for the test. My local supervisor for the field work 
was Dr Frank Bonsu (cc in this email). 
 
I generated a cascade of prevalence survey participants who did a sputum test using 
the findings from the prevalence survey which I intend to include in my thesis as 
justification for the study. 
However, I need permission from the TB Control Program to use the prevalence 
survey findings for this cascade. I will be grateful if you can grant me permission to 





















Appendix 10.6 Information sheets and informed consent forms 
 
Participant Information Sheet: component B (cross-sectional study) 
 
Project Title: Pathways to tuberculosis diagnosis and treatment in Ghana: identifying 
the gaps and seeking solutions 
Investigators: 
London School of Hygiene and Tropical Medicine, UK: Joyce Der, Prof Alison Grant, 
Dr Virginia Bond, Dr Daniel Grint 
National TB Control Program, Ghana: Dr Frank Bonsu 
[Greetings], my name is [  ]. I am a researcher or part of a research team 
based at the London School of Hygiene and Tropical Medicine, UK. We would like to 
invite you to take part in this study. This information sheet explains the study. You are 
free to decide if you want to take part or not. If you decide to take part, I will ask you 
to sign on a consent form or give a thumbprint. Signing or thumbprinting the form 
means that you agree to take part in the study. It also means that you are aware of 
your right not to take part, or to stop taking part at any time. If you decide not to take 
part, this will not affect your right to health care at this health facility. 
Why are we doing this study? Tuberculosis (TB) remains one of the top 10 causes of 
death worldwide. A survey in 2013 showed that TB remains an important health 
problem in Ghana, and that people with TB may experience delays before they are 
given correct treatment. If we can identify where and why people are delayed, then we 
can make recommendations for improvement so that people with TB can be identified 
early and put on treatment. 
If you take part in this study, what will happen? If you agree to take part in this study, 
we will ask you some questions about TB symptoms, the reason you visited the hospital 
and whether you were asked to do a sputum TB test. If you report a cough of 2 weeks 
or more, we will ask you to produce a sample of sputum (spit from the chest) which 
will be sent to the laboratory for testing to find out if you have TB. The study will pay 
for the cost of the test. If you permit, we will review your hospital folder to see what 
the doctors have written concerning your sickness. The questions will take 10-
15minutes. It will not cost you any money to take part in this study and there is no 
payment to people who take part. 
 
What are the risks and benefits of taking part in this study? There are no risks to your 
health if you take part in this study. The potential benefit is that, if you need to have a 
sputum test done, we will do the test for you and if the result is positive, we will contact 
you to tell you and refer you to the TB clinic at the municipal hospital for further 
assessment and appropriate treatment. TB is a treatable and curable condition and 
treatment is provided free of charge at the municipal hospital. Apart from that, this 
study will not benefit you directly, but your answers will help us come up with solutions 
so that people with TB can be treated faster. 
 
What happens if I do not agree to take part in this study? You do not have to take 
part in this study. If you do not take part, this will not affect the medical care that you 
receive at this health facility. You can decide to stop taking part in the study at any 




How will the information collected during this study be kept confidential? We will do 
everything we can to keep your personal information private and confidential. This will 
be done by separating your personal details from your sensitive data. If you are able 
to give us a sputum sample for testing, we will contact you to let you know the result, 
either by phone or in a way that we will agree with you. If the result is positive for TB 
we will help you link to the TB clinic for further assessment and appropriate treatment, 
so that the TB can be properly treated. If the result shows TB in your sputum and we 
are unable to contact you after trying several times, we will give the result to the TB 
clinic and they will try to contact you, so you can start treatment. Also, at the end of 
the study we would like to make information from this study available for other 
researchers to use but only after that information has been completely separated from 
any details which identify the people who took part. This will be done by assigning a 
unique study number to your data and not using your personal details. 
What if I have more questions I wish to ask about this study? If you have any 
questions about this study, please ask us now. If you have questions later you can ask 
study staff, or telephone: 
 
Person Designation Telephone Number 
Joyce Der Principal Investigator 0244667985 
Dr Frank Bonsu Local Supervisor 0244318134 
Madam Hannah Frimpong Administrator-GHS-ERC 0507041223 
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Consent form: component B (cross-sectional study) 
 
 
Project Title: Pathways to tuberculosis diagnosis and treatment in Ghana: identifying the gaps and 
seeking solutions 
London School of Hygiene and Tropical Medicine, UK: Joyce Der, Prof Alison Grant, Dr Virginia Bond, 
Dr Daniel Grint 
National TB Control Program, Ghana: Dr Frank Bonsu 
 
 




I have read the information sheet about this study (or the information sheet about this study has been 
read to me) and I understand what will be required of me and what will happen if I take part in the 
study. My questions concerning this study have been answered. 
 
I understand that I may withdraw from this study at any time without giving a reason and without 
affecting the services I receive from this health facility. 
 




Study participant’s name Signature/thumbprint
 Date (Literate/illiterate) 
 
 
If the participant cannot read or write, enter the name of the person who witnessed the consent here 
and their signature: 
I was present when the information sheet for this study was read and explained to the participant in 
the language he/she understands. His/her questions concerning the study were answered and 
he/she willingly agreed to take part in the study. 
 
 
Witness name Signature/thumbprint Date 
 
 
The participant has read the information sheet about the study (or I read the information sheet to 
the participant) and answered all questions concerning the study. The participant willingly agreed to 
take part in the study. 
 
 
Interviewer’s name Signature Date 
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Participant Information Sheet: component A (prospective cohort study) 
 
 
Project Title: Pathways to tuberculosis diagnosis and treatment in Ghana: identifying 
the gaps and seeking solutions 
Investigators: 
London School of Hygiene and Tropical Medicine, UK: Joyce Der, Prof Alison Grant, 
Dr Virginia Bond, Dr Daniel Grint 
National TB Control Program, Ghana: Dr Frank Bonsu 
[Greetings], my name is [  ]. I am a researcher or part of a research team 
based at the London School of Hygiene and Tropical Medicine, UK. We would like to 
invite you to take part in this study. This information sheet explains the study. You are 
free to decide if you want to take part or not. If you decide to take part, I will ask you 
to sign on a consent form, or give a thumbprint. Signing or thumbprinting the form 
means that you agree to take part in the study. It also means that you are aware of 
your right not to take part, or to stop taking part at any time. If you decide not to take 
part, this will not affect your right to health care at this health facility. 
Why are we doing this study? Tuberculosis (TB) remains one of the top 10 causes of 
death worldwide. A survey in 2013 showed that TB remains an important health 
problem in Ghana, and that people with TB may experience delays before they are 
given correct treatment. If we can identify where and why people are delayed, then we 
can make recommendations for improvement so that people with TB can be identified 
early and put on treatment. 
If you take part in this study, what will happen? If you agree to take part in this study, 
we will ask you some questions about your illness and the places you sought care 
before coming to this health facility which will take between 20-30minutes. One of the 
research team will call you every two weeks for the next two months to verify your 
contact information and find out how you are doing. If you do not have a phone to be 
called on then a member of the research team will visit your home after one month and 
two months of recruitment into the study to find out how you are doing. If you permit, 
we will review your hospital folder to see what the doctors have written concerning 
your sickness. We will also use a device to locate where your community/village is and 
the health facilities you have visited because of your current illness before coming to 
this health facility. 
It will not cost you any money to take part in this study and there is no payment to 
people who take part. 
 
What are the risks and benefits of taking part in this study? There are no risks to your 
health if you take part in this study. The potential benefit is that, at the end of the two 
months, if you are still not feeling well and have not received any medication, we will 
help you get care at the hospital. Apart from that, this study will not benefit you directly 
but your answers will help us come up with solutions so that people with TB can be 
identified faster. 
You will be given mobile phone airtime of GHc 2.00 of any network of your choice one 
month after you have been part of the study and airtime costing GHc 2.00 at the end of 
the study. This is to enable you to maintain contact with the research team. 
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What happens if I do not agree to take part in this study? You do not have to take 
part in this study. If you do not take part, this will not affect the medical care that you 
receive at this health facility. You can decide to stop taking part in the study at any 
time, without giving a reason. 
How will the information collected during this study be kept confidential? We will do 
everything we can to keep your personal information private and confidential. This will 
be done by separating your personal details from your sensitive data. We will ensure 
that all information is held securely and accessible only to study staff, and all personal 
details will be removed before data are analysed. Also, at the end of the study we 
would like to make information from this study available for other researchers to use 
but only after that information has been completely separated from any details which 
identify the people who took part. This will be done by assigning a unique study number 
to your data and not using your personal details. 
 
What if I have more questions I wish to ask about this study? If you have any 
questions about this study, please ask us now. If you have questions later you can ask 
study staff, or telephone 
 
Person Designation Telephone Number 
Joyce Der Principal Investigator 0244667985 
Dr Frank Bonsu Local Supervisor 0244318134 
Madam Hannah Frimpong Administrator-GHS-ERC 0507041223 
219  
 
Consent form: component A (prospective cohort study) 
 
 
Project Title: Pathways to tuberculosis diagnosis and treatment in Ghana: identifying the gaps and 
seeking solutions 
London School of Hygiene and Tropical Medicine, UK: Joyce Der, Prof Alison Grant, Dr Virginia Bond, 
Dr Daniel Grint 
National TB Control Program, Ghana: Dr Frank Bonsu 
 
 




I have read the information sheet about this study (or the information sheet about this study has been 
read to me) and I understand what will be required of me and what will happen if I take part in the 
study. My questions concerning this study have been answered. 
 
I understand that I may withdraw from this study at any time without giving a reason and without 
affecting the services I receive from this health facility. 
 








If the participant cannot read or write, enter the name of the person who witnessed the consent here 
and their signature: 
 
I was present when the information sheet for this study was read and explained to the participant in 
the language he/she understands. His/her questions concerning the study were answered and 
he/she willingly agreed to take part in the study. 
 
 




The participant has read the information sheet about the study (or I read the information sheet to 
the participant) and answered all questions concerning the study. The participant willingly agreed to 
take part in the study. 
 
 
Interviewer’s name Signature Date 
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Participant Information Sheet: component C (HCW in-depth interviews) 
 
 
Project Title: Pathways to tuberculosis diagnosis and treatment in Ghana: identifying 
the gaps and seeking solutions 
Investigators: 
London School of Hygiene and Tropical Medicine, UK: Joyce Der, Prof Alison Grant, 
Dr Virginia Bond, Dr Daniel Grint 
National TB Control Program, Ghana: Dr Frank Bonsu 
[Greetings], my name is [  ]. I am a researcher or part of a research team 
based at the London School of Hygiene and Tropical Medicine, UK. We would like to 
invite you to take part in this study. This information sheet explains the study. You are 
free to decide if you want to take part or not. If you decide to take part, I will ask you 
to sign on a consent form, or give a thumbprint. Signing or thumbprinting the form 
means that you agree to take part in the study. It also means that you are aware of 
your right not to take part, or to stop taking part at any time. If you decide not to take 
part, this will not affect your right to health care at this health facility. 
Why are we doing this study? Tuberculosis (TB) remains one of the top 10 causes of 
death worldwide. A survey in 2013 showed that TB remains an important health 
problem in Ghana, and that people with TB may experience delays before they are 
given correct treatment. We are interested in your experiences in TB diagnosis among 
patients with symptoms of TB and the challenges you encounter in this regard. Please 
note that we are NOT doing this study to blame or find fault with any individual health 
facility or healthcare worker. Health facilities will not be able to trace the source of 
information. Reports will not identify healthcare workers. 
If you take part in this study, what will happen? If you agree to take part in this study, 
we will ask you some questions about your awareness of the national guidelines for TB 
diagnosis and your experiences in diagnosing persons with symptoms of TB. We will 
ask you questions about the challenges you encounter in diagnosing persons with TB 
and what you think can be done to improve the situation. We would be very grateful if 
you would allow us to record the interview on tape so that we don’t miss any of the 
things you say. We will also make notes on your answers during the interview. These 
questions will take about 45-60 minutes in total. 
 
What will we do with what you say? Sometimes in interviews, people say things that 
are very useful in understanding the situation being studied. Therefore, if you give 
permission, we may quote things you say in future reports and we will not include any 
details that will identify you. 
 
What are the risks and benefits of taking part in this study? There are no risks to your 
job or direct benefits to participating in this study. This study will help us identify the 
gaps in the diagnostic pathway and the challenges you encounter in diagnosing TB. 
 
What happens if I do not agree to take part in this study? You do not have to take 
part in this study. You can decide to stop taking part in the study at any time, without 
giving a reason. 
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How will the information collected during this study be kept confidential? The 
information you will give will be strictly secured. We would like to make the 
information available for other researchers to use but only after that information has 
been completely separated from any details which identify you. If you permit us to 
record the interview, the tapes will be stored with only study numbers. After the study, 
the tapes will be stored for 10years. 
 
What if I have more questions I wish to ask about this study? If you have any 
questions about this study, please ask us now. If you have questions later you can ask 
study staff, or telephone 
 
Person Designation Telephone Number 
Joyce Der Principal Investigator 0244667985 
Dr Frank Bonsu Local Supervisor 0244318134 
Madam Hannah Frimpong Administrator-GHS-ERC 0507041223 
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Consent form: component C (qualitative study) 
 
 
Project Title: Pathways to tuberculosis diagnosis and treatment in Ghana: identifying the gaps and 
seeking solutions 
London School of Hygiene and Tropical Medicine, UK: Joyce Der, Prof Alison Grant, Dr Virginia Bond, 
Dr Daniel Grint 
National TB Control Program, Ghana: Dr Frank Bonsu 
 
 




I have read the information sheet about this study (or the information sheet about this study has been 
read to me) and I understand what will be required of me and what will happen if I take part in the 
study. My questions concerning this study have been answered. 
 
I understand that I may withdraw from this study at any time without giving a reason and without 
affecting the services I receive from this health facility. 
 
I agree that things that I say might be quoted in future reports: Yes No 
Participant’s initials 
 








The participant has read the information sheet about the study (or I read the information sheet to 
the participant) and answered all questions concerning the study. The participant willingly agreed to 




Interviewer’s name Signature Date 
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Appendix 10.7 Clinic observations checklist 
 
 
Project Title: Pathways to tuberculosis diagnosis and treatment in Ghana: identifying the 




Health facility observations checklist 
Date completed  /  /   Time completed  /  /   
 
Person completing the form:   
 
During the day’s health facility observation, complete the checklist below: 
 
No Key areas Yes No Comment 
1 Did you notice any TB related posters in the waiting 
area? 
   
2 Did HCWs provide any health talks at the waiting 
area? 
   
3 Was TB mentioned in the health talks?    
4 Were clients waiting for a long period before being 
attended to? 
   
5 Were HCWs asking clients about cough and related 
symptoms? 
   
6. Were clients who were visibly coughing or reporting 
a cough separated from other clients at the waiting 
area? 
   
7. Did any client report a cough to a HCW?    
8. When a client reported a cough, did HCW use a TB 
symptom questionnaire to screen the client? 
   
9. If ‘No’, did HCW ask about other symptoms of TB 
(fever, night sweats or weight loss)? 
   
10. Did HCW record the reported cough in a cough 
register? 
   
11. Did the HCW request for sputum test for patients 
who reported cough? 
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12. Did the health care worker provide any education 
on cough etiquettes and how to produce sputum 
for testing? 
   
13. Was a client who has been asked to do a sputum 
test escorted to the laboratory by HCW? 
   
14. Were clients with a request for sputum test asked 
to go to the laboratory by themselves? 
   
15. Did you see any client submitting a sputum to the 
laboratory? 
   
16. Did you see any client who had come for a follow 
up visit with a sputum test result? 
   
17. If a test result was positive, was the client directed 
or escorted to the TB clinic for treatment? 
   
18. Was there any significant event happening at the 
health facility today? 
   
 
 
19. During the period of your observation today, how many people reported a cough?   
 
20. How many people were asked about a cough?   
 
21. Of those who reported a cough, how many were asked to do a sputum test?   
 






23. What is the average contact time between a HCW and a client reporting a cough?   
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Appendix 10.8 Healthcare worker in-depth interview guide 
 
Pathways to tuberculosis diagnosis and treatment in Ghana: identifying the gaps and seeking solutions 




Interviewer Code:   Note-taker Code:   
 
 
Date:  /  /   Start time:   
 
 
Name of Interviewer:   Health facility:   
 
 
Description of place of interview: 
 
A. Participant Identifiers 
1. What is your full name?    
Surname First Name 
2. What is your date of birth?  /  _/   
DD   MM YYYY 
3. What is your age in years? 
 
4. Preferred telephone number:__________________________________________________ 
 
5. Alternative telephone number:_________________________________________________ 
 
B. Demographic Characteristics 
1. Sex: Male 
Female 
 
2. Profession:   _______________________ 
 
3. Health Facility Unit:   _______________________ 
 
 
C. Training in TB Control 
 
1. How long have you been working at this health facility?  ____ 
2. What role(s) do you play at this health facility?  ___ 
3. What type of TB services are provided in your unit? (probe for: education, diagnosis, laboratory, 
treatment, referral)  ___________ 
4. How long have you been involved with TB control at this health facility?   
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5. Have you had any training on TB diagnosis and treatment? If yes, how many times have you been 
trained?   
6. How long ago was your last training on TB?   
 
 
D. Practices in TB diagnosis and treatment 
7. Do you have a cough register and how often are entries made in it? 
(look at a cough register with the HCW and discuss the gaps in the register (variables entered, last entry 
date etc) 
8. What do you do with the data entered in the cough register?   
9. If a patient reports a cough, what do you do? (Probe: if HCW does not mention the use of a symptom 
screening questionnaire, then you ask about its use). 
10. How do you identify patients needing a TB test? (Probe: for use of TB symptom screening questionnaire) 
11. If a patient is identified as requiring a sputum test, what do you do? (Probe: education on sputum, lab 
request form, provide sputum container, refer to the TB lab) 
12. What do you do when a patient who has been asked to do a sputum test return with 
a. a positive test results? (Probe: counselling, TB treatment) 
b. a negative test results? (Probe: counselling, normal treatment) 
13. Do you provide health education in your unit and does it include TB? (Probe: how often health education 
is done (both group and individual education), content of TB it covers) 
14. What infection prevention and control measures do you take in this facility to prevent spread of TB 
(Probe: promptly attending to patients with cough, promptly identifying and separating potential 
infectious TB patience) 
15. What guidelines do you follow in diagnosing TB in this health facility?   
16. Do you have the guidelines available?   
(If yes, then look at the guidelines with the HCW and probe reasons for aspects of the guideline that are 
implemented or not implemented, what is done at the waiting areas, OPD, consulting rooms, wards, 
laboratory and special clinics (ART, Diabetic, ANC, Hypertension Clinics). But if No, show your guideline 
and go through the same procedure described above) 
 
E. Experience in TB case finding 
17. What will you say has been your experience with TB diagnosis and treatment in this health facility? 
• What has been your experience with different categories/attitudes of patients (Probe: age, 
sex, occupation, religion, tribe, location (rural, urban, country: Ghana, Togo)). 
• What has been your experience with screening for cough among patients visiting the health 
facility? (Probe: recognition of symptoms, use of symptom questionnaire, referral from the 
consulting room) 
• What has been your experience with requesting for sputum test? 
o How easy is it for patient to do the test, receive results and initiate treatment for 
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those with a positive test result? (Probe: duration of sputum production, test duration, 
informing patient of results, patient initiation of treatment) 
o What are the laboratory related factors that hinder requesting for sputum test? 
(Probe: unavailability of sputum container, industrial strikes) 
• If a patient is diagnosed with TB and comes frequently to the facility, do you build a relationship 
with them (Probe for the kind of relationship: friendly, cordial etc) 
 
F. Barriers to TB diagnosis and treatment 
18. What in your view will you say are barriers to TB diagnosis and treatment in this health facility? 
• In your opinion, what challenges do patients with TB symptoms face being diagnosed with TB 
and put on treatment in this facility? (Probe: patient behaviour, human resource capacity at 
the facility, diagnostic capacity, logistics, infrastructure, program level challenges) 
• Are there any health worker challenges that undermine TB diagnosis? (Probe: knowledge of 
TB, commitment/motivation, communication, risk of infection, stigma) 
• Away from the health facility, are people with TB symptoms facing challenges which make it 
harder for them to present at the facility? (Probe: financial, social, religion, stigma). Is there 
anything that you do as a HCW about this? 
 
G. Suggested Solutions 
19. What do you think can be done to improve TB case finding in this facility? 
 
 






Interview end time:   
